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VERSION HISTORY AND REVISION SUMMARY 
This version of the Protocol for Auditory Brainstem Response-Based Audiological Assesmsent (2018.02) supersedes all previous 
versions of this document. Notable revisions/additional protocol elements and dates are listed below. 
 
VERSION DATE  DOCUMENT TITLE PREVIOUS VERSION 
APRIL 2016 Protocol for ABRA 2016.01 IHP Audiological Assessment Protocol 2008 
JUNE 2016 Protocol for ABRA 2016.02 Protocol for ABRA 2016.01 
OCTOBER 2018 Protocol for ABRA 2018.01 Protocol for ABRA 2016.02 
OCTOBER 2020 Protocol for ABRA 2018.02 Protocol for ABRA 2018.01 
 
Revisions within this version are largely due to a change in the equipment being used to conduct ABRA within the IHP from the 
Biologic NavPro to the Vivosonic Integrity. Most reflect technological differences with the current equipment that require a 
modification in strategies used to determine thresholds. Others are changes due to updated evidence and/or experience with the 
previous protocol. Minor revisions related to the implementation of the hearing loss risk factor screen on the dried blood spot have 
been included. 
 
TOPIC  DESCRIPTION SECTION 
Sorting tracings The Clinical Sort feature should be used to display the suite of 
tracings. The compound tracing, its primary waveforms A and B, and 
A-B (A minus B) make up the suite of tracings. The clinical sort feature 
groups tracings by descending level with the compound tracing above 
the A and B primaries, which are separated to improve the ability to 
follow individual waveforms. A-B (A minus B) should also be displayed 
for all tracings below the A and B primaries. For every BC ipsi suite of 





BC ABR threshold at 4 kHz is conditionally mandatory when 4 kHz is 
the only AC threshold abnormality. 
DPOAEs are mandatory for suspected or confirmed sensorineural 
hearing loss. They remain mandatory for the ANSD sub-protocol and 
discretional for infants with ABR consistent with normal hearing or 




Minimum levels for 
500 Hz Air 
Conduction 
Mandatory minimum for 500 Hz AC is 40 dB nHL. AC Smin for 1, 2 and 
4 kHz are 35, 30 and 25 dB nHL, respectively. 
 
3.05 
Amplifier Gain & 
Kalman-weighted 
Averaging 
Using Kalman-weighted averaging, artifact rejection is not necessary. 
Due to the nature of Kalman-weighted averaging, there is no need for 
an artifact rejection criterion. Amplifier gain is fixed at 150,000. 
3.06 
Tracings and the 
use of A and B 
primaries, and the 
A-B feature 
In addition to the compound tracing there are two primaries, each 
with half the sweeps of the compound tracing; these are referred to 
as the A and B primary tracings. The A and B primaries have the same 
statistical independence as if they were obtained sequentially. 
Comparison of A and B is used to verify RP or NR. Only when A and B 
do not replicate should an additional tracing at that particular 
frequency/intensity be collected. A-B must be displayed as part of the 
suite of tracings. By subtracting B from A, it provides a visual 








categories & criteria  
The software provides labels for ‘RP’ (Response Positive), ‘NR’ (No 
Response), ‘TH’ (Threshold), or ‘INC’ (Inconclusive). For any frequency 
with hearing loss for which bracketing is complete, TH should be used 
to label the intensity (dB level) one step above NR. This applies to AC 
and BC where bracketing is completed. It is acceptable on occasion to 
have one level of INC in between TH and NR. However, once all 
mandatory and conditionally mandatory elements have been 
completed an attempt should be made to resolve any INC with an 
additional tracing. If INC occurs regularly, consultation with a DTC is 
required 
3.09 
Residual noise and 
No Response 
judgements 
Identifying a small ABR near threshold requires an RN of no more than 
about 20 nanovolts (nV) or 0.020 µV. 3.10 
Adjusted vs Actual 
number of sweeps 
If a group of sweeps in a particular tracing is very noisy (high noise, 
low SNR) they are weighted less. Gathering more sweeps will be 
necessary to achieve the necessary amount of adjusted (quiet) 
sweeps. This results in a discrepancy between the actual number of 




The ABR threshold estimate in dB nHL at 500 Hz will be corrected by 
15 to derive perceptual threshold in eHL at this frequency. This is due 
to the change in Smin at 500 Hz (See 3.05). 
3.13 and 
Appendix G 
Number of sweeps 
& tracings 
For compound tracings, the recommended adjusted sweep count is 
between ~2000-4000 sweeps. This will result in the A and B primaries 
having between ~1000 to 2000 sweeps each. Generally, compound 
tracings in the search phase will have ~2000 sweeps, and those in the 




Two compound tracings that are collected for a given 
frequency/intensity may be summed together to create one tracing, 
the ‘SUM’. This tool is useful for resolving INC tracings and for 
converting a tracing from the search phase into one that meets the 




For an ABR assessment collected under general anaesthesia to be 
accepted for IHP purposes it must meet protocol requirements with 
the exception of test environment (1.24). Other deviations might be 
necessary but these must be documented. Additionally, specifically 
for ABR under general anesthetic (GA) the following is required: 
 Documentation that reasonable effort was made to reduce 
noise  
 Indication of whether the ABR was done in combination 
with other medical/surgical procedures. If yes, 
documentation of what those procedures were, when the 
ABR was performed in relation to them, and any limitations 
they may have posed for the interpretation of the ABR. 
 Documentation of physician’s report of middle ear status if 
immittance is not performed by the audiologist. 
 Otoscopy must be performed preferably by the audiologist, 




The DPOAE test frequencies have been modified to align with the 
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Months: 1.5, 2, 3, and 4 kHz. The frequency 1 kHz is no longer 
required (Hunter et al, 2018). 




Added appendix for quick reference 
Appendix C 
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PROTOCOL EXECUTIVE SUMMARY 
This protocol document includes a tabular synopsis of all key protocol elements, followed by expanded sections that may include 
additional details, rationale, challenges, and solutions for each topic area, plus appendices with selected references and further 
technical or procedural specifications. There are numerous changes from the 2016 Infant Hearing Program Audiologic Assessment 
document; the most important areas of change or emphasis are indicated by shading of the topic section number.   
The following synopsis can stand alone as a summary of the current ABRA protocol including all changes from previous versions. 
Areas within the 2008 IHP Assessment Protocol that relate to the protocol for Visual Reinforcement Audiometry (VRA) and 
Conditioned Play Audiometry (CPA) are included in the Protocol for Audiometric Assessment for Children Aged 6 to 60 months. 
 
SECTION 1: THE INFANT HEARING PROGRAM (IHP) SERVICE CONTEXT 
 
 TOPIC DESCRIPTION 
1.01 WHAT IS IHP ABRA? Auditory brainstem response-based audiological assessment (ABRA) is an 
audiological assessment that is authorized & funded by the IHP. Its core 
components include puretone air and bone conduction threshold estimation & 
site-of-lesion inference using ear-specific, frequency-specific ABRA, and 
tympanometry. Additional techniques may include click-evoked cochlear and 
neural potentials, distortion product otoacoustic emissions (DPOAE), and 
acoustic reflexes. 
1.02 WHO CAN CONDUCT 
ABRA? 
Only Audiologists registered and in good standing with the College of 
Audiologists and Speech Language Pathologists of Ontario (CASLPO), who are 
in good standing with the College and who are trained and authorized by the 
IHP to conduct this protocol may provide ABRA services with IHP funding. The 
IHP audiologist must personally conduct the testing and interpret the results. A 
trained assistant such as a communication disorder assistant (CDA) may 
prepare the baby for the ABRA. Students and trainees may also participate 
with full supervision from the IHP audiologist. 
1.03 PROTOCOL 
ADHERENCE IS A 
REQUIREMENT 
All IHP ABRA must be conducted in adherence to this protocol; such adherence 
is an expectation for continued authorization to provide IHP ABRA services. 
Continued failure to adhere to the protocol may result in a competency review 
The protocol includes three classes of procedure: mandatory, conditionally 
mandatory in specific circumstances, and discretional. Discretional procedures 
can be carried out provided they do not compromise accuracy or timeliness of 




It is acknowledged that case-specific situations that justify departure from 
mandatory protocol elements can arise. Such departures must be noted in the 
ABR records with a brief explanation. All such notes must be accessible to IHP 
standard practice review or case audits (see later) as well as to other IHP 
audiologists sharing the care of the child. 
1.05 CHANGES TO THE 
ABRA PROTOCOL 
Prior approval by MCCSS is required in order to change substantively any 
element of this protocol. Program-wide changes can occur only through 
MCCSS directive or by a systematic process that may include survey of 
Audiologists’ experiences or concerns, evidence review, and recommendation 
by a Designated Training Centre (DTC). 
1.06 TARGET POPULATION  
Candidates for ABRA include all Ontario-resident babies who bypass or do not 
pass newborn hearing screening, or who test positive on hearing loss risk 
factor screening on the dried blood spot, and any other child under 6 years 
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1.07 TARGET DISORDERS The IHP target disorder set includes permanent hearing loss (PHL) of 30 dB HL 
or more at 0.5, 1, 2, or 4 kHz in any ear, ANSD, and auditory brainstem 
pathway disorders that may be detectable using ABR techniques. 
1.08 CONDUCTIVE 
HEARING LOSS (CHL) 
The IHP is complementary to OHIP-based, physician-driven audiology services 
and does not replace them routinely. Purely conductive hearing loss identified 
by ABRA is not an IHP target unless obviously or presumptively structural, such 
as in congenital atresia or if a syndrome associated with structural, conductive 
anomalies is identified or suspected. For minor conductive losses, discharge 
from the IHP with caregiver counseling and discretional referral to a physician 
is the norm. 
1.09 ABRA OBJECTIVES The objectives of ABRA are to detect and quantify hearing loss and, wherever 
feasible, to infer the site(s) of lesion(s) in each ear. The overall assessment 
goes beyond audiometry itself and includes informational and counselling 
components that help families to become informed, engaged, and 
empowered. 
1.10 AGE AT START OF 
INITIAL ABRA  
‘Initial ABRA’ is the first audiologic assessment in a young infant, typically 
following either referral from hearing screening (i.e., refer result on AABR or 
screening bypass) or a positive result on the hearing loss risk factor screening 
on the dried blood spot. Initial ABRA may involve more than one test session. 
With the exception of cCMV and confirmed meningitis, the first ABRA session 
is targeted to occur by six weeks and no later than eight weeks corrected age, 
wherever medically feasible. Widespread achievement of this target is a high 
priority. See 1.12 regarding exceptions to this. 
1.11 AGE AT COMPLETE 
INITIAL ABRA 
A widely-accepted international performance benchmark is completion of 
ABRA by three months corrected age at the latest, wherever medically 
feasible. To improve the provincial level of achievement of this objective is a 
high priority for IHP Continuous Quality Improvement (CQI).  
1.12 SCREENING BYPASS 
IN VERY HIGH RISK 
BABIES 
Babies with congenital aural atresia, proven meningitis, proven congenital 
cytomegalovirus (cCMV) infection, or CHARGE syndrome should bypass IHP 
hearing screening. For babies with confirmed meningitis or cCMV, ABRA is 
targeted to occur as soon as possible after acute recovery which may be as 
early as 2-4 weeks corrected age. The others listed here should be routed 
directly to ABRA by six weeks and no later than eight weeks corrected age, as a 
high priority. 




DTCs are authorized by the MCCSS to provide IHP support, including advanced 
training, consultative and ABRA referral services, protocol support, and clinical 
decision support to IHP Audiologists. DTCs also conduct standard IHP practice 
reviews, provide second opinions on IHP funded assessments and 
interventions, provide continuous quality improvement review for competency 
of IHP trained audiologists, and implement audits of services as directed by 
MCCSS. 
The DTCs for ABRA and conditioned behavioural audiometry (CBA) are CHEO, 
(Ottawa) and Humber River Hospital (HRH, Toronto). The National Centre for 
Audiology (NCA; Western University, London) is the DTC for Amplification and 
Screening.   
1.14 ABRA PROTOCOL 
SUPPORT BY DTCS 
Audiologists who have questions or concerns about any aspect of the ABRA 
protocol are encouraged to contact the CHEO or HRH DTC. This is also a 
mechanism for protocol clarification and improvement. 
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1.15 DTC CONSULTATION 
OR REFERRAL 
IHP Audiologists are encouraged to consult a DTC if they wish to discuss ABRA 
procedure, interpretation, or next steps for any specific child. Real-time 
support during testing is not feasible. Email contact is preferred. Records sent 
by email for review must be anonymized, with a unique numeric or 
alphanumeric indentifier. Audiologists may also elect to refer a baby to a DTC 
for ABRA. Such referral may be in response to case complexity, or difficulty 
obtaining a satisfactory test. See Appendix B for the referral procedure. 
1.16 TIMELINESS OF ABRA 
COMPLETION 
Incomplete ABRA after two appointments attended compromises the IHP’s 
primary objective; it is a quality-of-care challenge and a CQI priority. DTC 
consultation must be considered in a timely manner, then testing under 
general anaesthesia/sedation or referral to the DTC may be the next step. 
Prolonged deferral of assessment, such as to VRA several months later, must 




The IHP does not support repetition of initial complete ABRA unless it is 
elected by the primary IHP Audiologist or is determined to be appropriate by a 
DTC, in which cases the process is considered as consultative referral. 
Where a second opinion request is driven by a caregiver, the Audiologist can 
offer the option of a DTC review as the IHP’s standard procedure. In 
consultation with the Audiologist, the DTC will examine results and issue a 
written report on diagnostic inferences and recommendations. The 
recommendations may include retesting locally or at a DTC.  
The Audiologist must ensure that the caregiver is aware of the right to seek 
audiology services outside the IHP, but must be informed that the results of 
any such testing may have no impact on any future IHP services. See IHP 
Guidance Document for second opinion procedure details. 
1.18 ABR TESTING 
OUTSIDE THE IHP 
Results of ABR testing done outside of the IHP must be reviewed by a DTC for 
validity, accuracy, and relevance, prior to provision of subsequent services 
funded by the IHP. 
1.19 ABRA THAT IS OUT-
OF-PROTOCOL 
ABRA results that are suspected by any IHP Audiologist to be substantively 
non-adherent to the relevant IHP protocol at the time the results were 
obtained must be reviewed by a DTC prior to being considered in relation to 




The IHP is required to implement quality assurance and quality management 
on an ongoing basis, for funding accountability. This is being done through a 
CQI program that targets all major service components, including ABRA. The 
CQI includes enhanced training and clinical decision support, as well as 
performance monitoring. Test timeliness, accuracy, efficiency, protocol 
adherence, and use of supports and referrals are areas of focus for 
improvements. 
1.21 IHP STANDARD 
PRACTICE REVIEWS 
ABRA providers must participate in document-based practice review. A 
streamlined process specified by the MCCSS will be implemented through 
DTCs. Practice review is a routine, support-oriented procedure aimed at quality 
of care verification and improvement. See IHP Guidance Document for process 
specifics. 
1.22 ADVERSE EVENT 




The IHP is obligated to review instances of possible shortfalls in quality of care 
for individual children and families, irrespective of how such events come to 
light. If an adverse event is verified, a case-specific clinical remedy will be 
sought. Depending on the nature of the event, the service involved may be 
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subject to a detailed audit by a DTC, where directed by MCCSS. This may in 
turn lead to a Continuous Quality Improvement Review for Audiologist 
competency (Feb 23, 2018 v1)  
1.23 INFECTION CONTROL 
(IC) STANDARDS 
Infection control practices are typically governed by site-specific, institutional, 
or agency protocols and are outside the purview of this document. If local 
protocols are not available, generally accepted standards must be applied. The 
guidelines issued by Speech-Language and Audiology Canada (SAC-OAC) in 
2010 are a possible source of further information.   
1.24 APPROVED TEST 
ENVIRONMENTS 
 
With the exception of medical/surgical facilities used for ABRA under sedation 
or general anaesthesia (see 3.24), ABRA test areas must satisfy current ANSI 
standards for manual puretone audiometry. If deviations from this cannot be 
avoided, they must be clearly documented. If PHL is suspected in a test area 
other than a surgical suite that does not satisfy ANSI standards, it must be 
confirmed at a later date in a test area that meets the standards.  
1.25 APPROVED TEST 
INSTRUMENTATION 
& SUPPLIES 
All instrumentation and supplies used for ABRA must be approved by the 
MCCSS. ABRA testing must be done using the Vivosonic Integrity with its 
appropriate corresponding software and hardware. Ancillary equipment for 
DPOAEs, tympanometry, and acoustic reflex testing must satisfy the functional 
specifications detailed in the relevant Appendices and must be approved by 
MCCSS. 
1.26 APPROVED DEVICE 
PROTOCOLS & 
PARAMETERS 
All device protocols and parameters must be configured exactly as specified in 
relevant Appendices. Departure from specified parameters may compromise 
ABRA validity or efficiency and will be considered to be out-of-protocol. Setup 
is recommended to be done by the IHP Audiologist who will conduct the ABRA, 
with support from a DTC if required. Vivosonic Integrity software and 
hardware setup may be arranged with the local device supplier (Vivosonic), for 
new devices. 
1.27 CLINICAL RECORDS & 
DATABASE 
REPORTING 
Clinical records must include the test session listing of records that details the 
exact order of acquisition of tracings. This information is available in both the 
Abbreviated and Comprehensive Report printouts within the Integrity 
software. 
1.28 PERSONAL HEALTH 
INFORMATION 
Requirements of the Personal Health Information Protection Act, 2004, S.O. 
2004, c. 3, Sched. A must be met. ABRA data files stored on laptops and 
removable media must not be identifiable. Data communicated for approved 
monitoring and review procedures must be de-identified and code-referenced. 
 
SECTION 2: ABRA PRELIMINARIES 
 
 TOPIC DESCRIPTION 
2.01 URGENCY OF ABRA 
APPOINTMENTS 
Timely attendance for ABRA is critical for achievement of international 
benchmarks for ABRA completion. It is affected by timeliness of screening, 
appropriateness of messaging to caregivers at screening referral, and the 
effectiveness of ABRA appointment scheduling, all of which are IHP CQI 
priorities. 
2.02 REQUIRED STATE 
FOR SUCCESSFUL 
ABRA  
Accurate ABRA threshold measurement is possible only in natural sleep or 
under general anaesthesia/sedation. Natural sleep is the first choice, except 
given long-distance travel or prior failure to sleep, when GA/sedation may be 
indicated. Success at sleep induction and maintenance depends on the child’s 
age, pre-test instruction adherence, test environment, and tester skills. Natural 
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sleep is readily achieved in most infants under 3 months corrected age, but 
becomes increasingly challenging thereafter. 
2.03 PRE-TEST BABY 
STATE 
The baby should arrive for ABRA hungry and tired but not asleep. Variable 
adherence to pre-test instructions was identified by IHP Audiologists as a 
barrier to timely ABRA completion. More effective processes and stronger 
messaging about pre-test sleep and testing failure are both essential and 
feasible.  
2.04 TEST ENVIRONMENT 
& PARTICIPANTS 
Test areas should be as conducive as possible to baby sleep and caregiver 
comfort. Important factors are low sound levels, adequate heating, ventilation, 
and air conditioning (HVAC), low lighting, good electrical shielding, negligible 
in-room 60 Hz electrical interference, and effective positioning of the 
equipment and all persons present. Caregiver presence is preferred and their 
assistance is often effective, given appropriate instruction. 
2.05 TONEPIP STIMULUS 
PARAMETERS 
 
IHP tonepip parameters of 2-1-2 cycle linear rise/plateau/fall modulation must 
be used. The accuracy of ABRA thresholds and derived behavioural threshold 
estimates are specific to these parameters and to all the other parameters and 




IHP stimulus transducer calibration settings must be used (Appendix D), with 
annual electroacoustic checks, daily listening checks, and stimulus verification 
if non-response occurs at high levels. Poor plug contact or defective leads are 
common causes of stimulus failure or intermittency. Backup transducers and 
leads are an obvious precaution. 
2.07 STIMULUS 
TRANSDUCERS 
IHP-approved insert and bone conduction transducers are required. Inserts 
must be used for AC testing. Supra-aural headphones are not supplied as they 
are not part of the routine protocol. Individual clinics can purchase 
headphones through Vivosonic at their own discretion. BC transducers may be 
discretionally hand-held by the audiologist or secured by a tensor band, with 
appropriate technique and/or instruction (see Appendix F). 
2.08 ELECTRODE 
POSITION 
The non-inverting electrode must be on the forehead midline, as high and as 
close as possible to the hairline. The inverting electrodes must be on each 
mastoid and the common must be on the forehead, with at least 3 cm 
between the proximal electrode margins. 
2.09 ELECTRODE 
IMPEDANCES 
The target electrode impedances are less than 5 kΩ. High impedances increase 
pickup of electromagnetic and movement artifacts. Furthermore, the target 
electrode impedance differences are less than 1 kΩ. Different impedances at 
non-inverting and inverting electrodes degrade the differential amplifier’s 
ability to decrease noise present at both electrode sites, which is the case for 
many types of large noise. These effects will reduce ABRA accuracy and 
increase testing time. 
2.10 RECORDING 
CHANNELS 
For both AC and BC tonepip ABRA thresholds, two differential recording 
channels are required. For AC ABR measurements, ensure that only the 
ipsilateral channel is displayed unless there is a unilateral sensorineural loss, 
severe or greater, with either normal hearing or a conductive loss in the other 
ear. This is necessary to ensure that in the case of unilateral SN loss, the 
responses in the test ear are not due to crossover from the non-test ear. (see 
example on page 35). For BC ABRA measurements, two channels must be 
used, with the high-forehead (non-inverting) electrode referenced to each 
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The clinical sort feature should be used to display the suite of tracings. The 
compound tracing, its primary waveforms A and B, and A-B (A minus B) make 
up the suite of tracings. The clinical sort feature groups tracings by descending 
level with the compound tracing above the A and B primaries, which are 
separated to improve the ability to follow individual waveforms. A-B (A minus 
B) should also be displayed for all tracings below the A and B primaries. For 




SECTION 3: HIGH-EFFICIENCY ABR THRESHOLD MEASUREMENT 
 
 TOPIC DESCRIPTION 
3.01 TEST EFFICIENCY IS 
CRUCIAL & FEASIBLE 
Efficient IHP ABRA is necessary and achievable. There are techniques which 
are scientifically valid and proven by experience in other EHDI programs which 
help. Examples include stronger control of EEG noise and stimulus strategies 




ABRA is a decision art quite unlike routine audiometry in a cooperative adult. 
In high-quality ABRA, every choice made for the next stimulus condition 
must be the one that would yield the greatest net clinical impact if the test 
were to be terminated immediately thereafter. The shift from standardized, 
rote procedures to adaptively optimizing the rate of information gain under 
time constraints is challenging, but is a defining feature of true ABR expertise. 
The following sections address key aspects of test efficiency optimization. 
3.03 MANDATORY & 
DISCRETIONAL 
PROCEDURES 
There are three categories of procedure: mandatory, conditionally mandatory 
(‘conditional’) and discretional. AC ABR thresholds are mandatory at 0.5, 2 and 
4 kHz, with 1 kHz conditional. BC ABR is conditional and may be done at 2 kHz 
and/or 0.5 and 4 kHz, where clinically indicated. DPOAEs are mandatory if part 
of a conditional sub-protocol for ANSD/retrocochlear lesions and for suspected 
or confirmed sensorineural HL. They are discretional for infants whose ABRs 
show conductive hearing loss or normal hearing. Tympanometry is always 
mandatory. Acoustic reflexes are discretional and should be done using either 
1 kHz or broad-band noise (BBN) stimuli, the latter being preferable. 
3.04 AC & BC TEST 
FREQUENCIES 
 
The only stimulus conditions for which ABR normative data and clinical 
experience are available and therefore acceptable for use in the IHP are: 
Air Conduction:  0.5, 1, 2 and 4 kHz     Bone Conduction: 0.5, 2 and 4 kHz 




Mandatory minima for stimulus levels are: 
AC Smin: 40, 35, 30 and 25 dB nHL at 0.5, 1, 2 and 4 kHz, respectively 
BC Smin: 30 dB nHL at 2 kHz (any age), 25 dB nHL at 4 kHz (any age), 25 dB at 
0.5 kHz (under 1 year of age) or 30 dB nHL (over 1 year of age)  
 
These equate to perceptual thresholds of approximately 25 dB HL, reflecting 
IHP targeted hearing loss of 30 dB HL or more. Current normative data to 
estimate hearing levels below 30 dB HL with ABR is lacking. 
Maximum AC levels (Smax) are 105, 105, 100 and 95 dB nHL at 0.5, 1, 2 and 4 
kHz, respectively; these correspond to about 95 dB HL, for which detailed 
calculations indicate no known hearing damage risk from tonepip ABRA. 
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3.06 AMPLIFIER GAIN & 
KALMAN WEIGHTED 
AVERAGING 
Gain is set to 150,000. Due to the nature of Kalman-weighted averaging, there 
is no need for an artifact rejection criterion. Large discrepancies between 
number of stim and noise adjusted sweeps (Neq) means either that there is 
too much noise and intervention is required, or that the stimulus was paused 




The efficiency of averaging in terms of signal-to-noise ratio improvement per 
unit test time decreases rapidly as the number of sweeps increases (see Table 
in Details and Rationale Section). 
3.08 TRACINGS AND THE 
USE OF A AND B 
PRIMARIES 
In addition to the main waveform (‘the compound tracing’), the software also 
concurrently generates two primary tracings, referred to as “A” and “B”, each 
with half the sweeps of the compound tracing. These two waveforms have the 
same statistical independence as if they were obtained sequentially and allow 
the clinician to compare the A and B waveforms without having to replicate 
the test. The A and B buffering is based on a statistical distribution of the 
estimated noise between the two concurrently generated waveforms.  
The compound tracing gives the best overall waveform estimate, whereas the 
A and B waveforms allow you to assess reproducibility. Do not be misled by 
inevitable similarity between the tracing and its component waveforms (A and 
B primaries). 
An “A-B” (A minus B) tracing is the difference between the two independent 
waveforms and serves as a Residual Noise estimate. This waveform gives the 
clinician a visual estimate of the noise in the tracing which can help in 
determining response absence or presence. 
If response presence or absence is still not clear, repeating the tracing at that 
same intensity level is an option. The two tracings can then be added together, 
and a judgement made on the summated tracing and its primaries. If it is still 
not clear, consider marking the intensity/frequency INC, and testing at a higher 
intensity. If the level in question is the upper or lower bracket, obtain a third 
tracing and compare. The need to collect three tracings at any 
frequency/intensity should occur only very occasionally. If this occurs regularly, 





In each ear, for any single stimulus route-frequency-level (such as AC 2kHz 60, 
for example), there will be one or more tracings but only one overall 
judgement of ABR presence or absence, aided by defined criteria (see the 
Details and Rationale Section, Topic 3.09). Each stimulus level, not each 
individual tracing, must have one overall judgement and be annotated with a 
single label as either ‘RP’ (Response Positive), ‘NR’ (No Response), ‘TH’ 
(Threshold), or ‘INC (Inconclusive). At each stimulus route-frequency (such as 
AC 2kHz), TH need only be marked for babies who have elevated thresholds to 
distinguish between RP during the Search phase and TH for confirmation of 
threshold estimation. See 3.13 for conversion of ABR thresholds to estimates 
of perceptual thresholds. 
When determining TH, only one intensity can be labelled INC between RP and 
NR. If sequential intensities are judged INC, one must be resolved as either RP 
or NR with further testing before bracketing can be deemed completed and TH 
designated. In grossly abnormal ABR, multiple sequential intensities may be 
designated INC, but it is understood that consequently, thresholds not 
determined, and TH cannot be used.  
3.10 RESIDUAL NOISE 
(RN) LEVELS & ‘NO 
The RN is the standard deviation of EEG noise in the accumulating tracing so 
far. It generally decreases as the sweep count increases - doubling the number 
 
 




of quiet sweeps reduces RN by about 30%. Identifying a small ABR near 
threshold requires an RN of no more than about 20 nanovolts (nV) or 0.020 µV. 
Low RN is an indicator of acceptable averaged noise but subjective flatness of 
the tracing is essential for any NR decision. 




All sweeps are generally included in the compound tracing. If a group of 
sweeps is very noisy (high noise, low SNR) then it is weighted less and more 
sweeps are required for these to have as much weight as a quiet group of 
sweeps in the waveform. This creates a discrepancy between the actual 
number of sweeps and the number of noise adjusted sweeps.    
3.12 TONEPIP ABR 
THRESHOLD 
DEFINITION 
Threshold is defined by upper (TH) and lower (NR) bracket stimulus levels 
separated by 10 dB or less; the upper bracket is the threshold in dB nHL. In 
cases of an INC response, the upper and lower brackets may be separated by 
as much as 20 dB HL. This large step size is why the use of INC between RP and 
NR should be relatively rare. An RP at an Smin or an NR at an Smax levels yield 




Tonepip ABR threshold estimates in dB nHL must be adjusted by the correction 
factors listed in Appendix G, in order to derive threshold estimates in dB eHL. 
The core of ABRA is the estimation of key puretone hearing thresholds in dB 
HL. This is based on determination of tonepip ABR threshold estimates in dB 
nHL, followed by adjustments that are based on known, normative statistical 
relationships between tonepip ABR and VRA-based behavioural thresholds. 
3.14 THRESHOLD SEARCH 
& BRACKET PHASES 
For each air conduction tonepip threshold frequency, there is a Search phase 
that gets to the threshold region as quickly as possible and a Bracket phase 
that focusses on accuracy of response decisions. The 2 kHz Search starts at the 
Smin value and ascends in large steps (30 dB) to find an RP quickly and use its 
morphology and latency as a detection guide for any lower levels. Descent step 
size after a 30 dB ascent depends on the RP clarity and speed of emergence. 
The 4kHz Search starts at 10 dB above 2kHz TH. The 0.5 kHz search starts 
discretionally at 50 dB nHL or at the Smin. Multiple, inconclusive tracings at 
the starting level should always be avoided in the Search phase. Go up in 
intensity instead. 
3.15 NUMBER OF 
SWEEPS & 
TRACINGS 
Each compound tracing should contain between ~2000 to~4000 adjusted 
sweeps (i.e. A, and B primaries with ~1000 to~2000 adjusted sweeps). ABRA is 
a balance between accuracy and efficiency. Where accuracy is paramount (e.g. 
upper and lower brackets, and minimum levels (Smin)), the sweep count 
should be at the higher end (i.e. ~4000). In the Search phase efficiency is 
paramount and so the sweep count is often in the lower range (~2000). 
Tracings with as few as 1000 adjusted sweeps (~500 in primaries A and B) 
showing a clear RP may be used in the Search phase. 
A tracing with an RN under 0.020 µV that is subjectively flat provides the lower 
bracket for an NR conclusion. If the candidate upper bracket is inconclusive, 




Two compound tracings at the same frequency intensity may be added 
together to make one tracing (SUM tracing). The handle will indicate which 
two tracings have been added to make the SUM tracing. This tool is useful for 
resolving INC tracings, and for converting a search-phase tracing into a lower 
or upper bracket tracing.  
3.17 THRESHOLD 
BRACKET STEP SIZE  
The threshold bracket size is 10 dB until all mandatory frequencies by AC and 
BC are completed bilaterally. Once these are completed, brackets of 5 dB may 
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be done with priority placed on levels above 70 dB eHL. Brackets of 5 dB are 
never mandatory though they are preferred in some circumstances. 
3.18 CONFIRMATION OF 
UPPER BRACKET 
RESPONSE 
If there is any doubt at all about ABR positivity at a candidate upper bracket 
level after obtaining the ~4000 adjusted sweeps tracing (~2000 in A and B 
primaries) go up 20 dB, for rapid response confirmation and latency guidance, 
rather than simply doing more tracings at the questionable bracket level.  




The top priority is to determine 2 kHz hearing loss presence, severity and type, 
in each ear that referred on AABR screening or bypassed it. If AC 2k is 
Response Positive (RP) at its Smin, test 4k then 0.5k. If AC 2 kHz is No Response 
(NR) at 80-100 dB nHL, BC 2 kHz should generally be completed next. There 
can be valid reasons to deviate from this, but these should be noted in the ABR 
assessment. AC/BC switching is easiest with hand held BC transducer 
placement. 
Important: Insert transducers need not be removed for BC testing. Occlusion 
effects are reported to be negligible in young infants at 4, 2, and 0.5 kHz. See 
the Details and Rationale Section, Topic 3.18, as well as Small & Hu (2011) in 
Appendix A. 
For bilateral screening referral or screening bypass, optimal strategy requires 
both AC/BC switching and adaptive ear switching. 
3.20 BC STIMULUS 
ARTIFACT 
Whenever BC at the 2 kHz Smin is NR, it is useful to go as high as possible to 
show unequivocal threshold elevation. Stimulus artifact can be a problem 
especially at 0.5 kHz. Artifact size varies across babies, sites and testers, 
suggesting effects of technique. Electrode leads should run directly away from 
BC transducers, as far as possible from its leads and very close together.  
Very large stimulus artifacts warrant forensic investigation. A DTC consult is 
appropriate if routine methods of artifact minimization fail. If artifacts are 
large enough to be seen clearly in the ongoing EEG, they may significantly 
reduce the number of adjusted sweeps.  
3.21 BC RESPONDING 
COCHLEA 
INFERENCE 
BC testing at 2 kHz is mandatory if AC testing yields No Response at 10 dB or 
more above the Sin. If AC 4k is the only elevated AC frequency, then 4 kHz BC 
is conditionally mandatory. If tympanometry results are abnormal and there is 
only a 10-dB elevation at 500 Hz, BC is discretional. Each suspect ear must be 
stimulated individually on the ipsilateral mastoid. Two recording channels 
must be displayed. In young infants and at near-threshold levels, the 
responding cochlea has the earlier and usually larger wave V-V’. The latency 
cue is the more important. If the dominant cochlea is unclear, go down 10 dB 
(even below the Smin) to try to eliminate response from one channel. If this is 
unsuccessful, contralateral noise masking is the only other option.  
Contralateral response dominance results in an inability to infer activation of 
the ipsilateral cochlea just because there is response in the ipsilateral channel.  
Such response may be a shadow from the other side. 
3.22 BC CONTRALATERAL 
MASKING 
Insert masking with broadband noise at 60 dB is often appropriate for most 
situations. Comparisons of masked and unmasked records usually give a clear 
inference about which cochlea is responding. Masking is not routinely used to 
determine the responding cochlea because it may not be easy to implement, 
and normative data on ipsi/contra ABR masking effects are limited. 
3.23 ELECTROMAGNETIC 
60 HZ ARTIFACT & 
NOTCH FILTERING 
Interference from 60 Hz power sources is not unusual and is most problematic 
for 0.5 kHz testing. It can be recognized by its slow, sinusoidal waveform, with 
a period of about 17 ms and sometimes obvious presence at the beginning of 
the tracing. Often, it can be proven present by not delivering the stimulus to 
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the ear (tube off or tube clamped) while otherwise recording as usual. Check 
for 60 Hz sources, and that electrode impedance and lead position are 
appropriate. Use of the notch filter is a last resort if 60 Hz activity cannot be 
controlled, as may be the case in operating rooms, for example. If 60 Hz-like 
activity is not eliminated by the notch filter, a no-stimulus run may still be 
informative. Use of the notch filter must be documented on the ABR printout. 
3.24 ABR UNDER 
GENERAL 
ANAESTHESIA (GA) 
For an ABR assessment collected under general anaesthesia to be accepted for 
IHP purposes it must meet protocol requirements with the exception of test 
environment (1.24). Other deviations might be necessary but these must be 
documented. Additionally, specifically for ABR under GA, the following is 
required: 
 Documentation that reasonable effort was made to reduce noise  
 Indication of whether the ABR was done in combination with other 
medical/surgical procedures. If yes, documentation of what those 
procedures were, when the ABR was performed in relation to them, 
and any limitations they may have posed for the interpretation of 
the ABR. 
 Documentation of physician’s report of middle ear status if 
immittance is not performed by the audiologist. 
 Otoscopy must be performed preferably by the audiologist, 
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SECTION 4: AUDITORY NEUROPATHY SPECTRUM DISORDER (ANSD) SUB-PROTOCOL 
   
 TOPIC DESCRIPTION 
4.01 OVERVIEW About 8% of infants with PHL have an ANSD component (e.g., Rance & 
Starr, 2011; Rance, 2005; Sharma et al, 2015). ANSD, conventional outer 
hair cell sensory hearing loss (SHL), and conductive hearing loss can occur 
concurrently. The challenge is to identify and disentangle the components 
and to know when detection of ANSD is not possible. OAEs and Cochlear 
Microphonics (CMs) are important tools but are not equivalent 
diagnostically. CM presence does not necessarily rule out SHL or rule in 
ANSD. 
4.02 ANSD SUB-PROTOCOL 
ENTRY CRITERION 
ANSD may be unilateral but is usually bilateral (e.g., Berlin et al, 2010; 
Roush et al, 2011; Sharma et al, 2015). One necessary condition for ANSD 
presence is an absent or highly abnormal ABR. The ANSD sub-protocol is 
ear-specific and must be done in any ear for which there is no clear ABR 
wave V-V’ complex with a wave V latency between 5 and 10 ms at any 
tested level above 75 dB nHL at 2 kHz, with at least one such level having 
been tested.  
4.03 ANSD SUB-PROTOCOL 
TIMING 
 
The ANSD sub-protocol usually should be deferred until ABR thresholds 
with 10 dB bracketing are completed in both ears. Responses at any 
frequency can inform ANSD interpretation, and ANSD presence may not 
invalidate all tonepip ABR thresholds. If a second ABRA appointment 
appears necessary, as is frequently the case, an opportunity to start the 
second session with OAEs may prove useful and efficient when executing 
the ANSD click sub-protocol. 
4.04 ANSD TEST PROCEDURES Stimuli are 90 dB nHL clicks at 21.5/s, with a 25 ms data window, a 
bandwidth of 150 Hz to 2 kHz and plotted full-page-width. The basic data 
unit is a 4000-sweep tracing, and a tube-off or tube-clamped 1000 to 
2000-sweep tracing for each polarity—rarefaction, and condensation—
separately. This specific suite of plots is mandatory and often useful to 
disentangle stimulus artifact, cochlear microphonics (CM), cochlear 
Summating Potentials (SP) and ABR (see Details and Rationale Section, 
Topic 4.04).  
4.05 INTERPRETATION OF 
CM/ABR TRACINGS 
Click stimulus artifact is identified using tube-off/tube-clamped records 
with no piece of equipment (including insert earphone), moved at all 
except for tube-off/clamped. CM is identified by reviewing tracings for R 
and C clicks overlaid at the first data point (‘butterfly’ plots) to look for 
anti-phasic deflections in the 0 to 3 ms range. CM is measured by 
subtracting R from C (CM tracing), and ABR is measured by adding R and C 
(ALL tracing). The ALL tracing also allows for identification of any 
summation potential. Comparing the R tracing to the C tracing reveals 
stimulus polarity effects on the ABR, which are not infrequent. When this 
occurs, the ABR/Wave V (if any) should be measured in the better polarity. 
4.06 CLICK ABR WAVEFORM & 
THRESHOLDS 
Click ABRs occasionally are detectable when tonepip ABRs are not, likely 
due to their broader cochlear excitation. If this is seen, it may be useful to 
track the waveform down to an approximate threshold. Additionally, in 
the R+C tracing (ALL tracing) there may be obvious Interruption of the 
wave I to wave V sequence, with clear early neural waves and delayed or 
absent wave V. This may reflect a retrocochlear lesion that may not be 
ANSD. Also, there may be marked differences between the R and the C 
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tracings, with V-V’ much clearer for one polarity than the other. The R and 
C records may even appear to be antiphasic in the region from 1.5 to 10 
ms. In all of these situations, approximate click thresholds may be useful 
but interpretation may be very challenging and consultation with a DTC is 
strongly recommended. 
4.07 DPOAE ROLE 
 
DPOAE measurement is mandatory both when sensorineural HL is 
suspected or confirmed, and within the ANSD sub-protocol. Normal 
DPOAE signal-to-noise ratios (SNRs) indicate functioning OHCs and are 
part of a test battery approach. Present DPOAEs and absent ABR are 
definitive for ANSD. Definite DPOAE presence at any frequency in the set 
[2, 3, 4 kHz] implies that a click ABR should be present. If the 
tympanogram is normal, repeatably absent DPOAEs at 2, 3 and 4 kHz 
nominal F2 values are consistent with ABR threshold elevation due to OHC 
dysfunction. If tympanograms are flat, absent DPOAEs are not 
interpretable, and may have little or no value for differential diagnosis of 
conventional SHL and ANSD components.                                                                                                                                                                                                                                                                                                                                                 
4.08 ACOUSTIC REFLEX (AR) 
ROLE 
Acoustic reflex testing is now always discretional in ABRA. The clinical 
value of ARs in the context of the detailed ABRA and ANSD protocols is 
limited. If ARs are done, they are best done with broad-band stimuli, for 
which ARs are usually the clearest and most likely to be elicited.    
4.09 ANSD OUTCOME 
CATEGORIES 
World Health Organization (WHO)-aligned clinical outcome categories are 
‘Not Suspected’, ‘Probable’, and ‘Definite’ for an ANSD component, based 
mainly on quantitative comparison of sensory (OAE/CM) and neural (ABR) 
measures. Key parameters are CM amplitude, ABR V-V’ amplitude and 
their ratio. The larger the CM or the ratio is, the greater the likelihood of 
an ANSD component. See the tabulated criteria in the Details and 
Rationale Section. 
4.10 CONDUCTIVE 
COMPONENTS IN ANSD 
 
Even a slight conductive loss may reduce or abolish DPOAEs; this can lead 
to missing ANSD. Mid-frequency CHL of 20 dB or more may abolish even 
the CM at 90 dB nHL, rendering some ANSD undetectable due to the lack 
of OHC/IHC measures to compare to the ABR. Current recourse when 
substantial CHL is present is presumptive diagnosis and management as a 
conventional, possibly mixed loss, with prompt VRA follow-up. Deferral of 
intervention for several months until VRA is not acceptable, given the low 
probability of ANSD relative to that of severe/profound SHL. Consideration 
of etiology of the loss, when known, informs this issue as well. Consult a 
DTC as needed.    
4.11 DTC CONSULTS & 
ADDITIONAL TESTS 
It is required that in all cases for which ANSD is considered to be Definite 
or Probable, the DTC for that region be notified by the Audiologist as soon 
as they suspect ANSD. Moreover, if there are challenges disentangling 
sensory and neural components or in determining the ANSD outcome 
category, consultation with a DTC is strongly recommended. Additional 
testing may be specified, to be done either by the referring Audiologist or 
at the DTC. Such testing may include very high stimulus rates and 
additional manipulations of tracings, to clarify interpretation of records. 
4.12 EARLY MANAGEMENT For definite or probable ANSD, tonepip and click ABR thresholds are either 
indeterminate or may overestimate true thresholds, but they can still give 
useful upper bounds for perceptual thresholds. If the baby’s age and 
behaviour permit it, repeat ABRA after 4-8 weeks may be informative. 
More typical is to wait for prompt VRA at about 6 months of age, to clarify 
thresholds and inform interventions.   
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Key points about ANSD and sources of valid information must be 
identified. Hearing loss and speech perception deficits vary widely. Most 
affected children experience significant speech perception deficits in 
noise. Amplification is beneficial in at least half of cases, as are CIs in 
others. Both interventions require establishment of reliable behavioural 
thresholds prior to proceeding (see IHP Provision of Amplification 
Protocol). Fluctuating hearing is an occasional finding but is not typical. 
Improvement in hearing over time is possible but is not well-established.  
4.13 ANSD FIELD ENTRY IN 





The data system (HCD-ISCIS) allows ANSD categories of ‘Not Suspected’, 
‘Probable’, and ‘Definite’. The last two terms correspond to the preferred 
clinical wording of ‘Probable ANSD component’ and ‘Definite ANSD 
component’, respectively. Permanent Hearing Loss should be entered as 
‘Yes’. Hearing threshold estimates, if interpretable, in dB eHL should be 
entered, even though they are likely to be biased.    
4.14 POST-ABRA REFERRALS Completion of ABRA, including the determination of ANSD outcome 
categories, is the responsibility of the primary ABRA Audiologist with 
support by a DTC if needed. When the ABRA is finished, referral to 
specialized centres other than a DTC is discretional and is beyond the 
scope of this protocol.   
 
 
SECTION 5: ANCILLARY PROCEDURES 
 
 TOPIC DESCRIPTION 
5.01 DISTORTION PRODUCT 
OTOACOUSTIC EMISSION 
(DPOAE) TESTING 
DPOAEs are mandatory both when sensorineural HL is suspected or 
confirmed and as part of the ANSD sub-protocol. They are discretional for 
infants whose ABRs show conductive HL or normal hearing. 
A DPOAE system that satisfies the collection parameters listed in this 
protocol shall be used. DPOAEs must be measured for nominal f2s of 1.5, 2, 3 
and 4 kHz, in descending frequency order. Measurement of DPOAE above 4 
kHz is discretional. To determine response presence or absence, stimulus 
levels, DPOAE amplitude, noise levels, reproducibility, and frequency profile 
are relevant. For a single f2, ‘presence’ requires 8 dB or more above the 
noise (SNR) and a test-retest difference of under 5 dB. For two or three 
adjacent frequencies, SNR of at least 5 dB at each f2 is sufficient. 
Replicated DPOAE traces are discretional for cases of sensorineural HL and 
mandatory for ANSD sub-protocol. Replications should be superimposed and 
left and right ear traces plotted side by side. The related tables are also 
required. 
5.02 MIDDLE-EAR ANALYSIS: 
TYMPANOMETRY 
Tympanometry is required. Equipment must meet the requirements 
specified in Appendix I. Supplies will be provided by the IHP lead agency. 
Tympanometry must be done with a 1 kHz probe for infants under six 
months corrected age and a 226 Hz probe for older children. It must be 
repeated if not clearly normal. 1 kHz or 226 Hz tympanograms must be 
plotted with either a hardcopy or electronic copy retained on file. 
Compensated peak static immittance criteria are age dependent and are 
given in the Details and Rationale Section 5.02. 
5.03 MIDDLE-EAR ANALYSIS: 
ACOUSTIC REFLEXES 
Acoustic Reflex (AR) measurement is now always discretional. ARs have 
limited value as a cautionary flag if present when ANSD has been inferred as 
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Definite or Probable. They also may be contributory if ABR thresholds are 
poorly defined yet severe hearing loss has been inferred. If measured, ARs 
must be retained on file as a hard copy or electronic copy. 
 
 
PROTOCOL TOPIC DETAILS & RATIONALE 
SECTION 1: THE ONTARIO INFANT HEARING PROGRAM (IHP) SERVICE CONTEXT 
1.01 WHAT IS IHP ABRA?  
 
IHP ABR-Based Audiologic Assessment (ABRA) is a detailed, multi-component assessment process for confirmation and 
characterization of hearing disorders that: 
 
a. Includes hearing threshold estimation and auditory brainstem pathway function evaluation using the ABR; 
b. Is authorized by the Ministry of Children, Community and Social Services (MCCSS) an IHP Designated Training Centre, (DTC, 
see below), or an IHP Regional Coordinator; and 
c. Is funded by MCCSS. 
 
In most cases, ABRA will be the first Audiologic Assessment on any given child. Complete ABRA usually requires a single test session, 
because the baby will sleep for the test and hearing will be found rapidly to be within normal limits. In other cases, such as those for 
which a hearing loss is found, additional test sessions may be required to complete the ABRA. 
1.02 WHO CAN CONDUCT ABRA? 
 
ABRA must be carried out only by persons who: 
 
a. Are Audiologists registered and in good standing with the College of Audiologists and Speech-Language Pathologists of 
Ontario (CASLPO); 
b. Are authorized by the MCCSS to conduct ABRA (henceforth ‘IHP Audiologist’); and 
c. Have satisfactorily completed IHP-designated training in this protocol and meet all the equipment requirements. 
   
At any given clinical encounter, the designated IHP Audiologist is completely responsible for both the conduct of the testing and the 
interpretation and reporting of the results. These activities cannot be delegated. CASLPO registered Audiologists who have been 
approved by MCCSS for ABR training may participate in testing. Where consented, students may attend and participate in the testing 
as long as their supervisor is present throughout. The presence of any observer must not compromise the effectiveness, efficiency or 
appropriateness of any aspect of the audiologist’s technical activities or interactions with the child and the family.   
 
If an IHP Audiologist authorized for ABRA does not carry out IHP ABRA for a period of six months or more, the IHP Regional 
Coordinator must advise the MCCSS of the lapse in practice. The MCCSS will contact the appropriate DTCs to notify them of the lapse 
in practice and will arrange for an assessment phone call to determine need for further training. The DTC and the Audiologist will 
discuss the Audiologist’s clinical context and possible options for re-engaging in ABRA. A plan for conducting ABRA within the IHP will 
be developed collaboratively. In some instances, the Audiologist may only require performance monitoring and adjustment as 
needed. 
1.03 PROTOCOL ADHERENCE IS A REQUIREMENT 
 
This protocol replaces and overrides all previous IHP documentation relating to ABRA. This protocol is based on extensive review of 
published evidence, analysis of program outcome data from the IHP and from other programs worldwide and, where necessary, 
from expert consultations globally. A structured comparison of the Biologic NavPro and Vivosonic Integrity EP systems was 
conducted prior to the release of the 2018.01 protocol in order to determine what changes, if any, needed to occur when using the 
Integrity. Every effort to limit the number of protocol changes was made, though some were required due to inherent differences 
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between the two systems. The protocol is considered to be evidence-based. Its purpose is to promote the highest possible quality of 
clinical services, as reflected in service effectiveness, equity and cost-efficiency. 
 
Experience indicates that if significant deficiencies in the quality of care do occur, they are usually associated with a clinical error or 
omission that is in non-conformance with protocol. Therefore, program due diligence requires that protocol adherence be specified, 
facilitated and monitored. Clinical adverse events that are deemed attributable to protocol non-adherence are not defensible 
programmatically, in contrast to events that could be deemed unpredictable or idiosyncratic.     
1.04 LEGITIMATE DEPARTURE FROM PROTOCOL 
 
Special situations may arise in individual cases, wherein departure from procedures specified in this protocol may be judged by the 
Audiologist to be appropriate and clinically justifiable. It is expected that this will occur occasionally, not routinely. When an 
Audiologist does elect to depart from protocol, the reason must be documented on the clinical ABR records. The reasoning should 
be brief but cogent and clinically defensible. The three core issues underlying this requirement are quality of care, program risk 
management, and the ability of any IHP process of records review to evaluate adherence to protocol. If the departure is documented 
and reasonable, then the departure would not be considered as a non-adherence event.  
1.05 CHANGES TO THE ABRA PROTOCOL 
 
Systematic changes to ABRA protocol locally or regionally can only be authorized by MCCSS. Such changes may be prompted by 
regional or local characteristics or challenges, sometimes affecting specific groups of service recipients. The process for systematic 
change is led by a regional coordinator. It includes documentation of the proposed change, its rationale and anticipated impact, 
followed by submission to MCCSS; this may be followed by evaluation, discussion, modification and explicit authorization. 
 
A different type of protocol change process arises if any individual IHP Audiologist has a significant concern regarding a specific 
protocol element. The first step is to discuss the issue with a DTC Audiologist, to ensure that the element and its rationale are fully 
understood. This raising of issues is welcomed as a way to resolve misconceptions or miscommunications and, potentially to 
facilitate protocol improvement.  
 
As already noted, the IHP ABRA protocol is based on comprehensive evidence reviews as well as decades of clinical experience. 
Many data sources are evaluated on an ongoing basis by the DTCs. This can result in specification of procedures that differ from 
opinions of individuals or the conclusion of specific published reports. Raising an issue may trigger discussion, re-examination of 
evidence, and provincial consensus development process, prior to province-wide or region-specific protocol change, if the case for 
change is substantiated. 
 
The negative effects of unaddressed protocol concerns include misunderstandings, clinical errors, and opinion-driven non-adherence 
to protocol. Variations in viewpoint are inevitable but raising of concerns gives an opportunity to re-examine procedures and change 
them where change is justified, or at least render a mandatory element discretional if the evidence for it is determined to be 
inadequate. Engaged professionals are a major resource for protocol evolution and improvement.  
1.06 TARGET POPULATION 
 
The target population for ABRA includes neonates or young infants who: 
 
a. Refer on the Newborn Hearing Screening (AABR) and/or Hearing Loss Risk Factor Screening on the dried blood spot (cCMV, 
genetic mutations) or 
b. Bypass screening in accordance with IHP protocol; or 
c. Cannot be tested successfully by behavioural methods, or 
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1.07 TARGET DISORDERS 
 
A target disorder is an audiologic phenotype that renders any qualifying child with the disorder a candidate for IHP services. IHP 
target disorders in the defined target population are:  
 
a. Permanent hearing loss (PHL) of 30 dB eHL or more at any frequency in the range 0.5 - 4 kHz, in any ear; 
b. Auditory Neuropathy Spectrum Disorder (ANSD); 
c. Retrocochlear disorders that may be detectable using the ABR. 
 
The qualifier ‘permanent’ embraces most hearing losses caused by disorders of the cochlea or the brainstem auditory pathways. It 
also includes so-called ‘structural’ conductive losses, which are associated with abnormalities affecting sound conduction through 
the external or middle ear structures. The essence of the ‘permanent’ attribute is that the hearing loss will not resolve 
spontaneously and, therefore, will confer a sensitivity loss indefinitely in the absence of any intervention. 
 
The IHP target disorder definition is more inclusive than that of many programs internationally, in that unilateral, mild and 
frequency-specific impairments are included, as well as ANSD and certain retrocochlear disorders such as space-occupying or 
demyelinating lesions affecting the auditory brainstem neural pathways. 
 
IHP target disorders do not include hearing losses less than 30 dB HL or outside the range 0.5 - 4 kHz. At its core, the IHP is a system 
of care based on newborn hearing screening and hearing loss risk factor screening and such non-target losses do not satisfy World 
Health Organization (WHO) criteria for population screening that include proven burden of the disorder, accurate screening and 
confirmatory tests, effective interventions and acceptable benefit-cost balance. For a review and discussion of the WHO criteria, see 
Hyde (2011). In principle, a hearing loss may be clinically significant yet not satisfy WHO population screening criteria. Hearing losses 
designated as ‘slight’ are an example. However, this protocol addresses ABR-based threshold measurement and there is no good 
evidence that ABR techniques can quantify hearing loss of less than 30 dB reliably, nor is there any good evidence that current OAE 
or ABR-based screening tests and protocols could detect such losses with acceptable accuracy. In fact, there is good evidence they 
cannot do so. 
1.08 CONDUCTIVE HEARING LOSS (CHL) 
 
CHL that is not ’permanent’ is not an IHP target disorder. The term ’permanent’ is not easy to define operationally and 
parametrically. It reflects duration of continuous presence of the hearing loss, given usual otologic care. But how long, how constant, 
and what if ‘usual otologic care’ is not forthcoming or is ineffective? The simplest approach is to identify scenarios that are 
classifiable as permanent or not and then cover other scenarios by making them discretional but guided by defined principles. 
 
First and foremost, the ABRA Audiologist must demonstrate presence of hearing loss of severity and frequency within the target 
disorder range. If a sensory/neural component is ruled out, primarily by bone conduction ABR, the loss is deemed to be conductive. 
Absence or complete closure of the external auditory canal automatically confers permanence, but in all other cases, presence of 
conductive loss must be established audiometrically. If a syndrome that is known to be associated with conductive loss is already 
documented or is suspected by the Audiologist, the CHL may be presumed to be permanent. The same is true if a non-syndromic 
anomaly or external or middle-ear structure has been identified or is suspected. 
 
Where there is no sensory/neural hearing loss and a relevant syndrome or anomaly are not suspected, classification of permanence 
is presumptive and is at the Audiologist’s discretion, based mainly on tympanometry and ABR-based thresholds. For example, if the 
tympanogram using an age-appropriate probe frequency is clinically flat and the ABR threshold elevation is only at 0.5 kHz and less 
than about 55 dB nHL, it is reasonable to infer that the loss is likely to be attributable to a transient middle-ear disorder. Of course, 
actual presence of middle-ear fluid usually can only be determined definitively by careful otoscopy in experienced hands.    
 
The significance of the provisional classification of CHL permanence is that the IHP is not a systemic replacement for Ontario’s 
medically-driven Ontario Health Insurance Plan (OHIP) system for pediatric hearing health care but, rather, is complementary to it. 
The management of middle-ear disorders is a medical/surgical matter that should normally fall under the OHIP system, as should 
associated diagnostic audiologic assessment. Given the common occurrence of middle-ear disorders in infants, routine inclusion of 
their audiologic management would overwhelm IHP resources and compromise the quality of care for those who actually do have 
Permanent Hearing Loss. The usual course of events, given detection at ABRA of minor, conductive hearing loss that is audiologically 
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suggestive of middle-ear disease and asymptomatic, is to discharge the affected infant from the IHP, with appropriate caregiver 
information and counselling concerning self-referral to a physician if signs or symptoms of active middle-ear disorder occur. Such 
discharge does not preclude the infants from re-entering the IHP if and when external audiometric or otologic evidence suggesting a 
structural conductive or sensory/neural hearing loss component emerges and is confirmed by IHP audiologic assessment. 
 
With discretional exception of minor, conductive losses isolated at 0.5 kHz and accompanied by a flat tympanogram, detection of 
clinically significant hearing loss indicates referral to a physician. The criteria for and the timing of such referral are also at the 
discretion of the Audiologist. One view is that immediate referral of infants with isolated CHL is premature, given that watchful 
waiting is the usual course. It is also wasteful of valuable medical resources, with little tangible benefit to the child and family. One 
option is that if the CHL at 0.5 kHz is substantial, wherein it may include a loss at 2 kHz, the infant should be re-tested after a waiting 
period to allow resolution of the loss. On this view, the ‘complete’ initial ABRA includes confirmation of CHL stability. A merit of this 
approach is that CHL obstructs accurate and complete assessment, one reason being that BC ABR thresholds are inherently more 
variable than air-conduction thresholds. If the CHL has resolved on retest, definitive ABRA is then concluded and an arguably 
premature medical referral is avoided. In contrast, if the CHL is sustained the more informed medical referral is fully justified. 
 
The length of the wait period is discretional. If the infant failed newborn screening then that failure could be considered the first 
detection of loss, shown later to be conductive. If the initial ABRA occurred at say 8 weeks corrected age, then only a four-week 
delay before retesting could be sufficient to establish CHL presence over a three-month period, consistent with medical guidelines 
for management of Otitis Media. A longer delay gives more time for disorder resolution, but may result in the infant being both too 
old for easy ABRA and too young for reliable VRA. For these reasons, the retest interval is at the Audiologist’s discretion. 
 
Finally, as for the situation in which there is a conductive overlay on an S/NHL, any CHL is a complicating variable that can decrease 
the accuracy of ABRA and complicate or prevent effective audiologic management of the infant. This is a longstanding challenge that 
is not specific to the IHP. The management process in the presence of conductive overlays is at the Audiologist’s discretion. 
1.09 ABRA OBJECTIVES 
 
The main objectives of ABRA are to: 
 
a. Determine the presence or absence of a target disorder; 
b. Quantify hearing loss laterality, component types, severities, and configuration with sufficient accuracy and efficiency to 
inform and facilitate timely, appropriate provision of IHP intervention services elected by the family; 
c. Achieve a. and b. by three months corrected age where feasible medically; and 
d. Discuss test results with families in such a manner as to facilitate understanding, acceptance and positive engagement to 
the greatest extent feasible. 
 
Objective d. reflects the fact that accurate and efficient ABRA is ineffective unless it leads to prompt and appropriate action by the 
family. Therefore, laying the groundwork for successful intervention is considered a key component of ABRA that is primarily the 
responsibility of the Audiologist conducting the Assessment.  
1.10 AGE AT START OF INITIAL ABRA 
 
With the exception of cCMV and proven meningitis, ABRA must be targeted for six weeks corrected age or within four weeks of 
hospital discharge to home, for babies whose perinatal hospital stay extends beyond 44 weeks gestational age. A 4-week target 
minimum allows some time for transient external or middle-ear conditions to resolve, increasing the accuracy and efficiency of IHP 
ABRA. An 8-week maximum allows sufficient time to complete the ABRA in most cases provided that appropriate appointment 
scheduling procedures are utilized. It should be noted that corrected age is to be calculated using 37 weeks as full term.  
 
Assessment initiated by the IHP is always conditional upon the recipient’s medical condition being appropriate and stable. The 
timing just specified refers to the first ABRA appointment attended after discharge from hospital. If the baby’s treating physician 
orders ABR testing before discharge from hospital, whether in natural sleep or under general anaesthesia in the context of a 
medical/surgical procedure, compliance with such a signed order is at the Audiologist’s discretion and is a regional policy matter. It is 
reasonable to alert the ordering physician to the IHP protocol target and rationale, where feasible. If the order is clearly outside 
target, billing of the procedure to OHIP should be considered, where feasible. If this ABRA protocol cannot be followed by virtue of 
 
 
Page | 25  
 
the test context or timing, the test is to be considered out-of-protocol and its relevance to subsequent IHP testing is to be 
determined in discussion with an IHP DTC.   
 
For ABRA to begin at about six weeks, screening must be completed well before that. In so far as the total delay of the start of 
intervention is the sum of periods spent in the screening and the ABRA processes, the acute challenges of delivering babies to ABRA 
in a timely fashion increase the need for extraordinarily efficient and timely ABRA processes. This is especially true for babies who 
bypass screening and require urgent and priority ABRA (e.g., CMV, meningitis). Babies with cCMV should be seen as soon as 
possible (medical condition permitting) and no later than 4 weeks corrected age.  
1.11 AGE AT COMPLETE INITIAL ABRA 
 
The international performance benchmark is completion of the ABRA by three months corrected age; this timeline is typically 
necessary in order to begin intervention by the key benchmark of six months corrected age, where PHL is found. Examples of 
‘beginning intervention’ include fitting of verified hearing aid(s), or first attendance at an appointment for language development 
services. It does not include purely administrative preparatory steps such as ‘enrolment’ in intervention. In accordance with the 
benchmark, IHP ABRA is targeted to be completed at or before three months corrected age.  
 
Timely completion of ABRA in turn depends on timely screening and referral. Because the majority of babies referred from 
physiological hearing screening will not have a target hearing loss, ABRAs typically will be completed in one session and the three 
month benchmark is relatively achievable. Babies who refer on the hearing loss risk factor screening on the dried blood spot will be 
much more likely to have permanent hearing loss. When sensory/neural hearing loss is present, and particularly if there is 
concurrent conductive loss, several appointments may be required to complete the ABRA and these must also fall inside the three 
month completion target. It is these cases to which the three-month benchmark most critically applies, not just to the majority of 
referrals who have hearing within normal limits. This means that the timing of screening referral and initial ABRA generally must be 
such as to accommodate the delays inherent in booking of one or even two follow-up ABRA sessions.  
 
The entire scientific rationale and justification for population newborn hearing screening and risk factor screening is based on 
achievement of these benchmarks. Every month of delay beyond the benchmark for ABRA completion reduces the potential benefit 
of screening, as the age at identification of hearing loss increases towards what would have occurred typically in the absence of 
population screening.  
  
It is the responsibility of the Regional Lead Agency to develop and implement processes that enable the achievement of the timeline 
benchmarks to the fullest possible extent. It is the challenge of each IHP Audiologist to take all reasonable steps within her or his 
control to facilitate the earliest possible access to ABRA appointments. Key performance indicators would be the percentiles of 
babies whose ABRA was completed by three months corrected age, computed separately for three groups of babies: those who 
bypass screening (see later), AABR refers at risk and AABR refers not at risk. A plausible criterion for excellence would be 90%.   
 
Other important factors include rapidly decreasing likelihood of accurate and complete testing as well as rapidly increasing costs as 
babies grow older. Babies under about two months sleep a lot and are usually easy to test accurately and quickly, whereas babies 
over four months can be difficult or even impossible to test in natural sleep. If PHL is present, several test sessions may be needed 
and cumulative delays compound the difficulty and cost of an adequate assessment.  
1.12 SCREENING BYPASS IN VERY HIGH RISK BABIES 
 
There are several reasons why babies with certain, specific indicators of very high PHL risk should bypass newborn screening and be 
routed directly to ABRA. One basic principle is that screening becomes less and less appropriate, the higher the a priori likelihood of 
PHL presence; current screening technology has substantial false-negative rates due to multiple sources of random error and, 
furthermore, AABR screening with broad-band transient sounds (clicks or chirps) is not sensitive to hearing loss in restricted 
frequency regions of the cochlea. Another concern is that screening is a discrete event that can miss emergent or progressive PHL, 
especially in babies at substantial risk for deterioration in auditory system structure and/or function following an identified 
environmental insult (such as certain in utero or neonatal infections). A fourth concern is that passing a screen is likely to reduce a 
family’s vigilance with respect to late onset or progressive hearing loss, yet the likelihood of the latter increases in babies at very 
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Since 2019, babies who are identified promptly with either: 
 
a. Confirmed meningitis, irrespective of the pathogen (viral, bacterial, fungal);  
b. Confirmed Congenital Cytomegalovirus (cCMV) Infection; 
c. Unilateral or bilateral congenital aural atresia or meatal stenosis such that an ear insert cannot be placed easily; or 
d. CHARGE Syndrome.  
e. Positive result on hearing loss risk factor screening (positive genetic mutation, positive cCMV) 
 
will bypass IHP UNHS in accordance with the current IHP Screening Protocol. Such babies will receive a series of audiologic 
assessments beginning with ABRA, with timing according to risk-specific IHP Surveillance schedules. 
 
In serologically confirmed meningitis, the common belief that only bacterial meningitis is a genuine risk indicator for PHL per se is 
not well-proven. Issues in meningitis risk include the time of onset of PHL and its progression. In bacterial meningitis, there is also 
risk of ossification of the cochlea that may compromise cochlear implantation. ABRA must be done as soon as is medically 
practicable following recovery from the acute phase of the illness, but in accord with the timelines stated earlier. Detection of any 
sensory/neural abnormality indicates referral to a Cochlear Implant program. 
 
If meningitis is suspected but confirmatory information is not accessible, screening is discretional. The decision to do ABRA or to 
defer to later VRA is also discretional and must be evaluated on a case-by-case basis. The conservative approach of routing to 
immediate ABRA has little downside, compared with the potential harm of missing an emergent PHL for several months. If a treating 
physician sees fit to refer the baby for ABRA on the basis of presumptive meningitis, the baby is at risk due to the physician 
determination itself and the ABRA should be done as soon as medical status permits. 
 
Confirmed congenital CMV (cCMV) infection should be treated equivalently, with initial ABRA as soon as is medically feasible and 
appropriate. Issues are the high probability of both congenital and late-onset PHL, as well as frequent comorbidities that may 
complicate or prevent later behavioural testing. Initial ABRA should be done as soon as possible. 
 
When there is an obvious, clearly recognisable anatomic anomaly of the external ear canal such as unilateral or bilateral congenital 
aural atresia or meatal stenosis, screening bypass is necessary because the probe tip cannot be inserted. The intent is to avoid 
inappropriate or persistently ineffective attempts to place a probe in a clearly absent or restricted ear canal entrance. Essentially, it 
is the occurrence of the obvious anatomical anomaly that triggers the screening bypass, not the success or failure of heroic efforts to 
insert the eartip. 
 
Any baby who has a malformation of one or both ears such that successful insert earphone placement for screening appears 
unlikely should bypass screening and be routed directly to ABRA. In the presence of a unilateral obvious anomaly, covert or invisible 
anomaly in the other ear is plausible and, in any case, initial ABRA is always an assessment of both ears. Screening of the unaffected 
ear is permitted.   
 
In any atretic or otherwise grossly malformed ear, the usual issue is primarily cochlear status. Therefore, bone conduction testing on 
the affected side is necessary, and if the ear permits, insert phone testing is optional once everything else is completed. There is no 
intensive follow-up sequence, only normal, clinical follow-up contingent upon the initial ABRA findings and typically including VRA as 
soon as it is likely to be viable with attempts to assess air conduction. Follow-up with special programs for infants with congenital 
ear malformations is recommended where such programs are accessible. Management options should be discussed with the family 
to support informed decision making. 
 
If a baby has a positive result for a genetic mutation on the hearing loss risk factor screening hearing screening bypass and direct 
referral for timely ABRA is warranted. 
 
While AABR screening can occur after 34 weeks gestational age, ABRA itself should not be initiated by the IHP before about 40 
weeks gestational age (GA) because neurodevelopmental immaturity can cause ABR interpretive difficulty, inaccuracy and 
inefficiency. ABRA at less than 40 weeks is contraindicated except when it is ordered by a treating physician as part of medical 
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Irrespective of satisfying the gestational age criterion, ABRA within about a week of birth may be prone to errors associated with 
transient perinatal conductive hearing loss due to unresolved debris or fluid in the external or middle ear. As noted in Section 1.10, 
the preferred age at initial ABRA is six weeks corrected age except in the case of cCMV and proven meningitis.  
1.13 IHP DESIGNATED TRAINING CENTRES (DTC) 
 
Three DTCs support the IHP Audiologists and report directly to the MCCSS: the Audiology Department at CHEO (Ottawa), the 
Audiology Department at HRH (Toronto), and Western University’s National Centre for Audiology (London). CHEO and HRH are the 
DTCs for ABRA and are responsible for matters relating to this protocol. 
 
The DTCs support activities including evidence review, technology assessment, protocol development and support, clinical decision 
support, outcome measurement, and various aspects of Quality Assurance and Continuous Quality Improvement (CQI), including 
Audiologist training, IHP standard practice reviews, and adverse event audits.  
 
The need for ABRA training are identified to MCCSS by IHP Regional Coordinators as they arise. Due to the complexities around 
testing infants, it is preferred that potential Audiologists who are interested in working in IHP have at least 1 year of past 
paediatric experience. If this pre-requisite is not met then either a minimum of 3 years of clinical experience, or a work place with 
direct support from another IHP audiologist in good standing is recommended. If approved, MCCSS will determine the priority of 
the training and arrange its scheduling with the DTC. 
 
ABRA training includes two parts. The first is a three-day in person hands-on course, involving technical tutorials, clinical 
observation, familiarization with instrumentation, hands-on testing of at least four babies, in-depth discussion of results, and rapid, 
intensive chart reviews. The second part involves monitoring and mentoring the trainee at a distance. This includes monitoring all of 
the trainee’s clinical results in the field, prior to their release, until procedures and interpretations are considered satisfactory by the 
DTC expert. The monitoring phase of training typically lasts 6 to 12 months, and the training is not considered successfully 
completed until after this process. It is expected that trainees will be engaged in their clinical practice within two weeks of 
completing the hands-on training component. 
 
Refresher training may be requested by any IHP Audiologist at any time, through their IHP Regional Coordinator and MCCSS.  
1.14 ABRA PROTOCOL SUPPORT BY DTCS 
 
This protocol includes several changes from the 2016 protocol based on the transition to different ABRA equipment. IHP 
Audiologists providing ABRA services are strongly encouraged to contact a DTC directly if they have a question or concern about any 
aspects of the protocol. While peer-to-peer consultation is sometimes helpful, the response of a DTC is definitive. Furthermore, by 
discussion with Audiologists in the field, the DTC is able to develop awareness of protocol areas that may require clarification or 
modification for all IHP Audiologists. All interactions with a DTC are confidential. 
1.15 DTC CONSULTATION OR REFERRAL 
 
Even the most skilled ABRA Audiologists may be confronted by difficult challenges of procedure, interpretation or next-step 
planning. There are many aspects of ABRA for which the underlying scientific evidence is lacking or for which expert consensus is 
incomplete. In many respects, ABRA is in part evidence-based and in part a clinical art. Clinical decision support from DTCs is not 
about what is right or wrong or about evaluating the Audiologist – it is about information transfer, two heads being better than one 
and how to do the best job delivering services for the infant.  
 
Challenges often arise in situations that involve, for example, an ANSD component or mixed conductive/cochlear hearing losses. It is 
recommended that such cases be referred promptly to a DTC if there is any difficulty of procedure or uncertainty in interpretation 
(see Appendix B). Some problems in repeated testing and some referrals may be avoided easily by discussion of initial results with a 
DTC.  
 
ABRA support has been provided by CHEO since January 1, 2015 and by HRH since August 1, 2017. The support may involve 
answering questions about procedure, protocol or interpretation, discussing a concern or challenge, commenting on next steps in a 
 
 
Page | 28  
 
current case or arranging a referral for further ABRA at the DTC. Real-time support during actual ABRA testing is currently 
impractical. While every effort is made to provide prompt feedback, it is helpful if support requests are timed such that the need for 
DTC response within three business days. 
 
The preferred contact method is email. Clinical records for review should be sent electronically. Faxes are no longer accepted. All 
records must be de-identified and assigned a unique alphanumeric ID to facilitate DTC record-keeping and referencing.    
 
Audiologists may sometimes wish to initiate a consultative referral for ABRA at a DTC. Reasons for this may include inconsistent 
results, records that are difficult to interpret or persistent challenges achieving a satisfactory test. Alternatively, the Audiologist may 
wish to procure testing under general anaesthesia/sedation. After discussion and reviewing case materials to date, where 
appropriate the DTC first may elect to attempt testing in natural sleep, which may be more practicable in a DTC context with 
additional in-house supports.  
 
When an infant is referred to a DTC for ABRA, the report from the DTC is sent to the referring Audiologist. The DTC acts as an expert 
laboratory or clinic providing a service to the referring Audiologist, who typically will retain responsibility for further case 
management on a local basis.  
 
There may be a perceived conflict when a DTC is involved in both clinical decision support and some aspects of CQI that include 
routine IHP review of Audiologists’ records. Audiologists are hereby assured that any specific case raised for discussion with a DTC 
for decision support will not be included or referenced specifically in any CQI or audit activity involving that Audiologist and the DTC. 
1.16 TIMELINESS OF ABRA COMPLETION 
 
A significant challenge is that completion of ABRA often does not occur in the timely manner defined by international benchmarks 
for EHDI programs. The two usual ways of quantifying timeliness are age at completion of ABRA and the time interval between 
referral to ABRA and its completion. Absolute age at completion is clearly dependent on age at referral from AABR screening and age 
at the first ABRA appointment attended. Timely referral is always a matter of importance. Delay between referral and first 
appointment attended depends upon the efficiency of both referral generation and ABRA appointment booking by audiology 
facilities. Both of these elements are also CQI priorities.  
 
It is presumed here that ABRA scheduling tactics such as reserved ‘emergency’ appointments, pre-linked appointment pairs that 
allow rapid follow-up to complete unfinished ABRAs, and age-driven appointment priority are routinely practiced by IHP audiology 
facilities that offer ABRA services. Excellent testing quality is of limited value if timely access is undermined by suboptimal 
appointment scheduling. 
 
This protocol item addresses the duration of initial ABRA, the time from the first assessment appointment attended through to the 
point of completion. Two obvious causes of delay are inadequate test conditions and audiologic complexity. The situation of interest 
here is one of little useful clinical information having been obtained after several ABRA attendances. Common causes include the 
baby being too old to sleep readily, developmental and/or behavioural factors, mismatch of appointment timing and diurnal sleep 
patterns, caregiver non-adherence to pre-test instructions, ineffective sleep induction techniques and inefficient testing strategy. 
The over-riding imperative is that ineffective testing cannot simply be repeated indefinitely - something has to be changed. 
 
Babies who refer on AABR screening bilaterally are especially compromised if testing is not timely. In such babies, if the ABRA is not 
completed within two attended sessions, the Audiologist’s options depend on the specific causes of non-completion. If the primary 
cause is audiologic complexity or difficulty with response identification or interpretation, a DTC must be consulted promptly. If the 
primary cause is insufficient sleep time or nonadherence to pretest instruction, the Audiologist should either arrange ABRA under 
sedation at a local facility (if available) or consult/refer to a DTC, which may also result in testing under sedation. Deferral to later 
VRA-based assessment is the least desirable option, acceptable only if the baby would be over four months corrected age at the date 
of the earliest available appointment for sedated ABRA and there is no clear contraindication to successful VRA at six months of age. 
 
Babies with difficult-to-complete ABRA must be discussed with the Regional Coordinator. Every IHP Audiologist and Regional 
Coordinator must be familiar with the MCCSS policy document relating to DTC referral (see Appendix B) and must have in place a 
well-defined process for securing testing under sedation, wherever feasible. Testing under sedation must be done by an IHP 
Audiologist who is authorized for ABRA and in accordance with this protocol to the fullest extent possible. 
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A ‘substantially completed’ ABRA means that enough information has been obtained within the two sessions attended to determine 
whether there is a need for prompt management and to define at least approximate amplification requirements, where 
amplification is indicated and elected. 
1.17 PARENT/GAURDIAN-DRIVEN SECOND OPINION 
 
Routine repetition of ABRA is not authorized by the IHP. Occasionally, after the results of the initial ABRA are explained the caregiver 
may express a strong wish for a second opinion, which may include repeating the ABRA (see IHP Guidance Document). There are 
several possible reasons, including poor understanding of results, denial of the findings, and lack of confidence in the assessment 
testing. Any caregiver expressing a strong desire for a second opinion must be informed of their right to have their child’s records 
reviewed by an independent expert at an IHP DTC. If this satisfies the caregiver, the Audiologist may proceed with the review 
procedure. The DTC will examine the records, discuss them if necessary and issue a review report to the IHP Regional Coordinator 
with a copy to the Audiologist. If necessary, the DTC may discuss alternative courses of action; occasionally, referral to a DTC for re-
assessment may be indicated. 
 
Any family always has a right to seek testing outside of the IHP. The issue that arises and must be explained to the family is that 
testing over which the IHP has no jurisdiction cannot be assumed to be a valid basis for subsequent receipt of IHP services. That is 
the situation for ABRA, because of the complex technical and procedural requirements for valid testing, as specified in this protocol.  
1.18 ABR TESTING OUTSIDE THE IHP 
 
ABR testing by individuals who are not specifically authorized by the IHP to conduct ABRAs must be reviewed by a DTC before they 
can be considered in relation to further audiologic services from the IHP. Authorization to provide VRA or amplification services does 
not confer authorization to conduct ABRA.  
1.19 ABRA THAT IS OUT-OF-PROTOCOL 
 
ABRA results that are suspected by any IHP Audiologist to be substantively non-adherent to the relevant IHP protocol at the time the 
results were obtained must be reviewed by a DTC prior to being considered in relation to further audiologic services from the IHP.   
1.20 CONTINUOUS QUALITY IMPROVEMENT (CQI) 
 
Accountability and transparency imperatives oblige the IHP to show that its targets for all major components are achieved and its 
protocols followed. Therefore, the IHP is implementing more intensive CQI sub-programming for key service areas. These activities 
are considered to be essential due diligence for program integrity and sustainability, are widely endorsed and are implemented in 
most leading UNHS-based programs worldwide. 
 
CQI for ABRA has multiple components that are directed towards enabling and supporting Audiologists to deliver the highest 
possible quality of care to affected children and their families. The key indices of quality are effectiveness, equity and efficiency, 
which are reflected in the accuracy, completeness, timeliness, and consistency of Assessments. 
 
The CQI components include enhanced training, regularly updated protocols, increased clinical decision support and protocol 
support, more systematic referral procedures, more intensive process and outcome evaluation, family experience surveys, 
systematic program practice reviews, and enhanced processes for audit of potential adverse events including continuous quality 
improvement review for audiologist competency (Feb 23, 2018 v1). Other internet-based quality improvement tools (such as an 
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1.21 IHP STANDARD PRACTICE REVIEWS 
 
MCCSS is obligated to demonstrate that its protocols in IHP are followed and its objectives are being achieved. To this end, 
authorization to provide IHP ABRA requires that samples of each Audiologist’s clinical records be reviewed periodically as part of the 
CQI program.  
 
Standard Practice Reviews for ABRA will be carried out by the CHEO and HRH DTCs. All IHP Audiologists providing ABRA services will 
be reviewed at regular intervals according to a schedule determined by MCCSS. The reviews are intended to be a constructive and 
helpful mechanism to improve IHP Audiologists’ practice. Their burden and obtrusiveness will be minimized. Audiologist feedback on 
review effectiveness will be sought. A separate document describes this process in more detail. 
1.22 ADVERSE EVENT REVIEWS & AUDITS & REVIEW FOR AUDIOLOGIST COMPETENCY 
 
Adverse Event Reviews (AERs) are completely different from Standard Practice Reviews. They occur as an obligatory program 
response to specific events or findings that suggest a significant program deficiency. Such events or findings may relate to groups of 
babies (such as an inference of concern from database process or outcome patterns) or to individual families, such as a concern 
arising from family complaint, an anomalous pattern of care or a poor outcome. An adverse event review might lead to a review for 
audiologist competency.  
 
If an AER by a DTC indicates that any specific care recipient is likely to have been significantly disadvantaged as a result of non-
adherence to this protocol or any other deficiency of IHP services, an Adverse Event Audit (AEA) may be initiated at the discretion of 
MCCSS. An AEA is a more rigorous, comprehensive and goal-directed type of AER, the goals of which include full documentation of 
events, remediation of case-specific disadvantage to the extent possible and implementation of program adjustments as necessary 
to avoid recurrence. 
1.23 INFECTION CONTROL (IC) STANDARDS    
 
All Assessments must be conducted in full compliance with any and all pertinent standards of the local ABRA facility relating to IC. In 
the absence of specific facility standards, provincial standards apply (CASLPO, 2010). The IHP does not presume to specify protocols 
in relation to IC. It does, however, require that where applicable standards exist locally, regionally or provincially, they must be 
adhered to rigorously with respect to each and every component of IHP service provision. 
1.24 APPROVED TEST ENVIRONMENTS 
 
With the exception of medical/surgical facilities used for testing under general anaesthesia, ABRA must be conducted in an 
environment complying with current ANSI standards for manual puretone audiometry (ANSI (R2013). American National Standard 
Maximum Permissible Ambient Noise Levels for Audiometric Test Rooms. ANSI S3.1-1999. New York: Acoustical Society of America.). 
Any environment considered for ABRA in natural sleep that does not satisfy this ANSI standard must be discussed with a DTC, 
approved by the MCCSS and be deemed satisfactory with respect to lighting, HVAC, visual distraction, transient and steady-state 
acoustic noise levels, electromagnetic artifact, and audibility of toneburst ABR stimuli at IHP mandatory minimum levels.  
1.25 APPROVED TEST INSTRUMENTATION & SUPPLIES  
 
All instrumentation and supplies used for ABRA must be approved by the MCCSS. ABRA testing must be done using the Vivosonic 
Integrity software and hardware. Ancillary equipment for DPOAE, tympanometry, and acoustic reflex testing must satisfy the 
functional specifications detailed in the Appendices.  
1.26 APPROVED DEVICE PROTOCOLS & PARAMETERS 
 
All device protocols and parameters must be configured exactly as specified in the Appendices. Any departure from the specified 
parameters may compromise ABRA validity or efficiency and will be considered to be out-of-protocol. Setup is recommended to be 
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done by the IHP Audiologist who will conduct the ABRA, with support from a DTC if required. The Integrity system setup may be 
arranged with the device supplier (Vivosonic) for new devices. 
1.27 CLINICAL RECORDS & DATABASE REPORTING  
 
ABRA records and reports must adhere to the requirements of the IHP, CASLPO, and the Personal Health Information Protection Act 
(2004). The records must be held securely as hardcopy or electronically in clinical case files. Hardcopy or electronic records must be 
sufficient to fully specify the subject, tester, test date and location, test parameters, source data (including ABR test tracings, DPOAE 
graphics and numerics, MEA graphics and numerics), interpretation, and contingent recommendations.  
 
ABR printouts must include the test session listing of records that details the exact order of acquisition of tracings. This 
information is available in both the Abbreviated and Comprehensive Report printouts within the Integrity software.   
 
As part of ABRA CQI, the importance of timely data entry into the HCD-ISCIS database system is imperative. After each ABRA session, 
Audiologists must complete the HCD-ISCIS report and send it to the regional lead agency within ten business days. If completion of 
an ABRA requires an additional appointment that can be scheduled within one calendar week, the HCD-ISCIS report may be deferred 
to include the results from the ensuing Assessment. Holding a pending report for more than two ABRA sessions or ten business days 
is not acceptable. 
1.28 PERSONAL HEALTH INFORMATION 
 
Management of all personal health information arising from IHP service provision must comply with all current legislation.  
 
Transmission of personally-identifiable health information must have the consent of a family member or authorized caregiver. 
Individual case information transmitted by email, fax, or hardcopy, such as for IHP training follow-up, IHP internal clinical decision 
support, Standard Practice Reviews Audits or Audiologist Competency review must be uniquely code-indexed and rendered 
personally non-identifiable to unauthorized third parties. 
 
ABR and OAE records held in databases on IHP Integrity laptops or archived onto removable media must not be personally 
identifiable by unauthorized persons. Filenames must comprise numeric or alphanumeric codes; code key lists, necessary for 
retrieval of cases upon request, must be held securely at a separate location from that of the Integrity system.  
 
 
SECTION 2: ABRA PRELIMINARIES 
2.01 URGENCY OF ABRA APPOINTMENTS 
 
Once a baby has referred on AABR screening, or referred to Audiology because of a positive result on the dried blood spot hearing 
loss risk factor screening or has bypassed screening, the need for timeliness of ABRA from its initiation to its completion cannot be 
overemphasized. First, there is harm due to caregiver anxiety that accumulates over time. Second, in order to meet international 
performance benchmarks and gain the greatest benefit from newborn screening, the initial ABRA process must be completed by 
three months corrected age, wherever this is feasible. This requires an early ABRA start, to allow for additional test sessions that are 
necessary in many babies who have hearing loss and to accommodate inevitable delays due to unforeseen events such as baby 
indisposition or competing caregiver demands. Third, as babies get older, natural sleep becomes increasingly challenging to initiate 
and maintain for the required length of testing. This can lead to incomplete ABRA, reduced test accuracy, inconclusive results and 
increased program resource consumption, including possible need for testing under sedation. The delay of a few weeks between 
final AABR referral and the first ABRA appointment is indicated in order to facilitate resolution of transient, perinatal ear conditions, 
ease of handling the baby and some undisturbed caregiver acclimatization to their new circumstance and daily routines. Despite this 
strong rationale, achievement of timely entry into ABRA continues to show substantial geographic variation throughout the IHP.     
 
It is essential that the caregiver understands the purpose and importance of prompt assessment. This begins with the AABR hearing 
screener giving appropriate and timely explanation and messaging, which should be reinforced at every opportunity through the 
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ABRA appointment booking process. Families must be made aware of the importance of securing the earliest available appointment, 
the reasons for the pressure of time and the possible consequences of delay, especially the necessity of sleep and its increasing 
difficulty over time. The key message is that the sooner the test is done, the quicker, easier and more accurate it is likely to be. 
Families also should be made aware that ABRA appointments are a scarce resource for which many other families are waiting, so (i) 
they should make every effort to keep the appointment and (ii) if they become aware of inability to attend, they should immediately 
notify the ABRA provider site and rebook as soon as possible (iii) they should follow the pretest instructions to ensure the best 
possible outcome of testing. 
 
While the timeliness of screening referral and subsequent program administration processes in seeking appointments for ABRA are 
rate-limiting, there are clear indications that access limitations to timely audiology appointments are an important additional delay 
factor, the size of which varies geographically throughout Ontario. Factors that are reported to facilitate prompt appointments and 
high attendance rates include: 
 
 Immediate ABRA booking at the time of AABR referral, wherever feasible. This has long been identified as a standard-of-
care practice, eg., by the national Newborn Hearing Screening Program in England.  
 Appointment slot filling taking due account of the 4-8 week target dates (i.e., not filling all available slots simply on a first-
come, first served basis). 
 Maintaining reserved slots for high-priority/urgent appointments. 
 Automatic allocation of prompt, linked follow-up slots for rapid ABRA completion in a proportion of primary slots (such as 
one in five, depending on referral population characteristics).  
 Reinforcing key messages at every booking/reminder contact, both in writing and verbally. 
 Maintaining a short-notice waiting list to fill late-notified non-attendance. 
 Routine two-week and two-day appointment reminders and confirmation requests. 
 
In situations of irremediable limitation of access to timely ABRA appointments, ABRA appointment filling should be done in such a 
way as to maximize program benefit within existing resource constraints. It is important to minimize the occurrence of late access to 
ABRA for babies who have the highest likelihood of having PHL, such as those who bypass screening, or who refer on AABR hearing 
screening, or have a positive result on hearing loss risk factor screening. It is known that the likelihood of PHL is much lower in 
babies who fail unilaterally, especially if not at risk. Scheduling of ABRA for low-likelihood babies should not saturate available 
appointments in such a way as to cause late access for babies with high likelihood of PHL. A relatively simple way to do this is to 
allocate babies into a stream of appointments that has priority levels mixed and tuned according to the observed characteristics of 
the local, referred population.  
2.02 REQUIRED STATE FOR SUCCESSFUL ABRA  
 
ABR threshold estimation can only be done with acceptable accuracy and efficiency in natural sleep or under general 
anaesthesia/sedation. Natural sleep is highly preferable and must be tried first unless in exceptional circumstances. Natural sleep is 
rarely difficult to achieve in babies under about eight weeks of age but it becomes progressively more challenging as age increases, 
such that testing of babies over about four months of age is often time-consuming and inefficient. 
 
Routinely successful induction of natural sleep in a wide range of babies is an adaptive skill that takes time and experience to 
acquire. It is important that the test environment be conducive to sleep, so it should be dimly lit, quiet and free from visual 
distractions or other disturbances. Eye contact, engaging facial expressions and verbal communication should be avoided. Physical 
restriction, gently rhythmic movement and soothing, simple sounds all may be helpful at the right time. Over-engagement with the 
baby is best avoided – the more interesting the scenario is, the more wakeful the baby is likely to remain. 
 
Testing under general anaesthesia or sedated sleep may be indicated by: 
 
 A known adverse behavior or medical condition;  
 Failure to achieve useful duration of natural sleep at up to two previous appointments;   
 Any predisposing factor that renders testing failure unacceptable (such as major access difficulty); or 
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2.03 PRE-TEST BABY STATE   
 
Most ABRA testing facilities in Ontario use testing schedules with targeted appointment start and stop times. A typical duration for a 
routine ABRA appointment is 1.5-2 hours. In that time, it is usually desirable that the baby sleep for at least half an hour, in which 
period a baby without PHL can often be confirmed as such. Typically, it is desired that the baby arrives for the appointment hungry 
and tired, though not overtired. After cursory otoscopy and ABR electrode attachment, the baby can be fed and prepared for sleep. 
It usually follows that the baby should be neither fed nor allowed to sleep within about an hour prior to the appointment. 
 
It is essential that families understand very clearly that successful ABR testing depends on their following pretest instructions 
carefully. The real underlying message is to ensure that the family understands that the baby needs to sleep readily for at least half 
an hour for any useful information to come from the visit. It is helpful to have them understand the importance of using both the 
IHP’s and their valuable time and resources to the best advantage. The strength and explicitness of this message differ according to 
the test facility’s standard procedures, the Audiologists’ level of comfort and assertiveness and the specific context. In a group 
practice or institutional situation in which staff who make family contacts for appointments may vary in their engagement and 
communication skills, obligatory scripts may be helpful to encourage strong and appropriate messaging. 
 
There are clear indications that the degree to which families adhere to pre-test instructions varies across ABRA test facilities in 
Ontario. Multiple factors are involved and some of those factors are within the scope of influence of the ABRA Audiologist. The best 
that reasonably can be done is that families hear and fully understand the message, then make an honest effort to comply with the 
instructions. The bare minimum process requirement to achieve this is that the messages are very simple, brief, clear, strongly 
directive and consistent, and are presented repeatedly both written and verbally. Written messages must be formatted effectively.  
 
The formatting clarity required are often underestimated. Examples are: 
 
DO NOT feed your baby within one hour before the appointment time, unless it is necessary medically! 
You will be feeding your baby at the beginning of the test. 
 
DO NOT let your baby sleep within one hour of the appointment time! 
Your baby MUST sleep during the test or it will not be successful. 
 
If you are driving OR bringing other children as well as your baby, it is preferable that someone come with you. 
You cannot keep your baby awake properly while driving or looking after other children by yourself! 
In verbal contacts, identical messages and wording are required, preferably followed by reinforcement and verification that the 
messages are understood – not, of course, by simply asking ‘do you understand?’!  
2.04 TEST ENVIRONMENT & PARTICIPANTS 
 
The infant’s safety and comfort are paramount and the infant must be monitored continuously. It is strongly recommended that the 
tester and ABR/OAE instrumentation be inside the soundroom with the infant. If the Audiologist is not in the soundroom with the 
infant, this should be clearly documented. Requirements for approved test facilities were noted previously in Section 1.24. The 
optimal test environment for ABRA is an audiometric soundroom that is electrically shielded. Soundrooms that are not shielded can 
be acceptable electrically if they are not adjacent to strong sources of electromagnetic (E/M) fields, such as heavy electrical 
equipment, elevators, HVAC motors, diathermy equipment, large scanners, etc. If a soundroom is shielded, then for optimal 
effectiveness against external fields, shield continuity (e.g., window mesh) and good grounding are important. Regardless of such 
shielding, AC mains power cable routing within the soundroom must be appropriately encased in grounded metal conduit and, to 
the extent possible, outlets that are unused should have metal cover plates. 
 
HVAC is important, especially for infant comfort, sleep promotion and stable electrode-skin attachment (which is affected by 
sweating). Lighting control is important for sleep promotion; battery-powered LED task lighting is optimal with respect to power line 
interference. Fluorescent bulbs and tubes are the least desirable option, giving limited control and high likelihood of electromagnetic 
interference at 60 Hz and its higher harmonics.  
 
Presence in the test room of the baby’s caregiver is common practice and is recommended but discretional. The majority of initial 
ABRA in the IHP is done with the baby, caregiver and Audiologist inside the test room. In some cases, the Audiologist tests the baby 
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alone, which requires special attention to optimal positioning of the equipment, baby, cot or bassinet and tester. If special assistance 
is required, additional personnel such as a nurse, second Audiologist or other assistant may be required.  
 
As is to be expected, caregivers vary in their knowledge of the most appropriate techniques to encourage an infant to sleep, and 
instruction may be needed to optimize their effectiveness in assisting ABRA. It is not reasonable to expect a lay individual to possess 
the understanding and skills that may be gained from testing hundreds or even thousands of babies. However, caregiver 
engagement with the ABRA process can contribute substantially to understanding of test results, the building of trust and the 
creation of a communicative relationship with the Audiologist that may prove crucial in subsequent management, should the baby 
be proven to have PHL. 
 
If a caregiver is present during the testing, it is important that the Audiologist pay special attention to appropriate communication of 
information as the test proceeds. Surveys of caregiver experience with diagnostic assessments in other programs indicate that 
caregiver satisfaction is often less than ideal, most frequently as a result of not being kept at least minimally informed about what is 
going on. At the start of the visit it is important to provide some key information about the testing session to the caregiver. In 
particular, it is helpful to explain first that for all ABRs regardless of outcome it is typical for the audiologist to look intently at the 
computer screen and at the baby, and to make adjustments to leads, the insert, other pieces of equipment and to the position of the 
baby. Secondly, that the test can be quite long due to many factors, and that the audiologist cannot easily predict how long the test 
will take. Thirdly, and most importantly, that the audiologist will explain the results at the end of the test, unless review by a DTC is 
required, so the family will not have to wait for example for the results to go to the baby’s physician. A running commentary by the 
Audiologist is neither appropriate nor practicable, given the technical demands of ABRA, but reasonably frequent, brief explanations 
of what is being done can alleviate the caregiver’s sense of being ‘kept in the dark’ and lacking control. Discretion and good 
judgement in communication are essential if the Audiologist is facing what appears to be a baby with major PHL. However, in that 
situation, some of the groundwork for imparting difficult news and encouraging acceptance and positive engagement can begin. One 
way of viewing this is that the process of intervention begins with the process of diagnosis, though some would argue that it really 
begins during the process of screening.  
2.05 TONEPIP STIMULUS PARAMETERS  
 
IHP ABR testing must be done using the Vivosonic Integrity system. ABR application software in current use is the Vivosonic Integrity 
8.8.1.2. All application test protocol and parameter files must be configured exactly to IHP specifications (see Appendices).   
 
The core of ABRA is estimation of hearing thresholds using tonepip ABR methods. The accuracy of the threshold estimates depends 
upon many details of the stimulation and recording methods specified in this protocol. Part of the estimation process involved re-
analysis of normative data on the relationship between ABR thresholds and subsequent behavioural thresholds obtained by VRA 
that were obtained by Stapells and his colleagues. The re-analysis involved switching dependent and independent variables, variable 
range restriction and censoring in linear and quadratic regression, use of nonparametric methods and data transformations. The 
results of this underlie the numeric bias adjustment factors (‘correction factors’) that are used to convert ABR thresholds in dB nHL 
to estimates of perceptual thresholds in dB HL. These values were validated through a chart review conducted by the Western DTC 
in collaboration with four IHP ABRA sites. Comparison of ABR threshold estimates to VRA thresholds using the nHL to eHL 
corrections from the ABRA Protocol 2016.02 indicated close agreement. Therefore, the current ABR correction factors provide a 
good prediction of perceptual thresholds infants with normal hearing and hearing loss. 
 
Furthermore, as part of an evaluation of the Vivosonic Integrity, it was determined that with calibration and collection parameters 
outlined in this protocol, threshold estimates were similar to the Biologic NavPro. Therefore, no further correction to the ABR 
threshold estimates are needed when using the Integrity with the current protocol. 
 
The correction factors used in this protocol are specific to the stimulus parameters, recording and analysis techniques described 
in this document. Use of any other types of stimuli, including Blackman tonepip envelopes and changes in nominal tonepip 
frequency, or changes in any of several specific aspects of ABR recording and analysis (such as averaging strategy or Residual 
Noise criteria) will render the threshold estimation process invalid and of unknown bias and precision. Conversely, the correction 
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This protocol specifies the use of constant correction factor values for an ABR threshold range from 25 to about 105 dB nHL. These 
correction factors do not apply for ABR thresholds less than the Smin specified for each test frequency. There is also a tendency for 
differences between ABR and VRA thresholds to decrease at high dB nHL values; this effect is to be expected from the known 
characteristics of auditory single-unit tuning curves in individuals with various degrees of conventional sensory hearing loss. 
However, the effect is small in terms of estimated behavioural threshold accuracy and is offset by the use of 5 dB steps in bracketing 
of high ABR thresholds. 
 
It should be noted that the IHP tonepip stimuli are specified to have trapezoidal envelopes with linear rise and fall; the rise, plateau 
and fall times are 2-1-2 cycles. Such stimuli may not be optimal for ABR elicitation; for example, the net energy-equivalent duration 
of the 4 kHz stimulus is only about 0.6 ms, whereas the wave V stimulus energy integration time for maximum amplitude is probably 
at least 2 ms. Conversely, the 0.5 kHz stimulus 4 ms rise time is arguably too long. However, the original choice of cycle-based 
tonepip envelope was dictated by the availability of high-quality normative data for these particular stimuli and the wealth of clinical 
and research experience gained with these stimuli has cemented the rationale for their continued use.        
2.06 STIMULUS CALIBRATION & CHECKING 
 
Manufacturer’s default calibration files for ABR stimuli must not be used, because their experimental and psychophysical basis is not 
available for evaluation. The calibrations to be used are detailed in Appendix D. ABRA tonepip and click stimuli must be calibrated 
electro-acoustically, annually. Listening checks for air and bone transducer malfunction or intermittency in leads and connections 
must be done at least at the start of each day’s testing. A backup insert and bone-conduction transducer, as well as spare leads, are 
recommended. 
 
In the course of clinical testing, immediate stimulus checks must be done whenever ABR absence is seen unexpectedly or is seen at 
the maximum level used for any stimulus type and route. The most common cause of stimulus insufficiency is eartip blockage.  
2.07 STIMULUS TRANSDUCERS  
 
All stimulus transducers must be of the type specified by the IHP. Where inserts are contraindicated anatomically, BC is the 
recommended choice in order to confirm the status of the inner ear. The use of supra-aural earphones is discretional.    
 
For BC ABR testing in infants, transcranial sound transmission losses can vary across infants from about 5 to 30 dB (Yang & Stuart, 
1990). Therefore, each ear must be tested individually, with transducer placement on the mastoid supero-posterior to the canal 
opening of the test ear. The transducer must be held firmly in place either by a Velcro band or tensor bandage, or by finger pressure 
perpendicular to the transducer rear surface (see Appendix F for clinical tips). Application force measurements are unnecessary, but 
positioning must be consistent and the pressure must be light but firm. Family members are not permitted to hand hold the BC 
transducer as they are not properly trained on the procedure.    
 
Note that it is not necessary to remove an ear insert transducer when testing a given ear by bone conduction ABR. Evidence to 
date indicates that occlusion effects are clinically insignificant in infants (see Small et al. 2007) and this is supported by substantial 
clinical experience with ABR thresholds in other EHDI programs.  
2.08 ELECTRODE POSITION 
 
Snap electrodes compatible with Vivosonic leads must be used. The non-inverting electrode must be placed on the midline forehead 
as high and as close to the hairline as possible. An inverting electrode must be on each mastoid process and the common electrode 
must be on the lateral forehead at least 3 cm from the non-inverting electrode. 
 
A common error is non-inverting electrode placement too low on the midline forehead, at which point ABR wave V amplitude loss 
will occur, relative to points higher on the midline. On the International EEG Federation’s 10-20 System for Electrode Placement, the 
goal is to position the non-inverting electrode as close as possible to Fz, not at the mid-forehead frontal pole denoted as Fpz. Using 
sticky pads on the skin, the anterior proximity to Fz is usually limited by the position of the hairline. See American 
Electroencephalographic Society (1994). 
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2.09 ELECTRODE IMPEDANCES  
 
Effort must be made to obtain impedances of 5 kΩ or less for all electrodes and, even more importantly, impedance differences for 
each forehead-mastoid pair of no more than 1 kΩ. 
 
Differences in non-inverting and inverting electrode contact impedance reduce the ability of the differential amplifier to reject input 
signals common to these two electrodes. This ability (common-mode rejection, CMR) is important to achieve the best ABR-to-noise 
ratio from the head. Large signals from the heart, for example, are similar at the forehead and mastoid and greatly reduced by 
differential recording. The same is true for signals from distant, off-body sources such as radio waves, for which the body acts as an 
antenna. 
 
Note that the ABR usually seen in a differential recording has the actual ABR at the mastoid subtracted from the actual ABR at the 
high forehead. Wave V is more broadly scalp-positive and larger in the midline. 
 
CMR reduction depends on the absolute difference in impedance, so 2 kΩ of difference is twice as bad as 1 kΩ. The lower both 
impedances are, the smaller the difference will tend to be, so it usually makes sense to reduce the larger impedance. When the baby 
is deeply asleep and the EEG is quiet, loss of CMR may not matter, but when the baby is lightly asleep or dozing intermittently and 
the EEG noise is larger, loss of CMR may determine whether ABR testing is successful.   
 
Higher but equal absolute impedances have negligible direct effect on CMR but they increase artifact voltage pickup due to 
electromagnetic current induction in the electrode leads or across the baby’s scalp. E/M current may be induced by any rapidly 
changing E/M field surrounding the electrode leads, such as may be generated by AC 60 Hz power leads, outlets, switches, lights, 
dimmers or other nearby electrical devices. Fluorescent lights can be problematic due to higher harmonics of 60 Hz. Battery-
powered LED lighting does not cause E/M current induction and is readily available at low cost.  
2.10 RECORDING CHANNELS    
 
For all ABR thresholds a two channel setup with the inverting mastoid electrode ipsilateral to the stimulated ear should be used. If a 
single channel is used, the rationale for the departure from protocol must be documented in the clinical records.  
 
For most AC ABR threshold measurement, the practical benefit from displaying two channels is negligible. Doubling the number of 
displayed or plotted tracings increases clutter and the difficulty of waveform organization and rapid visual inspection. An exception 
is unilateral sensorineural loss that is severe or greater, with either normal hearing or conductive hearing loss on the contralateral 
side. In these cases, two-channel recording might reveal a contralateral responding cochlea at high stimulus levels. When this 
occurs, the contralateral tracings must be displayed with the full suite of waveforms including A, B and A - B. See example below 
(Figure 2.10.1), which shows a clear response in the contralateral channel. Similarly, two channels might reveal a stimulated ear or 













































In BC threshold estimation, inference of which cochlea is responding to the stimulus requires comparison of ABR characteristics from 
channels ipsilateral and contralateral to the stimulated mastoid. Furthermore, much larger BC stimulus artifact in the ipsilateral 




Figure 2.10.1 Two-channel recording revealing a contralateral response at high stimulus levels. 
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2.11 SORTING AND DISPLAYING TRACINGS FOR PRINTOUT  
 
Consistent and optimal organization of waveform printouts facilitates rapid visual inspection and interpretation, as well as review by 
other persons such as colleagues or DTCs. It also expedites any type of review, including training or updating reviews, consultations, 
second opinions, standard performance reviews or adverse event audits. Therefore, a standard format is necessary and is 
mandatory. 
 
For all tonepip ABRs, the suite of tracings should be displayed using the ‘Clinical Sort' tool in the ‘split’ view; with the RIGHT tracings 
on the left hand side, and the LEFT tracings on the right (to correspond with the convention for the audiogram). The suite of tracings 
is made up of the compound tracing, the A and B primary tracings, and the A-B (A minus B) tracing. 
 
Using the ‘Clinical Sort’ tool for all tonepip ABR has three advantages. First, it separates the tracing suites, providing easy visibility of 
individual tracings and handles. Second, it improves the ability to see trends in the A and B primaries, which is often helpful in 
assessing reproducibility and identification of large noise artifacts in individual tracings. Third, the automatic separation of tracings is 
not subject to waveform identification bias that can easily arise when the examiner is free to superimpose potential response 
waveforms. The practice of arbitrary vertical shifting is to be avoided in record printouts, though it may be subjectively helpful in the 
course of data acquisition, to assess reproducibility and averaging needs.  
 
The A-B (A minus B) must be displayed. This will allow subjective evaluation of noise levels and allow comparison to the compound 
tracing for better identification of RP and NR judgements.  
 
For BC ABR, for each stimulus ear-frequency-level, ipsilateral and contralateral tracings are obtained and the full suite of tracings is 
displayed including the A and B primary tracings, and A-B (A minus B), with the contra immediately below the ipsi and with these 
units ordered overall by descending stimulus level. This facilitates the visual comparison of ipsi and contra waveforms and their 
trends across levels, usually necessary in order to identify which cochlea is being activated preferentially by the given stimulus. This 
is easily achieved by using the required clinical sort feature. 
 
SECTION 3: HIGH-EFFICIENCY ABR THRESHOLD MEASUREMENT 
3.01 TEST EFFICIENCY IS CRUCIAL & FEASIBLE 
 
In the IHP, as well as in many other programs worldwide, timely and accurate completion of ABRA is a challenge. Continuous effort 
and ingenuity are needed to increase the efficiency of ABR threshold measurement in particular, without loss of accuracy and, 
preferably, with increased accuracy and reduced errors or omissions. The emphasis here is on improvements in procedure that will 
increase the rate of clinical information gain and reduce the likelihood of significant clinical decision errors or omissions. Most of the 
protocol elements specified here are routinely practiced by the most skilled ABR testers globally. Even with rigorous adherence to 
this protocol, there is ample room for the additional exercise of great clinical skill and high-level judgement. For example, pervasive 
clinical questions are ‘in how few tracings can I define this ABR threshold to an acceptable level of precision and adherent to 
protocol?’ and ‘if this baby wakes up in one minute, have I done absolutely the best possible job in obtaining the most critical clinical 
information in the time I had available?’  
 
The following points illustrate some key aspects of more efficient testing that will be explained in more detail in the subsequent 
sections: 
 
 Throughout threshold estimation, make every choice of the next stimulus condition the one for which determining ABR 
presence or absence will have the greatest impact on clinical management, given what you already know or do not know 
at that precise moment of choice. 
 Don’t allow high-amplitude EEG into a good tracing; pause the collection if intervention is required. 
 The bigger (more sweeps) the tracing, the less efficient it becomes in terms of information gain per unit test time. Use 
sweep counts of about 2,000 sweeps (A, B buffer of about 1000 sweeps each) and stop there if clear RP. Clear NR almost 
always requires more than 2000 sweeps in the compound tracing 
 Start initial testing in a referred ear. The information gain from testing a passed ear is much smaller, as is the probability 
of a significant permanent hearing loss in a passed ear. 
 
 
Page | 39  
 
 Start at the minimum stimulus level but go up in large steps (30 then 20-30 dB) to get a clear response latency and 
waveform guide as quickly as possible in the event of an NR, or INC decision at Smin.  
 Use a strategy of progressive refinement of threshold accuracy. Do not use 5 dB brackets unless and until you have 
finished all 10 dB threshold bracketing. 
 Once you’ve established 2k AC threshold, go to either BC or AC 4k. 
 Use 10 dB ascent only to confirm response at a lower level, not in the search phase. 
 Proving response absence is often far more time-consuming than proving response presence, so try to minimize doing it. 
 More than two tracings per stimulus condition are rarely useful; go up instead. 
 If two consecutive intensities for a given frequency are INC, with a clear RP above and a clear NR below, a third tracing to 
resolve at least one of the INCs is indicated. 
 INC should only be used relatively rarely; once all mandatory and conditionally mandatory procedures are completed, an 
attempt should be made to resolve an INC with an additional tracing.  
 Use information obtained on previous ABR/CBA testing to inform testing choices such as starting level frequency, ear, 
and modality on subsequent ABR. Avoid repeating known information, instead try to ‘fill in the blanks’ to obtain as much 
information as possible. 
 
3.02 OPTIMIZING CLINICAL INFORMATION GAIN 
 
ABR threshold measurement must be done with the highest possible clinical efficiency, assuming that testing can be terminated at 
any time with no further attendance. Each and every choice of next stimulus condition must be such that clinical management will 
depend strongly on the answers obtainable for the chosen condition. 
 
Common situations that limit the efficiency of threshold measurement are: 
 
 Getting bogged down in threshold accuracy before answering bigger clinical questions. 
 Using ascending step sizes that are too small, losing time getting to threshold bracketing regions. 
 Lengthy or repeated averaging when response is highly questionable (i.e., chasing shadows), rather than going louder to get 
a clear guideline response. 
 Not doing BC early enough and/or switching ears early enough.  
 
The general strategy of successful ABRA is the opposite of standard audiometry in a cooperative adult subject. In an infant, the 
required mindset is that the testing may be terminated permanently at any moment, perhaps after the very next tracing. This means 
that the next stimulus condition (route, frequency, level…) to be chosen must be the one that will make the biggest difference to 
clinical management, of all the stimulus choices available. If this strategy were followed continuously, then no matter when the 
session does end, it would not have been possible to get more valuable clinical information in the time that turned out to be 
available. 
 
Time is a constant pressure in ABRA. It is challenging to achieve consistently accurate and complete initial ABRA followed by 
appropriate intervention within the timelines established as international benchmarks. There is never any time to waste taking 
measurements that are not clinically important. The need for a top-down approach with progressive refinement of information 
cannot be overstated. 
 
The first question to be answered in ABRA is whether any ear that gave a UNHS Refer has a target PHL. If the UNHS Refer is 
unilateral, the Referred ear is the starting point, whereas if bilateral, the starting ear is a matter of convenience. 
 
Absence of hearing loss is answered by ABR detection at the lowest appropriate stimulus levels across the target frequency range, 
denoted as Smin values. In the range 0.5 to 4 kHz, the most valuable of all single answers in relation to early language development 
and the epidemiology of hearing loss in newborns is at 2 kHz.   
 
Most babies referred from UNHS will have normal or near-normal hearing. It follows that the initial starting condition must be the 
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If there is no response at the 2 kHz Smin, important clinical questions are: (1) how big is the loss, (2) is it permanent, (3) what about 
other frequencies and (4) what about the other ear?   
 
When there is no response at the 2 kHz Smin, immediately go up 30 dB. Getting a positive response quickly at about 60 dB nHL is 
much more informative than getting an inconclusive or negative result having gone up by only 10 dB, for example. In addition, 
getting no response at 60 dB has major clinical impact and is much more informative than getting no response at 40 dB and avoids 
time wastage chasing shadows. 
 
If no response is obtained at 60 dB, the next step should be 80 or even 90 dB. If no response is present at 80 dB, Smax should be 
tested followed by BC.  
 
When going to BC, a question is whether to start at the BC 2 kHz Smin or a higher level, given no response for AC at 30 or 60 dB. The 
Smin has priority because the ability to state that BC is normal has major clinical impact. 
 
There are two important general points here. First, information theory tells us that in a situation of choosing between two 
alternatives, the more probable one is relative to the other, the less information is gained by knowing the answer; when one answer 
is almost certain, discovering that it is true yields little new information. It follows that the greatest information gain occurs when 
the alternatives are equi-probable. 
 
The second point is that the relative clinical importance of a given stimulus condition changes as the answers come in from other 
stimulus conditions, so the whole process of choosing the most influential next stimulus condition is dynamic and constantly 
evolving as the Assessment proceeds.                                                                                                                                                                            
3.03 MANDATORY & DISCRETIONAL PROCEDURES 
 
A complete ABRA must include otoscopy, ABR testing, and Middle Ear Analysis (Tympanometry). The ABR testing must include AC 
tonepip ABR threshold estimation; where indicated, it may include BC tonepip ABR and a sub-protocol for evaluation of ANSD as well 
as other retrocochlear disorders that commonly affect the ABR. MEA must include tympanometry and may include acoustic reflex 
testing. 
 
ABRA test components are specified below. The tests are grouped as procedures that must always be done (Mandatory), procedures 
that must be done if a specific situation occurs (Conditionally Mandatory) and procedures that may be done if the Audiologist so 




 AC ABR thresholds at 2 kHz, 4 kHz, and 0.5 kHz with 10 dB final bracketing 
 Tympanometry at 1 kHz under 6 months corrected age, 226 Hz at 6 months or more 
 
Conditionally Mandatory Procedures 
 BC ABR threshold at 2 kHz if AC 2 kHz is abnormal 
 BC ABR threshold at 0.5 kHz if 0.5 kHz is the only AC threshold abnormality and AC threshold is elevated by more than 10 dB 
 BC ABR threshold at 4 kHz if 4 kHz is the only AC threshold abnormality 
If AC 2 kHz and 0.5 and/or 4 kHz are abnormal, BC 2 kHz is Mandatory and BC 0.5 and 4 kHz are Discretional. 
 AC ABR threshold at 1 kHz (10 dB bracketing), if AC 2 kHz TH minus AC 0.5 kHz TH exceeds 25 dB nHL 
 DPOAE amplitude and noise measurements at 1.5, 2, 3 and 4 kHz nominal f2, where sensorineural PHL is suspected or 
confirmed. Replication of tracings is discretional if DPOAEs are absent in the presence of an ABR showing sensorineural HL. 
 Sub-protocol for ANSD or retrocochlear disorders, if there is no clear tonepip ABR wave V-V’ at 15 ms or less for any 2 kHz 
level tested above 75 dB nHL. The sub-protocol Includes: 
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Rarefaction and condensation clicks (separated) at 90 dB nHL, for assessment of: 
 Cochlear microphonic potentials (CM) 
 Cochlear summating potentials (SP) 
 ABR wave presence, morphology, latency, amplitude 




 DPOAE amplitude and noise measurements at 1.5, 2, 3 and 4 kHz nominal f2 for infants whose ABRs show conductive 
hearing loss or normal hearing. 
 Ipsilateral acoustic reflexes (preferably to wide-band noise bursts).  
 AC ABR thresholds at 2 and 4 kHz with 5 dB bracketing, if all mandatory measurements are completed and time permits. 
 Approximating click ABR thresholds within ANSD sub-protocol. 
 
Component Test Priorities and Order 
 
Otoscopy is a required preliminary in any Assessment. Its purpose is to detect foreign bodies, canal occlusion and any other physical 
condition of the ear that may invalidate or otherwise contra-indicate the Assessment or indicate referral to a physician. Otoscopy is 
usually followed by electrode attachment, then feeding to promote sleep. 
 
At the first ABRA session, tonepip ABR thresholds are the immediate priority as soon as the infant sleeps. Other procedures such 
as tympanometry (mandatory) or DPOAE (discretional) are usually deferred because they are secondary to ABR and can interfere 
with falling asleep. One of the facets of successfully inducing sleep in many babies is minimization of auditory, visual and 
somatosensory stimulation. 
 
Because abnormal AC tonepip ABR thresholds trigger BC measurements, direct hard evidence of conductive hearing loss is usually 
obtained thereby. Tympanometry is usually deferred at least to the end of the first session. Its findings complement ABR-based 
inferences and provide limited cross-validation of ABR air-bone gaps. 
 
Acoustic reflex measurements are now discretional. They have limited value as a crosscheck when ABRs are absent at high stimulus 
levels, in that reflex presence contradicts inference of both ANSD and profound conventional cochlear hearing loss. In general, reflex 
presence may be clinically informative whereas reflex absence is rarely so. 
 
After the tonepip thresholds are substantially completed, if the 2 kHz ABRs are absent or abnormal at high levels then ANSD 
presence must be evaluated, using both OAEs and the click ABR ANSD protocol. These tests are normally deferred to the end of the 
first ABRA session. 
3.04 AC & BC TEST FREQUENCIES 
 
AC tonepip ABR thresholds may be measured only at nominal frequencies of 0.5, 1, 2 and 4 kHz, where 2, 4 and 0.5 kHz are 
mandatory and 1 kHz is conditional. AC testing at other frequencies must not be done because there are no adequate normative 
data on the relationships between ABR and perceptual (behavioural) thresholds at other frequencies, for the type of stimuli 
specified in this protocol. 
 
BC 2 kHz must be done if AC 2 kHz shows no response at the minimum level. BC 0.5 kHz must be done if AC 0.5 kHz is the only 
abnormality, but is discretional if both AC 0.5 and 2 kHz are abnormal. Inference of conductive loss at 0.5 kHz does not imply that a 
loss at higher frequencies also must be conductive, whereas if a loss at 2 kHz is purely conductive it is reasonable to assume that a 
loss at 0.5 kHz is also conductive. Similar to 0.5 kHz, if AC 4 kHz is the only abnormality, then BC 4 kHz is mandatory. BC testing must 
not be done at any other frequency than 0.5, 2, and 4 kHz, again because there are no normative data of adequate quality. 




Page | 42  
 
The IHP target disorder set defines the lower limit of puretone hearing loss (25 dB HL) that it is desired to measure. This defines 
mandatory minimum stimulus levels (Smin) that depend on stimulus frequency and route and are in the range 25-40 dB nHL. Lower 
levels must not be used, primarily because the relationship between behavioural thresholds and ABR thresholds obtained with 
common, clinical protocols is currently unknown or non-existent at ABR threshold levels that correspond to about 25 dB HL or less. 
This is to be expected, given the typical variability of individual measurements of both ABR and VRA thresholds. The only exception 
to this is for BC testing when it may be necessary to go below Smin levels to isolate the responding cochlea (see p. 52).   
 
Absolute maximum levels for tonepips (Smax) are determined by the upper limit of transducer linearity. In terms of damage risk to 
the cochlea, there is no good evidence of auditory system damage risk for the tonepips used in ABR threshold measurement. Even at 
the highest tonepip levels with the largest feasible, high-frequency SPL increases in small canals taken into account, conventional 
noise exposure calculations indicate no damage risk. However, this is not necessarily the case for click stimuli (see later). Smax 
values are typically in the range 95-105 dB nHL. 
 
There are, however, unanswered questions about the nature and origin of large positive or negative waveforms that are sometimes 
seen under 5 ms latency at very high stimulus levels. E/M artifacts, transducer nonlinearity and ringing, amplifier ringing, unusual 
cochlear receptor potentials and vestibular potentials are all possibilities. 
 
Is there much clinical value in being able to differentiate hearing thresholds of, say, 90 vs 100 dB HL? The contribution to clinical 
management of such a discrimination is not obvious. Unless the benefit of such a distinction becomes established as substantial, it is 
reasonable to set a provisional maximum of 95 dB HL.   
 
AC Smin: 4kHz@25dBnHL (25dBeHL), 2kHz@30dBnHL (25dBeHL), 1kHz@35dBnHL (25dBeHL), .5kHz@40dBnHL (25dBeHL) 
BC Smin: 4kHz@25dBnHL (25dBeHL), 2kHz@30dBnHL (25dBeHL), .5kHz@25dBnHL <1yr old, .5kHz@30dBnHL >1y old (25dBeHL) 
 
AC Smax: 4kHz@95dBnHL (95dBeHL), 2kHz@100dBnHL (95dBeHL), 1kHz@105dBnHL (95dBeHL), .5kHz@105dBnHL (90dBeHL)  
3.06 AMPLIFIER GAIN & KALMAN WEIGHTED AVERAGING 
 
A fixed preamplifier gain of 150,000 is set in the Integrity software and can not be changed. If the EEG noise level increases, the 
proper course is to determine the cause of the increase and make every effort to fix it at the source.  
 
Large myogenic artifacts in the ongoing EEG are the most common cause of inefficient and inaccurate ABR thresholds. In the past, 
the Audiologist had the option of adjusting artifact rejection to provide cleaner sweeps when necessary. Using Kalman weighted 
averaging, artifact rejection is not necessary and is therefore disabled, but collection still needs to be paused if large myogenic 
artifact is seen in the EEG. Due to the nature of Kalman-weighted averaging, there is no longer a need for an artifact rejection 
criterion. Large discrepancies between number of stim and noise adjusted sweeps means either there is too much noise and 
intervention is required, or that the collection was paused. See Section 3.11 for details on actual versus adjusted noise sweeps.     
 
Collection should be paused if intervention is deemed necessary. A quiet, flattish EEG trace with fluctuations that occupy only a 
small fraction of the distance between the display y-scale (which at minimum is 0.15 µV but fluctuates with increasing noise) 
should be regarded as good because it is quiet. 
3.07 DIMINISHING RETURNS IN AVERAGING 
 
The standard model of signal-to-noise ratio enhancement by averaging is one of a constant ABR (signal) added to random EEG noise 
that has constant variability over time (the statistical term is ‘stationary noise’), as reflected in its underlying standard deviation (SD). 
Under that model, as the tracing progresses the value of the underlying ABR does not change because the average value of a 
constant is the constant itself. But, the standard deviation of the averaged noise decreases as a result of partial cancellation of 
positive and negative noise values. For standing averaging, after N sweeps, the SD of the averaged noise is the original SD divided by 
the square root of the number of adjusted sweeps. Therefore, the signal to noise ratio (SNR) increases by the square root of N; this is 
known as the ‘root N law’. Because the improvement in SNR follows the root N law, the amount by which the SNR improves in a 
fixed period of time decreases steadily as averaging progresses. What this means is the larger number of sweeps contributing to a 
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The Integrity system calculates and displays the SD of the A minus B buffers as it accumulates and this value is referred to as the 
‘residual noise’ or RN of the tracing. If the EEG noise is truly stationary, the RN will tend to decrease steadily as the number of 
adjusted sweeps increases. The value will fluctuate, because the EEG is random noise and samples from a random process will show 
some variability, but the larger the N, the smaller the fluctuation will be and the smaller the RN itself will be. Note that if the EEG at 
the baby’s head is contaminated by bursts of myogenic noise with a large SD, this makes the source noise non-stationary and 
violates the root N law. The Integrity system uses Kalman-weighted averaging which optimizes the reduction in RN. See section 3.11 
ACTUAL VS ADJUSTED NUMBERS OF SWEEPS below. 
  
The Table below shows model data for the RN in nV, which is basically the amount of wiggle in the tracing that is due to noise, after 
standard averaging for various numbers of sweeps, along with the reduction in RN achieved by adding another 1000 sweeps. Every 
extra 1000 sweeps takes about half a minute of test time. For example, going from 1000 to 2000 sweeps reduces the RN by 25 nV or 
about 50 nV of improvement per minute. In contrast, going from 4000 to 5000 sweeps reduces the RN by only 1 nV, or about 2 nV 
per minute. This means adding another 1000 sweeps to the first 1000 is more than twenty-five times as effective in reducing noise in 
the tracing as adding another 1000 to an existing 4000 sweeps. 
 
Table 1: This example is constructed for a fairly noisy EEG situation with a source noise SD of 2 microvolts or 2000 nanovolts (nV), 
yielding an RN of 58 nV after recording 1000 sweeps (2000/root 1000): 
 
Sweeps RN (nV) 
Change per 
1000 sweeps 
1000 58 - 
2000 33 25 
3000 31 2 
4000 28 3 
5000 27 1 
6000 26 1 
7000 24 2 
8000 24 0 
 
Now consider the best way to spend about two minutes of collection time. You could gather about 4000 sweeps, which at 37.7 per 
second means about 100 seconds. An alternative is to do two separate tracings of about 2000 sweeps. As will be shown in the next 
section, you would have two sets of A and B waveforms, with 1000 sweeps each, giving you the ability to assess the reproducibility 
of the waveforms. 
 
The practical bottom lines are: 
 
 Averaging rapidly becomes less and less efficient the more you do it. 
 If things are not becoming clear by about 6000 sweeps total in the compound tracing they will not become much clearer 
within a practicable amount of test time, so change the stimulus conditions (eg., go up 10 or 20 dB) instead of continuing 
on with more collections. 
 A tracing with 2000-4000 noise adjusted sweeps provides 1000 to 2000 noise adjusted sweeps in each of the A and B 
primaries allowing subjective assessment of waveform reproducibility. Nothing is lost as long as the A and B primaries 
are themselves of reasonable size and there are very few pairs of them. Assessing reproducibility across say 5 or 10 even 
smaller sweep count tracings is not recommended and is a completely different and more difficult pattern recognition 
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3.08 SUITE OF TRACINGS 
 
With the Integrity what is initially collected is a compound tracing that generates two separate primary tracings, referred to as A and 
B. The required display or plot for the tracings for a given stimulus is as a level-specific grouping called the suite of tracings; the 
compound tracing will be on top with its component primaries A and B immediately below, stacked closely together but with some 
separation such that A and B are individually identifiable. The A-B (A minus B) tracing is to be displayed directly below. This can be 
achieved by using the Clinical Sort tool found on the Integrity user interface.  
 
Figure 3.08.1 A compound tracing 
must never be plotted overlapping 
its component A and B primaries, 
because that creates a false 
illusion of reproducibility, which is 
inevitable because the tracing is 
made up from its A and B 
components.  the compound 
tracing is usually the best single 
sample estimate of the true 
waveform. It is, essentially, just a 
‘grand average’ of two 
measurements that simply happen 
to be waveforms collected 
simultaneously. The Clinical Sort 
feature is the “C” circled in blue at 
the top right of the figure, which 
allows for proper layout of the 
tracings. 
Some minor tweaking of the 
position of the waveforms may be 
necessary after using Clinical Sort, 
in order to avoid the waveforms 
being superimposed, and to 
improve the ability to follow 
individual waveforms.  
 
 
A-B should be displayed for all tracings. By subtracting B from A it provides a visual representation of the noise and helps to verify 
NR vs RP. 
 
Note: the number of actual and adjusted sweeps, stimulus parameters, as well as RN can be located at the bottom of the test screen 
under Test Conditions.  
3.09 RESPONSE JUDGEMENT CATEGORIES & CRITERIA 
 
For any given stimulus route (AC or BC) and frequency, there are three common overall outcomes from any given ABRA session:  
 
 The ABR threshold (TH) is considered bracketed. A bracket is complete when there are RP and NR tracings separated by no 
more than 10 dB; the RP then becomes TH. It is acceptable to have the occasional bracket which includes one INC step in 
between RP and NR. This would mean that the TH tracings is separated from the NR tracing by 20 dB. This should be the 
exception. If this occurs more than very occasionally, consultation with a DTC is required.  
 There is no response at the highest level tested, which yields a lower bound for the (unknown) threshold (TH > highest level 
tested), or 
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Both the levels and the crucial bracket or boundary decisions must be documented routinely (see Figure below). This greatly 
facilitates reporting, retrospective review or evaluation of threshold estimates, of particular value in serial testing or in cases of 
unexpected change or discrepancy across measurements. 
 
Response detection judgements at each threshold bracket level and at each range boundary must be categorized and annotated 
as ‘Response-Positive (RP)’, ‘Threshold (TH), ‘No Response (NR)’ or ‘Inconclusive (INC)’. For each such stimulus level, there is one, 
single response judgement that applies to the entire set of tracings at that given level. RP, TH, and NR decisions reflect high 
confidence and are NOT the result of guesswork or a ‘balance of probabilities’. INC decisions are required whenever RP, TH, or NR 
can not be determined with confidence. 
 
An RP decision at an Smin requires: 
 
 At least one tracing of a minimum of about 2000 sweeps that has a negative-going deflection with peak-to-trough 
amplitude of at least 50 nV (0.05 µV) in the interval 6 to 20 ms. Note: this is the latency range for 4k through .5k, a possible 
2k RP at 20 ms would be highly suspect, as would a .5k RP at 6ms. Note that if subjectively repeatable deflections are seen 
at several locations throughout the tracing, the repeatability at a plausible response latency loses significance and reliance 
on latency trend with stimulus level becomes more influential.  
 Deflection latency no less than that of the similar feature for the same stimulus at any higher level that gave an RP decision. 
 Absence of any NR decision for the same stimulus route and frequency at a higher level in the same test session  
 
A TH decision at any upper bracket level requires:  
 At least one tracing of a minimum of no less than 2000 sweeps and often closer to the ~4000 maximum, that has a 
negative-going deflection with peak-to-trough amplitude of at least 50 nV (0.05 µV) in the interval 6 to 20 ms. Note: this is 
the latency range for 4k through .5k; a possible 2k RP at 20 ms would be highly suspect, as would a .5k RP at 6ms.  
 Deflection latency no less than that of the similar feature for the same stimulus at any higher level that gave an RP decision. 
 Presence of a NR decision for the same stimulus route frequency 10 dB lower in the same test session (or rarely 20dB lower, 
with INC in between).  
 
For TH decisions, wave V should be marked on the tracing where the Audiologist believes it to be for infants with hearing loss. 
The purpose is to aid in the clinical decision process as it helps to understand the reasoning behind RP and TH judgements. This is 
especially important for records sent to DTC for review.    
 
An NR decision at any lower bracket level or at an Smax requires: 
 
 At least one tracing of a minimum of about 4000 sweeps for which the maximum and minimum amplitude in the range 6-21 
ms differ by no more than 0.05 µV (50 nV), and 
 For which the corresponding A and B buffers, and A-B (A minus B) are subjectively ‘flat’, and 
 Absence of any RP decision within the same test session at the same level or lower. 
 
An INC decision applies to any scenario that is not RP, TH, or NR. Common examples are somewhat noisy tracings that are not quite 
flat enough to qualify as NR, or tracings where a potential RP appears present in only one primary waveform, but not in the other. In 
either case, the best action is usually to go louder. In the Search phase, a large step up of 20-30 dB is indicated; in the Bracketing 
phase a smaller step size is usually better. It is permissible to have the occasional INC separating a TH and NR. However, this means 
that the resultant audiogram will only be resolved to within 20 dB for that frequency, which will impact the accuracy of degree of 
loss and the effectiveness of the ensuing intervention. For this reason, a substantial effort should be made to resolve any INC 
decision after all mandatory and conditionally mandatory elements are completed. INC can usually be resolved by collecting an 
additional compound tracing at the intensity in question and summing the two tracings together if needed. This summed tracing 
should be the one labelled. Remember that a tracing that is not valid (e.g. electrode fallen off, baby awake and moving, less than 
1000 sweeps, etc) is not INC, but is simply uninterpretable and invalid and should not be used to make a decision regarding response 
presence or absence. 
 
Note that for TH and NR tracings, while a sweep count of 2000 is acceptable with a clear V-V’ deflection for RP, and a very quiet and 
flat tracing for NR, it is more common and generally recommended to have about 4000 adjusted sweeps (A and B primaries of about 
2000). While tracings with as few as 1000 adjusted sweeps (A and B with around 500 sweeps each) showing clear RP may be used in 
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the Search phase. Upper and lower brackets (TH, NR) and minimum levels (Smin) require between ~2000 to 4000 adjusted sweeps in 
the tracing (~1000-2000 adjusted sweeps in A and B buffers). See section 3.11 for important notes about numbers of sweeps 




An NR decision is NOT simply the absence of an RP or TH decision. For a valid NR decision, it must be true that if a response were 
present then it would surely have been recognized. Therefore, to decide on NR or TH, EEG noise conditions and averaging tactics 
must be good enough to detect the minimal ABR waveform required for an RP or TH decision.  
3.10 RESIDUAL NOISE (RN) LEVELS & ‘NO RESPONSE’ (NR) JUDGEMENTS 
 
The data model underlying averaging is that the signal (ABR) is identical for each stimulus and the electrical noise from all sources 
(brain, musculature, etc.) is random with constant standard deviation (SD), a condition called ‘stationarity’. In that case, the signal to 
noise ratio (SNR, the ratio of ABR amplitude to noise SD) approximately increases on the Integrity from its value in a single sweep by 
the factor root N, where N is the number of noise adjusted sweeps in the tracing. The ABR is assumed constant but, in contrast, 
there is partial cancellation of the stationary random noise. As N increases, the tracing becomes less and less variable, converging 
either to a flat zero line or to a nonzero response waveform. The averaged noise on the Integrity is called the ‘Residual Noise’ or RN 
level and is obtained by calculating the SD of A minus B buffers during the post-stimulus period 1 to 13 ms. The RN is displayed 
continuously as the tracing progresses and its value in microvolts (µV) is printed in the test conditions tab on the bottom of the test 
screen. 
 
The earlier section on artifact rejection addressed an issue of bursts of high-amplitude noise in a background of quiet EEG. This is a 
situation called noise ‘non-stationarity’. For standard averaging, it violates the root N law because a burst of high noise can cause the 
RN to suddenly increase dramatically. The Integrity system optimizes this problem by using Kalman-weighted averaging which 
assigns a lower weight to sweeps that contain higher noise. A lower weight reduces the contribution of a noisy sweep to the tracing. 
During noisy periods, the adjusted number of sweeps (reported as Neq.) will increase more slowly than the actual number of 
stimulus presentations (reported as N). 
 
In the real world, a ‘small’ ABR would be no bigger than about 0.1 µV (100 nV) peak-to-peak for the positive-negative complex V-V’, 
typically the most prominent ABR waveform feature in threshold estimation. The SD of fairly quiet EEG in infant ABR measurement is 
about 1 µV, so the SNR in the raw EEG (a single sweep) is about 0.1. After about 2000 sweeps, for which root N is about 45, the SNR 
Figure 3.09.1 Example of proper response judgement and labelling. 
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is 4.5 and the SD of the averaged noise would be about 1/45 µV which equals 0.022 µV or about 22 nV. A random process with mean 
zero and SD 0.022 µV will fluctuate over time within about ± 2 SD from a zero baseline, or ± about 0.044 µV. An averaged ABR of 
about 0.1 µV would be easily visible and usually highly replicable. In fact, it can be shown that an ABR V-V’ as small as only about 50 
nV peak-to-trough will be detectable most of the time, given typical, quiet EEG and an efficient averaging protocol based on  
tracings of about 2000-4000 sweeps. 
 
If we require that a response of only 0.05 µV must be detectable with quite high probability, then we require that the RN be no 
greater than about 0.020 µV; this will mean that the V-V’ for the smallest response deemed acceptable is at least twice the RN, 
which adds up to reasonable detectability in a reasonable time-frame for a typical signal, noise and test time scenario.  
It is easy to fail to detect a genuine ABR; all that is required is to do too little averaging. But in order to decide that a response is 
absent in a valid and reliable way, we must achieve sufficient statistical power to be able to detect the smallest ABR that would be 
considered as of interest. Only then can failure to observe any such ABR be interpreted as that it is really not present. If we define 
the minimum ABR to be 0.05 µV, then it can be shown statistically that an RN of about 0.020 µV is a reasonable net target for the 
averaging at any given stimulus condition for which we wish to conclude that there is no response. 
 
An RN of about 0.020 µV is a reasonable target to be able to make an NR decision, but it is not a ‘hard’ target in the sense of being 
rigid or mandatory. 
 
Except when very close to ABR threshold, the RN has less influence on RP decisions than it does on NR decisions. RP decisions are 
based primarily on the SNR and response reproducibility. When well above ABR threshold, large responses can be identified with 
confidence even if the RN is above 0.03 µV. At threshold, however, a quiet EEG and a low RN are necessary in order to detect a small 
ABR.           
3.11 ACTUAL VS ADJUSTED NUMBERS OF SWEEPS 
 
The minimum number of adjusted sweeps in any compound tracing must be targeted to be no less than about 2000 sweeps.  
When the Integrity accumulates a tracing while computing the RN, it displays the updated tracing and RN. Therefore, all collected 
sweeps contribute to the final display and parameter listing and therefore no time is wasted regardless of where the sweep count 
stops.  
 
It is important to monitor the discrepancy between the number of sweeps and the number of noise adjusted sweeps. If the 
tracing has not been paused, a large discrepancy will mean poor sweep collection and intervention is required.   
3.12 TONEPIP ABR THRESHOLD DEFINITION 
 
For any tonepip route (AC or BC) and frequency, the ABR threshold, denoted as TH, is the lowest level judged as RP (the ‘upper 
bracket’ level) for which there is a level either 5 or 10 dB lower that is judged as NR (the ‘lower bracket’ level). If the lowest RP 
level is a minimum stimulus level (Smin), then the ABR threshold is denoted as ≤ Smin and is an upper bound of a threshold range 
considered ‘within normal limits’ (WNL) for IHP purposes. Conversely, if the highest level tested is judged as NR then the ABR 
threshold is ‘ > NR level’ and NR level is the lower bound of a range. If NR level is a maximum stimulus level (Smax), the threshold 
cannot be specified. Very occasionally TH is separated from NR by one intensity step designated INC. This should be the 
exception. Time permitting, once all frequencies have been completed, an attempt should be made to resolve any INC tracings by 
a second tracing collecting at the same intensity. If INC occurs regularly, consultation with a DTC is required.  
 
In some ABR instrumentation, objective, statistical response detection criteria that are implemented and validated appropriately are 
not available. Implementations of a correlation coefficient in the Integrity system must not be used in IHP Assessments because they 
have not been properly validated for use with this protocol. Therefore, ABR threshold must be estimated subjectively. The reliability 
of this process is improved by extensive training, ongoing decision support, and a standardized and consistent protocol grounded in 
statistical decision theory and random process analysis. 
 
In practice, ABR threshold is defined using the V-V’ downslope as the key feature, because V-V’ is usually the most detectable peak-
to-trough component of the ABR waveform at stimulus levels near threshold. Note that there may not be any actual peak (local 
maximum) developed for wave V, nor any actual trough (local minimum) developed for wave V’. One or both of these may not 
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necessarily appear but, even when that is the case, a clear and reproducible downslope is a consistent feature of ABR presence. This 




Figure 3.12.1.  Clear ABRs for tracings at the minimum stimulus levels required by this protocol. 
The dB nHL levels shown are all equivalent to 25 dB Estimated Hearing Level (25 dB eHL). Note the marked increase in wave V latency 
and loss of fine structure at 0.5 kHz. The tracing with 2000 sweeps takes less than 30 seconds each. 
 
If earlier waves (eg., I or III) are clearly present but V-V’ is not, an ABR threshold cannot be defined in conventional terms because 
historically most normative ABR threshold data are based on wave V. Moreover, absence of V-V’ with present wave I implies 
retrocochlear pathology, for which ABR threshold inferences are inherently questionable. 
3.13 ESTIMATED HEARING LEVELS 
 
Tonepip ABR threshold estimates in dB nHL must be adjusted by the correction factors listed in Appendix G, in order to derive 
hearing threshold estimates in dB eHL. 
 
The core business of ABRA is the estimation of key puretone hearing thresholds in dB HL. This is based on determination of tonepip 
ABR threshold estimates in dB nHL, followed by adjustments that are based on known, normative statistical relationships between 
tonepip ABR and VRA-based behavioural thresholds. Note the changes for AC 500 Hz correction factor from the values previously 
listed in the 2016.02 IHP ABRA protocol. 
 
ABR thresholds are generally not the same as true perceptual thresholds but they are usually good statistical correlates or predictors 
of them. The answers obtained in ABRA are point estimates of true puretone thresholds in a statistical ‘maximum likelihood’ sense, 
that is, in answer to the question ‘given the observed ABR threshold estimate, for what value of the (unknown) true puretone 
threshold would the observed ABR threshold have the highest probability?’. While a more complete outcome would be a probability 
distribution over a range of dB HL values, the simplicity of single point estimates is popular. What should not be forgotten is that 
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The correction factors used in this protocol have been derived by statistical re-analysis of published and unpublished normative 
data, particularly that of Stapells and his colleagues. The corrections are similar to those used in the British Columbia Early Hearing 
Program, but are not identical in every case. The correction factor for a given stimulus route and frequency is based on the 
estimated population median difference in dB between reliable, paired ABR and VRA thresholds in large, representative groups of 
young infants. The overall value of the median difference (ABR minus VRA) is rounded to the nearest 5 dB, for simplicity of use. The 
median is more appropriate than the mean because the difference distributions at various values of the ABR threshold are 
systematically skewed with occasional extreme values. The ancillary regression analysis testing for linear and nonlinear trend has the 
behavioural threshold as the dependent variable and the ABR threshold as the independent variable. The range of the independent 
variable must be restricted from about 30 dB nHL to about 90 dB nHL. Between those limits there is an approximately constant 
relationship between the two types of threshold. Below 30 dB nHL, there is no apparent relationship at all, and above about 90 dB 
nHL the relationship is distorted by distributional censoring of either the ABR or VRA thresholds at device intensity maxima. 
Extension of regression analysis below 30 dB nHL introduces systematic, segmental nonlinearity that renders a straight-line fit over 
the entire range of dB nHL inappropriate. This was validated during the comparison of the Biologic NavPro and Vivosonic Integrity 
systems prior to program-wide implementation. 
 
In conventional, sensory hearing loss of the type affecting first the outer hair cells then the inner hair cells as well, there is a weak 
tendency for the median threshold difference to decrease progressively above about 70 dB nHL. The convergence is approximately 
linear, but is clinically insignificant relative to other sources of bias and imprecision in behavioural threshold estimation (such as 
inflation of VRA thresholds due to responsiveness effects).    
 
The IHP correction factors are valid only for the stimulus parameters and recording techniques specified in this protocol. They do not 
apply to estimation of hearing levels lower than the IHP target disorder limits and they cannot be assumed to apply to stimulation 
and recording methods that do not follow this protocol. It is important to note that publications to date purporting to address the 
appropriateness of IHP adjustment factors have not satisfied these criteria, nor have the data analytic methodologies used been 
comparatively evaluated with respect to validity, bias and precision. 
3.14 THRESHOLD SEARCH & BRACKET PHASES 
 
Each ABR threshold determination sequence can be conceptualized as a Search phase followed by a Bracket phase. In the Search 
phase, the goal is to reach the threshold upper bracket level very quickly. In the Bracket phase the emphasis is on response 
detection decision accuracy, especially a very low rate of false positive response detection at the upper bracket. It follows that 
stimulus level tactics, averaging tactics and response detection decisions are different in the two phases. 
 
The Search phase is guided by the known epidemiology of PHL in newborns and infants, known properties of OAE and ABR screening 
tests, important results of statistical decision theory and clinical factors. The benefits of reaching an RP decision quickly are many, 
but the positive predictive value of AABR screening failure is small, especially in well babies who have no risk indicators. Thus, the 
Search phase typically starts at 2 kHz (arguably the single most important frequency psychoacoustically) at the Smin (because most 
babies tested will have hearing within normal limits) and then ascends in initially large but rapidly diminishing stimulus level step 
sizes. Search phase ascent in 10 dB steps (or, worse still, 5 dB steps) is usually extremely inefficient and is strongly discouraged 
unless there is a very strong clinical rationale.  
 
Decision theory shows that an optimal strategy for identifying a random number distributed uniformly over the range 40 to 100 dB 
with only yes-no questions is a series of questions ‘is it less than x?’ where x approximately bisects the current range of uncertainty. 
This is a crude but reasonable model of the Search phase, with an ABR RP as the answer ‘yes’ and an NR as the ‘no’, after first asking 
whether the mystery number (the true ABR threshold) is 30 or better. 
 
The clinical speculation that large ascending steps will awaken a sleeping baby is not valid for initial 30 dB ascent, nor for a second 
step of at least 20 dB. At levels above about 80 dB nHL, 10 dB steps are acceptably efficient. Close monitoring of the baby’s EEG 
myogenic noise level and physical behaviour allows for timely intervention, if needed.    
 
In general, number of accepted sweeps may be smaller in the Search phase. If after a large-step ascent there is no clear response, it 
is generally more efficient to go up again rather than replicate. Replication of tracings should be a rarity in the Search phase.  
3.15 NUMBER OF SWEEPS & TRACINGS 
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It is recommended that any tracing should not contain less than about 2000 or more than about 4000 adjusted sweeps. For any 
given stimulus condition, no more than three tracings or a total of about 12000 sweeps should be used. The only reasonable 
exception to this maximum is a situation in which one of the primaries (A and B buffers) in each tracing is clearly different from the 




For any given AC stimulus frequency and route, the usual starting condition is at an Smin, except for 4 kHz at which it is logical to 
start 10 dB above a previously obtained upper bracket level at 2 kHz. 
 
The first and most critical tracing might be judged as potentially an RP after as few as about 1000 sweeps. In that case, usually there 
would be an immediate attempt at conversion to a true RP by continuing to collect that tracing until sweep count was ~2000-4000.  
In contrast, the first tracing might yield a potential NR, after only 2000 sweeps. If it is flat or nearly so, it is usually more efficient to 
go up 30 dB. If the actual ABR threshold elevation were small, going up 30 dB would often give a potential RP after only 1000 
sweeps, confirming that the loss is minor and justifying an attempt to convert the provisional NR to a true NR at the Smin. If the up-
30 tracing also gives a potential NR, which would occur in a significant hearing loss, the ascent continues. This will avoid multiple 
tracings at the Sin when there is no indication yet that the threshold is even near-normal. Persistent, repeated recording at the Smin 
is not usually the most efficient way to prove whether hearing is WNL or not. The reason is that the initial potential NR has already 
increased the probability of hearing loss substantially beyond that of simply failing a prior AABR. 
 
If there is a potential NR at Smin and Smin+30, the next step is to go up another 20 or 30 dB. Ascent in 10 dB steps is rarely 
appropriate, except near Smax. Given a potential NR at the Smin and a potential RP at Smin+30 or Smin+60, going up further or 
pursuing conversion of a potential RP to a true RP is a judgement call that depends on multiple cues, including the perceived 
likelihood that a potential RP is real, given its size, morphology, latency, and growth pattern. The ability to predict correctly most of 
the time whether to replicate recording or continue an ascent is a crucial clinical skill that usually grows with experience and critical 
self-evaluation of tactical efficiency.  
 
Bracket Phase 
An upper bracket RP must be based on at least one tracing, with ~2000-4000 adjusted sweeps.  
 
A lower bracket NR (or at Smax) tracing should not be based on less than about 4000 total sweeps. When judging the replication of A 
and B for a potential NR, the credibility of a subjectively flat record is inherently better than that of a questionable, response-like 
deflection. Comparing the compound tracing and its component primaries to the A-B (A minus B) is generally helpful. There are 
many ways in which a false impression of response may arise from constructive superposition of random noise but, if there is a 
genuine response present, a flat record would require that the random noise happened to summate in exactly the right antiphasic 
waveform needed to cancel out the true ABR.  
3.16 SUMMING COMPOUND TRACINGS 
 
Two compound tracings that are collected for a given frequency/intensity may be summed together to create one tracing, referred 
to as the SUM. The handle of the summed tracing will indicate which two compound tracings have been added together to create 
the sum. This sum will result in the primaries of each tracing being added together (summed A and summed B primary waveforms).  
 
This tool is particularly useful for resolving INC tracings. The protocol allows for the occasional INC judgement between TH and NR, 
but it stipulates that once all mandatory and conditionally mandatory elements are completed, effort should be made to resolve any 
INC tracings. An additional tracing can be collected, and if needed summed with the earlier INC tracing. The summed tracing often 
yields a clear NR or RP. However, it is important to note that any compound tracing that is of poor quality (e.g. large artifact, noise, 
poor insert positioning, etc.) should not be summed. 
 
Additionally, this tool may be helpful in situations where in the search phase a given compound tracing was only collected to ~2000 
sweeps, but as the ABR progresses that intensity becomes a potential lower or upper bracket and a full ~4000 sweep tracing is 
desired for making a confident judgement. In this case, a second tracing at the same level should be collected with another ~2000 
sweeps and summed with the first one to make a ~4000 sweep tracing.  
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Compound tracings may be summed during the ABR collection, or afterwards when reviewing the ABR from the database.  
3.17 THRESHOLD BRACKET STEP SIZE 
 
For a completed ABRA, the final threshold bracket step size for all required AC frequencies must be no greater than 10 dB. Time 
permitting, once all AC/BC frequencies are completed, 5 dB steps sizes are recommended starting with TH above 70dB eHL. The 
increased precision may be relevant to accurate prescription of amplification, if the residual dynamic range is very limited. It also 
satisfies the level-dependent correction for estimating perceptual thresholds that has been shown in data comparing ABR and VRA 
thresholds in children with hearing loss (e.g., McCreery et al, 2015). However, frequently it is challenging to make clear RP and NR 
decisions with steps of only 5 dB, which can cost valuable test time to little clinical benefit, and if the threshold is below 70 dB eHL 
the clinical benefit is negligible or zero (McCreery et al, 2015). Therefore, 5 dB steps should not be used at levels below 70 dB eHL 
unless all core thresholds have been estimated satisfactorily to 10 dB brackets and hearing loss type(s) have been determined. 
3.18 CONFIRMATION OF UPPER BRACKET RESPONSE  
 
It is stressed that if there is any residual uncertainty about the presence of response at a threshold upper bracket level, a tracing 
of ~1000-2000 sweeps must be done at a level 10-20 dB above that upper bracket level, where allowable by Smax. Response 
presence must be clear in that tracing, in order to accept the threshold bracket as valid.  
 
If there is any doubt at all about ABR positivity at a candidate TH level, going up by 10- 20 dB for rapid response confirmation and 
latency guidance, rather than simply doing more tracings at the questionable bracket level is essential. The choice of step size (10 or 
20 dB) is guided by the level of doubt, the nearness to Smax, what is known about the TH at adjacent frequencies, and the same 
frequency in the other ear.  
3.19 STRATEGY OF STIMULUS FREQUENCY & ROUTE  
 
While test strategy must be responsive to many factors in the individual child and context, the following points reflect common 
principles of effective and efficient testing. It is assumed that cursory otoscopy indicates no canal occlusion and the baby is asleep: 
 
 In the absence of either prior IHP ABRA results or atresia/microtia/canal stenosis, testing must begin by AC at the 2 kHz 
Smin of 30 dB nHL in a Referred or otherwise suspect ear. In a baby who bypassed screening because of very high risk of 
PHL, both ears are assumed to be suspect. In the case of atresia/microtia/canal stenosis start with BC at 2 kHz Smin of 30dB 
nHL 
 
 If both ears are suspect and ear switching is practicable, pick any ear and do 2k at 30 dB. If it is RP, switch ears and do 2k30 
in the opposite ear and continue. If 2k 30 result in the first ear is NR, continue and switch later. Switching ears is usually 
easy in younger infants sleeping supine with two inserts in, but when the baby is in the caregiver’s arms special attention to 
positioning for ear accessibility and insert stability is needed.  
 
 If the 2 kHz Smin is RP, immediate shift to 4 kHz Smin is recommended, before shifting to Smin at 0.5 kHz. Responses at 4 
kHz are often very clear and confirmable quickly with smaller number of sweeps. Isolated hearing loss at high frequencies 
may be more common than formerly suspected and may foretell progressivity. 
 
 If AC 2 kHz is NR at 30 and 60 dB, go up to 80 dB. If still NR, go up to Smax 100. At this point it is important to determine the 
nature of the hearing loss; BC 2 kHz should therefore be completed next. Note that the insert need not be removed in 
order to apply the bone conductor by hand to the test ear mastoid. The occlusion effect is negligible for ABR thresholds 
in young infants. 
   
 After checking BC, if 2 kHz is NR at Smin and at Smin +30 dB, prompt verification of insert placement, eartip occlusion, 
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 If the AC 2 kHz abnormality is valid and BC is also abnormal, follow the AC Search phase ascent to bracketing then switch to 
0.5 kHz at the Smin for Search and bracketing, before shifting to 4 kHz. If a conductive component is found at 2 kHz, then 
the accuracy with which AC thresholds need to be bracketed is discretional.  
 
 If BC at 2 kHz reveals a conductive component, a conductive component at 0.5 kHz may be assumed and its proof by 0.5 kHz 
BC is discretional. The converse is not true; if a conductive component at 0.5 kHz is proven, it cannot be assumed that 
abnormality at 2 kHz is conductive and absence of a sensory component at 2 kHz must be proven definitively. 
 
 If AC 2 kHz is normal and 4 kHz has been completed, switch ears wherever possible if both ears have referred on screening. 
The immediate clinical question at that point is whether the other referred ear is normal at 2 kHz.  
 
 The BC 0.5 kHz Smin has been changed to 25 dB with a 0 dB adjustment factor, reflecting current normative data on BC ABR 
in young infants under one year corrected age. 
 
 If 4 kHz is the only AC abnormality, 4 kHz BC testing must be done. 
 
 AC at 1 kHz must be done if there is a difference of 25 dB or more in the AC thresholds at 0.5 and 2 kHz in dB nHL. If the 
difference is less than 25 dB, testing at 1 kHz is discretional but not recommended unless all other ABR measurements have 
been completed.  
3.20 BC STIMULUS ARTIFACT 
 
The amount of electromagnetic (E/M) BC stimulus artifact is variable across babies and across Audiologists. It tends to be most 
intrusive at 0.5 kHz because of the electroacoustic properties of the transducer and the relatively long stimulus duration at that 
frequency (about 10 ms). It is sometimes large at levels above about 40 dB nHL. Appropriate procedures to minimize BC stimulus 
artifact must be used. The most important steps are routing transducer leads and electrodes as far as possible from each other, 
keeping electrode leads close together and pointing away from the transducer, and the electrode impedance factors noted earlier.   
If the AC threshold at 0.5 kHz were, say, A dB eHL then BC testing capability up to that level would be desirable. Maximum dB eHL 
level for BC at 0.5 kHz is about 55 dB, but stimulus artifact is often very large at that level for some babies. If BC 0.5 kHz is NR at its 
Smin, the next step is to go up as high as possible, up to including A dB eHL or the level of maximum tolerable artifact, whichever is 
the lower. The closer the highest acceptable stimulus level is to A, the more helpful the BC ABR is in resolving conductive and 
sensorineural hearing loss components.  
 
BC-evoked ABRs that are near threshold at 0.5 kHz typically have V-V’ latencies of about 10 ms or more, so even a large stimulus 
artifact of 10 ms total duration will not necessarily render the ABR undetectable. At 2 kHz, the artifact tends to be smaller and its 
duration is only about 2.5 ms, so it is rarely a problem.  
3.21 BC RESPONDING COCHLEA INFERENCE  
 
BC measurements must be done with transducer placement on the mastoid of each desired test ear, using two forehead-mastoid 
recording channels (Fz - M1 and Fz - M2). The responding cochlea is inferred by comparing the ABRs in the channels ipsilateral and 
contralateral to the test ear (see example in the figure below). 
 
In contrast to standard BC testing in adults, in infants the BC transducer must be placed on each test ear of interest. Transcranial 
acoustic field patterns differ in infants, the result being as if there were transcranial attenuation differences as high as 20 dB and 
highly variable across subjects. The exact mechanism of these differences may be dynamically very complex, but the net effect is 
superficially as if the bony plates of the skull were less strongly coupled in infants, to varying degree. 
 
Using two forehead-mastoid channels, if one channel shows a clear ABR wave V-V’ and the other channel does not, the response 
channel indicates the responding cochlea. This is a puzzling phenomenon that is not well-understood, bearing in mind that 
conventional wisdom is that wave V is primarily forehead-registered and the two channels have the forehead in common. Clearly, 
lateral differences are attributable to mastoid field effects on the net differential waveforms in each channel. This effect is most 
apparent at low stimulus levels and in young infants, but the detailed effects of level and age are not fully understood. 
 
 




Figure 3.21.1 Inference of the responding cochlea in 
BC testing. 
In this example, there is clear contralateral 
dominance, showing that the right cochlea is 
responding preferentially.  
 
If there is response in both channels, wave V 
latencies are compared and the shorter latency 
indicates the responding cochlea. In the event of no 
clear latency difference, response amplitude may be 
used if there is a clear amplitude difference, the 
larger amplitude indicating the responding cochlea. 
If there is no clear difference in latency or amplitude, 
stimulus levels should be reduced in an attempt to 
isolate the responding side, even by going below the 
BC Smin if necessary. If none of these manoeuvers is 
successful, then it is necessary to resort to 
contralateral insert noise masking. 
If there is response in both channels and the 
responding cochlea is inferred to be contralateral, 
the presence of response in the ipsilateral channel 
does not imply that the cochlea on the stimulated 
side is necessarily responding. The ipsilateral 
waveform could be a shadow response from the 
contralateral cochlea. The converse is also true: if 
the inference is that the responding cochlea is 
ipsilateral, presence of a response in the 
contralateral channel does not imply that the 
contralateral cochlea is also responding. 
3.22 BC CONTRALATERAL MASKING 
 
Normative data for contralaterally masked ABR tonepip thresholds are limited for BC stimulation, one reason why in the IHP, 
contralateral masking is not used as the first-line approach to ensuring activation of the desired cochlea. The need for contralateral 
masking in tonepip ABR threshold estimation is limited to situations in which: 
 
 Channel comparisons have not proved informative for inference of the responding cochlea in BC testing,  
 Interaural AC threshold differences of at least 60 dB at any given frequency. 
 
For the BC situation, wide-band insert masking at 60 dB is usually appropriate. For the situation of large interaural threshold 
difference, the concern is that an RP at a very high stimulus level in the poorer ear could result from cross-activation of the 
contralateral cochlea. This is only a possibility given direct extra-cranial acoustical leakage and a stimulation level exceeding about 
80 dB nHL in the poorer ear, such that the effective AC stimulus to the contralateral ear is at least 20 dB nHL. This may be less 
problematic than it appears, because upper bracket RPs at high levels in ears with severe sensory losses usually show well-defined 
responses with relatively short latencies just above the ABR threshold, whereas contralateral responses would have latencies and 
waveform characteristics more typical of low dB nHLs.  
3.23 ELECTROMAGNETIC 60 HZ  ARTIFACT & NOTCH FILTERING 
 
Systematic procedures must be in place to minimize contamination of tracings by 60 Hz power line artifact from sources within 
the test area. 
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ABR threshold estimates can be seriously compromised by the presence of power line artifact at 60 Hz. Such artifact is usually 
sinusoidal with a typical period of about 17 ms. Power line artifact is most problematic for threshold measurements at 0.5 kHz, 
because of the artifact duration and the similar morphology of 60 Hz artifact and near-threshold ABRs at that frequency. However, 
large 60 Hz interference can render tracings uninterpretable or unreliable for any tonepip frequency and higher harmonics of 60 Hz 
may be present. The best fix for 60 Hz contamination of tracings is to avoid or at least minimize it by controlling its sources and 
pickup. 
 
When 60 Hz artifact is present, there is often an environmental or procedural issue that can be identified and addressed. To reduce 
problematic near-field 60 Hz electromagnetic radiation pickup, the baby and the ABR electrodes should be as far as possible from 
the closest live power outlet (used or unused) and essential power leads. Outlets that are never used should have metal cover 
plates. Non-essential power leads should not be plugged into outlets. Long power leads should NOT be coiled; the least-radiating 
configuration is planar and Z-folded like a concertina. 
 
E/M artifact pickup generally increases, the larger the area of the loop formed by the inverting and noninverting electrode leads, the 
baby’s head and the headbox. The electrodes should be physically arranged to run as close together as possible to the headbox. In 
any given test area, changing electrode lead positions and orientations may change pickup levels significantly but the absolute 
amount of pickup will vary from baby to baby, due to multiple factors, especially electrode impedance asymmetry.  
Tracings always must be inspected for possible 60 Hz artifact. Suspicion is high if a smooth, slow wave is large and clearly begins in 
the first 10 ms of a tracing. If suspected, the stimulus condition should be repeated immediately with the insert tube clamped or 
detached and moved away from the transducer. If the slow wave remains then it is probably not a physiologic response. 
Procedures to reduce or eliminate the source of the artifact must be implemented, such as those outlined in the preceding section. 
If large 60 Hz artifact cannot be eliminated, the 60 Hz notch filter may be tried. The use of that filter must not be routine and must 
be documented. Consultation with a DTC is strongly recommended if 60 Hz artifact problems are persistent. 
3.24 ABRA UNDER GENERAL ANAESTHESIA 
 
ABR testing under general anaesthesia (GA) poses some unique challenges. The environment has multiple hazards that run the risk 
of reducing the ability to find responses at low intensity levels. Electrical artifact must be carefully monitored, reported, and 
managed as far as possible. Environmental noise is another pitfall. There are generally at a minimum two additional people in the 
room—anesthesiologist, and RT/RN at the patient’s head talking, with equipment noise from monitors etc. also positioned at head 
level. In some instances, the room may have three or more additional people—surgeon, interns, nurses— all talking. There may be 
pagers and telephones ringing, and in some locations overhead announcements. Clearly, environmental noise must be managed. 
The audiologist needs to be able to request silence, to have monitors at the softest level acceptable, and to have any additional 
noise sources managed as best as possible. As with any instance of non-adherence to the ABRA protocol, it must be clearly and 
completely documented in the chart.  
Another important aspect of ABR under GA that must be considered and documented is whether the ABR was the sole procedure, or 
was done in combination with other procedures. This becomes particularly important when the ABR is performed in combination 
with ENT procedures such as myringotomy, tube insertion, and suctioning of the outer and/or middle ear. Temporary threshold shift 
(TTS) from suctioning is well documented. The only way to ensure that this has not occurred is to measure BC before and after the 
procedure. This is not always feasible due to time constraints, but any elevated AC or BC threshold after suctioning is suspect. Dry 
myringotomy does not pose the same threat of TTS but does run the risk of blood in the canal. Clearly, in the case of myringotomy, 
or myringotomy with tube insertion, otoscopy must be performed after the procedure to ensure the canal does not contain blood. 
Without this confirmation, elevated AC thresholds are suspect. Ciprofloxacin and dexamethasone (Ciprodex) drops are generally 
used following myringotomy with or without tubes; obviously their use renders elevated AC results invalid. Again, all of this must be 
documented in the report. 
Other procedures at the patient’s head, due to surgical draping, may make inspection of the electrode placement, insert tip 
placement, and BC placement difficult or impossible. If elevated thresholds are found, and draping or other hazards may have 
impeded careful inspection of placement, this must be documented.  
Finally, if previous audiological testing exists for a given patient, it must inform the testing strategy for the ABRA under GA. ABRA 
under GA poses some risk to the child, is a finite and relatively costly resource often with long wait times, and is usually performed 
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under difficult conditions with significant time constraints put on the audiologist. Consequently, the IHP audiologist must carefully 
and completely review previous audiological results and have a clear and detailed plan for what needs to be collected and a strategy 
for how best to accomplish this. This needs to be documented. An ABRA under GA performed by an IHP audiologist for IHP purposes 
that fails to meet this requirement could be considered an adverse event and result in an adverse event review. 
For an ABR assessment collected under general anaesthesia to be accepted for IHP purposes, it must meet protocol requirements 
with the exception of test environment (1.24). It is understood that other deviations from protocol might be necessary, but as with 
any deviation in any circumstance, these must be documented. Additionally, specifically for ABRA under GA the following is 
required: 
• documentation that reasonable effort was made to reduce noise (e.g. request for silence or whispered voice during testing, 
reduced sound level on monitors if possible) and indication if acceptable quiet was achieved throughout the test. 
• indication of whether the ABRA was done in combination with other medical/surgical procedure. If yes, what those procedures 
were, when the ABRA was performed in relation to them, and any limitations they may have posed for the interpretation of the 
ABRA must be documented. This is particularly important for any procedure done at the ear including but not limited to 
suctioning, myringotomy, and tube insertion.  
• documentation of physician’s report of middle ear status if immittance is not performed by the audiologist.  
• Regardless of physician’s report of outer and middle ear status (which may have been done before other procedures and 
therefore not account for current conditions in the ear) otoscopy must be performed, preferably by the audiologist, immediately 
before the ABRA with documentation of results. 
 
 
SECTION 4: AUDITORY NEUROPATHY SPECTRUM DISORDER (ANSD) SUB-PROTOCOL   
4.01 OVERVIEW 
 
Current evidence suggests that 7-10% of infants who have significant PHL may have ANSD. So-called ‘conventional’ cochlear hearing 
loss affects the outer hair cells (OHCs) first and at greater severities may also involve loss or damage to the inner hair cells (IHCs) and 
supporting structures. In contrast, ANSD is a disorder that is not known to affect OHC function but reflects abnormalities of the IHCs, 
their synaptic linkages to primary auditory neurons or the neurons themselves. Only the last of these alternatives is a true 
neuropathy, but in 15-20% of all ANSD cases there is MRI evidence of dysgenesis or agenesis of the cochlear nerve. It cannot be 
assumed that only one site or mechanism of ANSD expression is necessarily involved in any given individual. For a recent, detailed 
exposition on the pathophysiologic mechanisms of ANSD, see Appendix A: Rance & Starr (2015). 
 
One functional result of ANSD-type pathology is a deficiency in the number and/or the temporal pattern of afferent nerve impulses 
elicited by sounds. Such abnormalities have a range of perceptual sequelae that are measurable psycho-acoustically in older children 
and adults, notably including reduced ability to detect temporal modulations of sound and difficulties with speech perception in 
noise that are more marked than in cases of conventional cochlear pathology with matched severity of sensitivity loss. 
A further complication is that some ANSD phenotypes appear to share etiologies (such as severe perinatal hypoxia) with 
conventional cochlear hearing loss. Because there is no reason to assume that ANSD, conventional cochlear hearing loss and 
conductive hearing loss are necessarily mutually exclusive, they are referred to here as ANSD, OHC-based SHL and CHL components.   
 
Mismatch between gross measures of OHC and afferent neural function is the initial hallmark of ANSD. The first necessary condition 
is an ABR that is absent or at least significantly depressed and/or delayed. At present, it is widely (but not universally) accepted that 
any elicitation of a complete ABR wave sequence at normal latencies rules out ANSD. Conversely, a completely absent ABR to a high-
intensity click stimulus indicates that an ANSD component is possible but other causes include profound OHC-based PHL and 
mixtures of it with CHL. Between normal and absent ABR lies a spectrum of ABR abnormality within which differential diagnosis of an 
ANSD component can be very difficult.   
 
The second necessary component is a measure of OHC function. The best indicator of normal OHC function is normal OAEs. CMs are 
an alternative tool but they are NOT equivalent to OAEs in either simplicity of interpretation or diagnostic strength. OAEs are a pure 
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OHC phenomenon with fairly well-understood generation place characteristics, but click CM may be generated by IHCs even if the 
OHCs are extensively damaged; also, gross CMs at a periauricular skin electrode may arise from any part of the cochlea, not 
necessarily the 2-4 kHz region that normally dominates the click ABR at high levels. This raises the concern of comparing phenomena 
from what may or may not be different parts of the cochlea, parts that might be subject to different pathophysiology. 
A major limitation of OAEs in the ANSD context is that they are reduced or abolished by even small CHLs.  Therefore, while OAE 
presence is highly informative, OAE absence is not. When both OAEs and the ABR are absent, two possible explanations are either 
severe, OHC-based sensory hearing loss plus a minor conductive overlay or ANSD, so the ANSD could be missed because of the OAE 
absence. 
 
In addition, there are many possibilities that are less well-defined than ‘present OAE and absent ABR’, such as situations of abnormal 
but not absent ABR and/or reduced or partial OAEs. Also, the click may be more effective at ABR elicitation that a tonepip. 
Therefore, it is appropriate to try high-level clicks when ABR to high-level tonepips are absent or poorly defined and an added 
benefit is that responses to condensation and rarefaction stimuli are easily available. For these reasons, it is appropriate to measure 
click ABR and CM whenever the possibility of ANSD is indicated in the course of tonepip threshold estimation. Such measurement 
should be deferred until tonepip ABR thresholds are completed to 10 dB bracketing. Bracketing tonepip thresholds to 5 dB is not 
appropriate if the ANSD sub-protocol indicates ANSD component presence. 
4.02 ANSD SUB-PROTOCOL ENTRY CRITERION 
 
The ANSD sub-protocol is ear-specific and must be done in any ear for which there is no clear ABR wave V-V’ complex with a wave V 
latency between 5 and 10 ms at any tested level above 75 dB nHL at 2 kHz, with at least one such level having been tested. In the 
rare event that this condition is satisfied but there is an unequivocally normal wave V ipsilaterally to BC 2 kHz at any level, the entry 
into the ANSD sub-protocol is discretional. 
 
The requirement for the ANSD protocol is ear-specific, that is, it may be required in one ear only or in both ears. The majority of 
ANSD is bilateral, but unilateral ANSD or asymmetric ANSD severity are not uncommon. In any given ear, as soon as presence of PHL 
is confirmed at any frequency, the probability of ANSD has increased from about 0.0002 in the newborn population at large through 
about 1% in all AABR Refers to at least 5% in all cases with confirmed PHL. But, as soon as a clear positive response is obtained with 
a wave V latency within normal limits well above threshold, the ANSD probability becomes close to zero. ABR threshold definition 
and wave V clarity and latency are often much better defined at 2 kHz than at 0.5 kHz, so a rational ANSD flag is lack of an RP record 
having a wave V latency under 10 ms at any level above 75 dB nHL at 2 kHz. This criterion is satisfied, for example, by 2 kHz results 
such as an NR at 80 dB, an INC at 100 dB or an RP at 90 dB with wave V latency over 10 ms. 
 
The ANSD sub-protocol may be done discretionally if the audiologist considers the tonepip response data to be anomalous, even if 
the criteria for mandatory entry are not satisfied, provided that so doing does not compromise efficient capture of mandatory 
threshold data. An example of anomalous data might be very poor suprathreshold growth of 2 kHz response amplitude over a large 
intensity range.   
4.03 ANSD SUB-PROTOCOL TIMING 
 
The ANSD sub-protocol usually should be deferred until after all required tonepip ABR thresholds have been established bilaterally 
to 10 dB bracketing. Given that there is at least severe HL or ANSD present (or both), the requirement for the ANSD protocol 
sometimes is established early in the initial ABRA appointment. However, it does not follow that the ANSD protocol should be 
entered immediately. First, unless OAEs have already been done and are normal, which is not usually the case, even complete 
absence of ABR at high 2 kHz tonepip levels is much more likely to have been caused by OHC-based PHL than by ANSD, so tonepip 
thresholds may well be valid. Second, testing at 500 Hz and 4 kHz may be clinically useful even if ANSD is present, not the least 
because any measurable ABR strongly suggests auditory perceptibility at the evoking stimulus level or lower. Even abnormal ABRs in 
ANSD can give clinically useful threshold upper bounds, and if the ABR is completely absent, the time spent confirming that for all 
key frequencies will be small. It follows that at least the basic threshold Search phase for 2, 4 and 0.5 kHz in each ear should be 
attempted first, with 10 dB AC bracketing in the event that a late wave V is recognized. 
 
If and when AABR Referral is bilateral, neither ear tests normal and at least one ear has the ANSD Sub-Protocol indicated, then it 
would be unusual to complete the basic mandatory protocol in both ears within the first ABRA session. It follows that the ANSD 
protocol will usually be done in a second session.  
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4.04 ANSD TEST PROCEDURES 
 
The following procedures must be followed in each ear for which the ANSD sub-protocol entry criteria are met. For all tracings, the 
following (modified from 2008) parameters must be used: 
 
Clicks, 90 dB nHL, 21.5/s, window (sweep) length 25 ms, 0 ms delay, bandwidth 150-2000 Hz, full page-width plotting. All 
compound tracings must be ~4000 sweeps each. Important: Masking is required if ANSD is suspected in one ear and the other ear 
is normal. 
 
1. One Rarefaction tracing, denoted as R.  
2. One 2000 sweep Rarefaction tracing with tube clamped or tube off, Rns (Rarefaction, no-stim). 
3. One Condensation tracing, C. 
4. One 2000 sweep Condensation tracing with tube clamped or tube off, Cns. 
5. Add R and C into combined overall average, ‘All’. This is done using the “+/-“ 
6. R and C are subtracted in Step 5 to generate the CM tracing.  
 
Then organize, plot and annotate the tracings (see Appendix J), in the following sequence from the top down: 
 
Superimposed R and C 
“Butterfly plot”  
Superimpose the R and C compound tracings, exactly, at the 
first data point: this ‘butterfly’ plot accentuates antiphasic 
CM components and latency-shifting ABR components  
Rns: Reveals Rarefaction stimulus artifact 
Cns: Reveals Condensation stimulus artifact 
All (R + C) Best overall estimate of the ABR; removes CM and stimulus 
artifact 
CM (R – C) Best overall estimate of CM, removes ABR if R and C ABRs are 
identical 
 
Note: Alternating Split is an option offered in the CM modality of the Integrity system. At this time, not enough evidence is available 
to support its use in the IHP ANSD sub-protocol. Recording tracings in Alternating Split is a discretional part of this sub-protocol and 
should only be done after all mandatory and conditional elements are completed; if Alternating Split is recorded, about 4000 sweeps 
is recommended 
4.05 INTERPRETATION OF CM/ABR TRACINGS 
 
Stimulus artifact for each polarity is revealed by the tube-off (or tube-clamped) tracings. This helps to identify genuine CM 
components, though the artifact is brief, earlier than the CM and usually easy to distinguish from it. Click stimulus artifact is usually 
over within about 0.5 ms. If it is very large, the EEG preamplifier may generate ‘ringing’ due to the artifact impulse; interpretation is 
more complex and review by a DTC is recommended. 
 
Antiphasic (mirror-image) CM components are revealed most clearly by the CM butterfly plot. Asymmetry of the CM is reflected in 
the curve formed by the ‘butterfly wing intersection points’ (nodes), which should match the All waveform over the first few 
milliseconds. Clear departure from zero reflect asymmetry of the CM, which is usually interpreted as SP; this may overlap with wave 
I (if present) after about 1.5 ms. 
 
The record denoted as ‘CM’ may show high-frequency oscillation of variable duration, in the region from 0.5 through 1.5 ms. It is 
recommended that the maximum peak-to-trough or trough-to-peak amplitude should be recorded, along with the total number of 
high-frequency antiphasic segments or wing-spreads in the butterfly and their approximate overall duration. Such parameters may 
become useful clinically as new knowledge is acquired about CM properties in relation to ANSD subtypes, severity gradation and 
mixtures with other hearing loss types.  
 
ABR components also may be present at any point after about 1.5 ms. They may or may not be different in the R and C records, both 
in amplitude and latency. If different, there may be partial or complete wave cancellation as well as a visual impression of phase 
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shift in the ‘All’ tracing. Additional testing is likely to be required in order to resolve the neural components. If a wave V candidate 
response tracing is clearly identifiable, the peak-to-trough amplitude should be recorded. If there is partial or total wave cancellation 
in the ‘All’ tracing relative to the R and C tracings, the larger of the R and C wave V-V’ complexes should be used. 
4.06 CLICK ABR WAVEFORM & THRESHOLDS 
 
Given that the 2 kHz tonepip ABR was absent or at best showed a small and/or late ABR wave V-V’ complex above 75 dB nHL in 
order for the ANSD sub-protocol to be entered, a normal click ABR at 90 dB would be a rare occurrence. Far more common is a late 
and broad waveform that is presumptively a V-V’. If a clear and replicable such waveform is identified in response to clicks at 90 dB, 
the click ABR threshold must be approximated as quickly as possible by bracketing. Step size of 20 dB is sufficient but 10 dB is 
discretional. If there is a clear difference in wave V-V’ size or Rarefaction and Condensation clicks, the polarity with the larger V-V’ 
must be used, otherwise alternating polarity may be used for threshold. The click threshold correction to dB eHL is to subtract 10 dB.  
 
Such thresholds should be noted in any clinical report but are not entered into the HCD-ISCIS database. Clinically it can be noted that 
hearing in the middle or higher frequencies is X or better, where X is the approximate dB eHL of the upper bracket. 
If the Rarefaction and Condensation waveforms show marked latency differences or morphology in the region of the later ABR 
waves (typically from about 4 to 10 ms), it may be very difficult to distinguish these waves from long CM, for example. Additional, 
specialized and situation-specific testing may be required and review by the HRH or CHEO DTC is strongly recommended.  
 
Another occasional occurrence with click testing at 90 dB is an ABR waveform in the ‘All’ tracing that shows early ABR waves with a 
clear delay or absence of wave V. This pattern suggests a possible retrocochlear lesion (such as an acoustic tumour or other 
brainstem lesion) that may not be typical of ANSD. Again, review by the HRH or CHEO DTC is strongly recommended. 
4.07 DPOAE ROLE 
 
DPOAE measurement is discretional for infants whose ABRs show conductive hearing loss or normal hearing. They are mandatory if 
sensorineural HL is suspected or confirmed, and as part of the ANSD sub-protocol. Including DPOAEs in a test battery of infant 
hearing assessment supports the cross-check principle. When coupled with absent ABRs, normal DPOAE amplitudes and signal-to-
noise ratios exceeding about 5 dB at F2 frequencies from 2 to 4 kHz are virtually definitive for either ANSD or, more rarely, other 
neuropathies that compromise action potential generation in the auditory nerve. Repeatable DPOAE presence at even a single 
frequency of 2, 3 or 4 kHz is incompatible with absent ABR, though presence isolated to lower frequencies is not. 
 
DPOAEs are known to originate in the OHCs specifically. As such, they can provide clear evidence of OHC functional status, though 
they do not offer a clear quantification of residual OHC function or a means of accurate prediction of hearing thresholds in their own 
right. Absence of DPOAEs an any specific F2 frequency suggests an SHL of about 40 dB or more at or near that frequency, but the 
overlap of DPOAE amplitude distributions for groups with and without SHL of about 30-40 dB is substantial and the distributions are 
quite broad. 
 
The contribution of DPOAE testing to identification of ANSD is limited by their reduction or abolition by even minor conductive 
pathologies and hearing losses. DPOAEs that are clearly present are highly informative in relation to ABR characteristics, whereas 
DPOAEs that are absent or questionable are not. For example, an absent ABR and absent OAE cannot be reliably interpreted as 
uniquely indicative of severe SHL, because ANSD in combination with a minor middle ear pathology would be likely to give the same 
results. 
 
Normal tympanometry suggests the absence of substantial middle ear pathology but does not rule out minor conditions that might 
compromise DPOAE development, so even if high-frequency tympanometry is normal, absence of OAEs does not guarantee major 
OHC dysfunction. 
 
It could be argued that the specific finding of normal DPOAEs removes the need to do the CM component of the ANSD protocol. 
However, it is often not appropriate to do DPOAE testing before ABR testing and the measurement of CM is a helpful adjunct 
outcome of click ABR testing, which is necessary in any case to explore the causes of abnormal ABR waveforms and thresholds. CM is 
generally less affected by minor middle ear pathology than are the DPOAE, and the combination of DPOAE and click CM/ABR results 
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4.08 ACOUSTIC REFLEX (AR) ROLE 
 
AR testing is now discretional throughout any ABRA. It might be useful in the context of ABRA only if ANSD is under investigation 
and even then only if tympanometry is normal. ARs are reportedly absent in most cases of an ANSD component, but the actual 
sensitivity of this finding is unknown and absence due to severe/profound, conventional sensory loss or significant conductive loss 
(the other differentials) is to be expected. Absent reflexes add little clinical information when tonepip ABRs are absent or have very 
high thresholds. In contrast, reflex presence is an anomaly if ABRs are absent at very high stimulus levels and should prompt critical 
re-evaluation of test findings, so AR testing could be seen as a crosscheck. However, it might be reasonable to assume that in the 
context of this protocol, such crosschecking should be considered redundant. If ANSD is considered definite, such as in a situation of 
normal OAEs and absent ABR, reflex testing is not useful because even reflex presence would not carry sufficient weight to change 
the ANSD inference.  
4.09 ANSD OUTCOME CATEGORIES 
 
It is a requirement that the tracings associated with all ANSD outcome categories except Not Suspected be anonymized and sent 
to the HRH or CHEO DTCs for information and review. This will allow the assembly of a provincial IHP dataset that will be used to 
improve ANSD category definition and protocol efficiency. 
  
Category Determination 
a. If DPOAEs present at 2, 3 or 4 kHz and click ABR V-V’ < 0.1 µV: Definite ANSD component 
b. If DPOAEs present at 2, 3 or 4 kHz and click ABR V-V’ 0.1 - 0.2 µV: Probable ANSD component  
c. If DPOAEs absent or unreliable at 2, 3 and 4 kHz, apply table below: 
  
CM, pk-pk, µV Click ABR V-V’ pk-pk, µV 
 < 0.1 0.1 – 0.2 > 0.2 
< 0.1 NS NS NS 
0.1 - 0.2 Probable See Ratio NS 
> 0.2 Definite Probable See Ratio 
     NS = ANSD Not Suspected 
 
In cells labelled ‘See Ratio’, calculate the amplitude ratio CM/ABR using the peak-to-peak values. If the ratio exceeds 1.5, the 
outcome is ‘Probable ANSD component’, otherwise it is ‘ANSD is not suspected’.    
The ‘ANSD component’ terminology is used to remind report recipients that ANSD, conventional (OHC) sensory and conductive 
hearing loss components may be present concurrently and that ‘Sensory/Neural HL’ does not mean simply either conventional 
sensory hearing loss or ANSD.  
4.10 CONDUCTIVE COMPONENTS IN ANSD 
 
When the ANSD protocol is indicated by AC 2 kHz it is very unlikely, though not impossible, that a clear ABR with normal wave V 
latency is obtained with BC 2 kHz at 55 dB or below. That finding implies a substantial conductive component, which renders the 
ANSD protocol virtually useless. A CM will not be seen to a 90 dB click with a mid-frequency conductive component of 20 dB or 
more. Also, it is almost certain that DPOAEs will be absent. Because these clues concerning the functionality of OHCs are not 
available, ANSD cannot be detected or classified with adequate reliability. Fortunately, with a normal BC ABR waveform and a 
correctly attributed responding cochlea, ANSD can be presumed to be absent and the ANSD sub-protocol can be treated 
discretionally. 
 
If AC 2 kHz ABRs are absent at high levels and BC 2 kHz ABRs are also absent, a conductive component cannot be ruled out except by 
normal DPOAEs. If DPOAEs are absent, a flat tympanogram suggests a conductive component but does not prove it and does not 
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quantify it. Alternatively, absent DPOAEs and a normal age-appropriate tympanogram strongly suggests absence of a substantial 
conductive component. The ANSD click CM/ABR protocol is indicated in both cases and may prove informative. 
 
All in all, if a substantial conductive component cannot be ruled out, ANSD is unlikely to be detectable and a conventional SHL 
component may be overestimated. The overall interpretation will default to a severe or profound sensory/neural hearing loss with a 
possible or probable conductive component and ANSD not suspected. In this situation, it is desirable to wait at least 4-6 weeks and 
retest with tympanometry, OAEs and tonepip ABR at 2 kHz, to determine and interpretable change. 
4.11 DTC CONSULTS & ADDITIONAL TESTS 
 
It is required that in all cases where the ANSD protocol is entered and the ANSD outcome category is definite or probable, either the 
HRH or the CHEO DTC should be notified by email and sent the anonymized full ABRA including toneburst and ANSD sub-protocol 
printout. This notification increases the program’s information bases relevant to planning, protocol and resource allocation, as well 
as triggering useful DTC comment on individual cases, if requested or indicated. 
 
In complex ANSD cases, such as those with no DPOAE and unusual or inconsistent response morphology to rarefaction or 
condensation clicks, additional testing may be indicated and undertaken by referral to a DTC. Such testing may include very-high-
rate (91.1/s) click ABR to suppress and delay neural components, as well as manipulations of tracings to clarify CM, SP, and neural 
response components. A common challenge is overlap and confusion among oscillatory CM, SP, and the ABR. 
 
When ANSD is present, audiometric threshold estimates are impossible or at best biased and potentially unreliable. Waiting for VRA 
remains an option that is far from ideal but the options are limited at present. For infants aged six months or more in whom VRA is 
either likely to be, or is found to be, unsuccessful, advanced Assessment may include threshold estimation using late cortical 
potentials (LCPs) (typically of 200-400 ms latency) in response to long tone bursts, which are far less sensitive to loss of neural 
synchrony than the ABR. LCP testing is currently not available through the IHP. See, for example, He et al (2013) in Appendix A of this 
protocol, for information on cortical testing in children with ANSD. 
4.12 EARLY MANAGEMENT  
 
ANSD may in some cases be determined to be present under about two months corrected age, in which case repeat ABRA at about 
four months is usually appropriate; the ANSD sub-protocol should be prioritized at such retests. More commonly, in the IHP ANSD is 
initially confirmed at about 3-5 months corrected age. It is common to wait for behavioural thresholds by VRA, prior to considering 
amplification (IHP Amp protocol, Walker et al, 2016). VRA should be tried at the earliest reasonable opportunity, typically at about 
six months, unless there are contraindications. Agreement or discrepancy between ABR and VRA results may alter the diagnostic 
picture and follow-up recommendations. Careful communication with caregivers is required if the ANSD test outcome category is 
‘definite’ or ‘probable’. ANSD is not easy to explain, especially its relationship to ‘ordinary’ hearing loss, the consequent inaccuracy 
of the ABR and the waiting period prior to VRA and decision-making about interventions. Other issues include the variable quality of 
information about ANSD available on the internet, as well as the number of misconceptions that exist about the disorder, even 
across hearing health professionals. 
  
Some basic, key points to be explained to families are: 
 
 When ANSD is present, hearing cannot be predicted from the ABR test. 
 Infants with ANSD have a wide range of hearing losses, but most have some degree of loss. 
 Behavioural hearing testing usually will be tried at about 6 months of age. 
 Family observations of response to sounds may give useful information. 
 Many children with ANSD have difficulty understanding speech, especially if there is a lot of background noise or other 
people talking. 
 The extra difficulty understanding speech happens because ANSD interferes with the timing of sound signals as they travel 
up the hearing nerves to the brain. 
 Some children (about 50%) with ANSD will benefit from amplification. 
 Amplification is usually not provided until reliable behavioural thresholds are obtained. 
 Some children with ANSD who do not get much benefit from amplification may do well with cochlear implants. 
 
 
Page | 61  
 
 Much information about ANSD available from the Internet is incomplete or invalid. 
 
See Roush et al (2011) in Appendix A for a comprehensive review of audiologic management of children with ANSD. See Teagle et al 
(2010) on cochlear implants in ANSD. See Walker et al, 2016 for language outcomes of children who have ANSD. 
 
It is often quoted and written that fluctuation of hearing and possible improvement in hearing over time are common occurrences 
with ANSD, or even key characteristics of it. These statements are incorrect. Fluctuation of hearing levels in ANSD is not a common 
finding and is probably confined to specialized sub-types of ANSD. Similarly, while it is possible that hearing levels may change over 
time in a few cases, the actual incidence of progression or improvement is not well-understood and may be very low. The evidence 
to date for improvement in hearing levels is not of high quality; it should be evaluated critically in relation to individual candidacy for 
interventions such as cochlear implants.    
4.13 ANSD FIELD ENTRY IN THE IHP DATABASE  
 
If ANSD is definite or probable, tonepip thresholds are likely to be positively biased and in many cases will comprise a lower bound 
value expressing No Response at the required maximum stimulus levels. These values must be entered in the HCD-ISCIS database 
frequency threshold fields as if they were valid, but must be qualified by an entry indicating ANSD as ‘Not Suspected’, ‘Probable’, or 
‘Definite’. PHL must be reported as ‘Yes’. 
4.14 POST-ABRA REFERRALS 
 
It is the responsibility of the individual IHP Audiologist, preferably with support from a DTC, to determine the ANSD category and 
complete the ABRA protocol. When those steps are completed, if ANSD is definite or probable then referrals for additional 
investigations are discretional and are outside the scope of this protocol. It is suggested that all referrals that normally would be 
undertaken for an infant with non-ANSD PHL should be considered. The special concerns, particularly with definite ANSD, are 
primarily related to delay in definitive audiometry and the increased likelihood of agenesis or dysgenesis of the cochlear nerve(s) 
which are of clear relevance to amplification, CI candidature and planning of early communication development services. 
   
 
SECTION 5: ANCILLARY PROCEDURES 
5.01 DISTORTION PRODUCT OTOACOUSTIC EMISSION (DPOAE) TESTING 
 
Purpose and Priority 
DPOAEs reflect cochlear OHC function. They can be reliably recorded in sleeping newborns in a quiet environment. They are 
measured best with an f2/f1 ratio of about 1.22 and f1/f2 levels of about 65/55 dB SPL, respectively. DPOAEs yield an approximate 
yes/no (DPOAE absence/presence) test for significant sensory hearing loss at each f2 value tested, with an effective binary decision 
criterion at about 40 dB HL. 
 
DPOAEs do not yield accurate hearing threshold estimates. The sensory hearing loss that abolishes the DPOAE is widely distributed 
across the infant population. Some babies who have near-normal hearing may have reduced or absent OAEs, while some babies with 
sensory losses of over 50 dB HL have OAEs of near-normal amplitude. OAEs may be abolished by conductive losses as small as 5-10 
dB, so an unknown proportion of cases of OAE absence with apparently normal hearing may be due to conductive effects. This 
vulnerability to minor conductive disorders that may not be detected reliably with tympanometry limits the clinical value of DPOAEs: 
present DPOAEs may be very informative as a test of OHC functional status, but absent OAEs yield little diagnostic information. 
 
In the context of initial ABRA, DPOAE measurement is now mandatory only if the indications for ANSD sub-protocol entry are met. If 
not, DPOAE testing is discretional but before embarking on such measurement, the Audiologist should have a clear purpose and 
action plan for the possible test outcomes. When ABR absence or abnormality is established at high 2 kHz levels, ANSD has 
substantial probability. DPOAE testing is recommended to occur after tonepip thresholds are completed and before the rest of the  
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Because the primary purpose of ABRA is ABR threshold measurement, if a baby is sleeping then ABR testing is usually the immediate 
priority. Doing OAEs at the start of an ABRA test session is discretional but if the baby is merely drowsy, doing OAEs may interfere 
with falling asleep. OAEs are never a substitute for ABR thresholds, though if ABR thresholds are abandoned due to persistently poor 
EEG, trying OAEs may salvage at least some useful clinical information. 
 
Procedure 
DPOAE testing must adhere to this protocol, using the parameters specified in Appendix H. Nominal f2 frequencies are 1.5, 2, 3 and 
4 kHz, with descent from 4 kHz. If the SNR (the difference between the DPOAE and noise floor levels) at every nominal f2 frequency 
is at least 8 dB, the test is Normal and need not be repeated. If not, DPOAEs must be replicated. Results must be plotted with 
replicates overlaid and Left and Right ears side by side, where feasible. Hardcopy or electronic plots and tables are retained. The 
2008 IHP Protocol specified display of normative amplitude data percentile curves as part of the printout graphics, but it is now 
recommended that those data not be displayed because they are not useful clinically. Note that DPOAE testing above 4 kHz is 
discretional, pending normative data development 
 
Interpretation considers absolute DPOAE and noise levels, SNRs, and differences across replicates, at every f2 and for all of them 
collectively. Step 1 is to evaluate stimulus conditions. Systems often auto-calibrate to 65 and 55 dB SPL and show responses that are 
flat and level. A little droop at low frequencies is acceptable but suggests of imperfect probe fit. Major droop indicates inadequate 
probe fit that invalidates the test. 
 
Step 2 is to assess replicability. Test retest differences of similar size to the average SNR at any f2 cast doubt on inference of DPOAE 
presence or absence. Conversely, highly reproducible profiles or smooth trends across frequency strengthen inference of DPOAE 
presence even if the SNRs at individual f2s are small. Step 3 is an evaluation of specific numerical values of DPOAE, noise and the 
difference between them, frequency by frequency, noting reflex absence, presence or indeterminacy due to excess noise. Step 4 is 
to assess patterns. This is a search for trends across frequencies or remarkable differences in values at single frequencies. At each f2, 
the question is if the DPOAE level is real or due to noise. DPOAE amplitude and SNR are relevant. For a single f2, a conservative 
criterion for DPOAE presence is an SNR of at least 8 dB and a test-retest difference under 5 dB. An 8 dB criterion will yield about 1% 
false-positive detection whereas a 3 dB criterion would give about 10%. Infants may have greater SNRs than adults, and this may 
change with maturation, ear canal growth, and may be affected by the specific in situ calibration technique or measurement 
parameters used by the DPOAE equipment (Hunter et al., 2018). 
 
When two or more adjacent frequencies show positive SNRs, each frequency adds to the probability that the DPOAE is genuine, so 
use a 5 dB criterion for genuine DPOAE presence at each frequency in a string of adjacent, positive differences. High noise levels 
limit the opportunity for an OAE to be detected reliably.  
 
Clinical Implications 
DPOAE presence for all f2 suggests grossly normal functioning of the middle ear and the cochlear OHCs. Significant conductive 
disorders are ruled out. OHC-based cochlear hearing loss greater than 40 dB HL is unlikely; more than 60 dB HL is virtually ruled out. 
ANSD does not affect OAEs. Normal OAEs and an absent or grossly abnormal ABR to high-level 2 kHz tonepips or to high-level clicks 
are virtually definitive for an ANSD component, which is thereby ruled in, as noted previously. 
 
Unfortunately, many factors other than a target PHL can obscure, reduce or abolish DPOAEs. These include a noisy environment, 
active baby, inadequate probe placement, eartip blockage and an array of middle ear conditions. The net result is that absence or 
marked reduction of DPOAEs carries little diagnostic information. Their value lies in their presence and the consistency of that 
presence with observed ABR characteristics. DPOAE presence with, say, a 2 kHz tonepip ABR threshold above 50 dB nHL should lead 
to careful review of the ABR threshold validity. More marked discrepancy raises the ANSD index of suspicion more strongly than any 
other test finding, but there is a large gray zone of borderline incompatibility between clear DPOAE and abnormal ABR features for 
which current knowledge is insufficient for interpretation. 
5.02 MIDDLE EAR ANALYSIS: TYMPANOMETRY 
 
Tympanometry is mandatory in all ABRA (see Appendix I). Tympanometric abnormality criteria are set at the 5th percentiles of age-
specific normative distributions of compensated peak static admittance, where a clear peak or peaks have developed. In the case of 
double peaks, the larger peak is used. Admittance change without development of a genuine peak is abnormal regardless of the 
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amount of admittance change. Caution is required in applying these criteria to young neonates, in whom canal wall collapse may 
lead to steep negative tails. 
 
The clinical utility of other tympanometric measures such as peak pressure, width and gradient is unclear in infants. Reported 90% 
range boundaries for tympanic peak pressure are from approximately -150 to -100 daPa up to 0 to 50 daPa. 
 
The equipment required up to and including the IHP 2008 Assessment Protocol was the Tympstar. That has now changed to include 
any equipment capable of providing the measures and procedures specified in this 2018 ABRA protocol, that is, the specification is 
now functional. 
 
Babies and Infants of corrected age less than six months 
Tympanometry must be done with a 1 kHz probe frequency for neonates and infants under six months corrected age. The test must 
be repeated if the trace is noisy or if it is not clearly normal. A clearly normal tympanogram need not be repeated. The key 
abnormality criterion is a compensated peak static admittance of ≤ 0.6 mmho, compensated from the negative tail at -400 daPa. All 
tympanograms at 1 kHz must be plotted and retained on file.   
 
Infants of corrected age six months or more 
For infants aged six months or more, the probe frequency must be 226 Hz. The abnormality criterion in the range 6-12 months is a 
compensated peak static admittance of 0.1 mmho, compensated from the positive tail at +200 daPa. From 13-18 months, the 
criterion is 0.15 mmho. Above 19 months, the criterion is 0.2 mmho. At any age, a tympanogram that is noisy or not clearly normal 
must be repeated. Tympanograms at 226 Hz in all cases should be plotted and retained on file 
5.03 MIDDLE EAR ANALYSIS:  ACOUSTIC REFLEXES  
 
Acoustic reflex (AR) measurement is now always discretional but may be clinically contributory in the context of suspected ANSD. 
When an ANSD component is actually present, a clear AR is an unusual finding that should lead to careful re-evaluation of any 
evidence for inference of a Definite or Probable ANSD component. AR presence also has some clinical value as a crude crosscheck 
when AC ABR thresholds are poorly defined and suggest hearing levels over about 80 dB eHL. If such situations occur then the 
reliability of the ABR threshold should be re-examined and possible causes of poor threshold definition should be identified and 
remedied as a normal requirement of high-quality ABRA.  
 
If ipsilateral ARs are elected to be done, a 1 kHz probe must be used for infants under six months corrected age and a 226 Hz probe 
for infants aged six months or more. The eliciting stimulus may be a 1 kHz tone or Broad-Band Noise (BBN), which is a protocol 
change from the 2008 version. BBN is the preferred stimulus because it is usually more effective than tonal stimuli for reflex 
elicitation, which reduces false-positive reflex absence. The BBN option is a hardkey under ‘stimulus’ on the right side of the 
Tympstar. The goal is not to establish an accurate reflex threshold, but to show presence or absence of reflexes at an appropriate 
stimulus level. The starting level should be 85 dB. In infants under six months of age, the maximum nominal level must not exceed 
100 dB, because of the SPL variability across young infants due to differences in canal volume and geometry. For older infants, very 
small canals are uncommon and the maximum nominal stimulus level is discretional. Printouts are mandatory as reflex waveform 
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APPENDIX B: ACCESSING A DESIGNATED TRAINING CENTRE (DTC) FOR CONSULTATION OR REFERRAL 
 
Overview 
The Designated Training Centre (DTC) structure was put in place at the inception of the Infant Hearing Program (IHP) in 2001. 
DTCs provide protocol and clinical decision support, as well as training, and second opinion to IHP Audiologists. The goals of DTCs 
are to: 
 Support the timely and accurate execution of IHP protocols for assessment and the provision of amplification; 
 Help IHP Audiologists meet the IHP goals of early identification and intervention for children with permanent hearing 
loss; and 
 Serve as a clinical resource to IHP Audiologists. 
 
The DTCs for each aspect of the IHP are as follows. For Assessment, a regional breakdown of which DTC to contact is included. 
DTC 
Topic Area for 
Support 
Contact Information Regional Breakdown 
 
 





CBA: VRA & CPA 
 









Kenora Rainy River 




Children’s Hospital of 




CBA: VRA & CPA 
 





















Support is available to IHP Audiologists for a range of topics such as: 
 Answering questions about IHP protocols; 
 Case discussion and records review; 
 Recommendations for additional testing; 
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APPENDIX C: SUMMARY OF KEY INTEGRITY STIMULATION AND RECORDING PARAMETERS 
 
PROTOCOL FILES See detailed SETUP procedure notes following this summary Table. 
ELECTRODE SITES Noninverting: High midline forehead, referenced to 
Inverting for Channel 1: Left mastoid 
Inverting for Channel 2: Right mastoid 
Common: Lateral forehead > 3 cm from Noninverting electrode 
CHANNELS Air Conduction: Two channel or single channel ipsilateral to stimulated ear 
Bone Conduction: Two channel, ipsi and contra to stimulated ear 
FILTERS 
HIGH-PASS (‘LOW’) Tonepip thresholds   30 Hz 
All click recordings 150 Hz 
LOW-PASS (‘HIGH’) Tonepip thresholds 1500 Hz 
All click recordings 2000 Hz 
NOTCH FILTER Off, except as a last resort when 60 Hz artifact is severe. 
ARTIFACT REJECT Off 
AMPLIFIER GAIN 150,000 (not adjustable) 
AVERAGING 
2000-4000 adjusted sweeps per tracing, 1 to 3 tracings per condition.  
EPOCH LENGTH 25 ms 
RESIDUAL NOISE TARGET ≤ 0.020 µV, recommended for Response-Negative judgement.  
INTENSITY LEVELS Starting at 0, 5 dB intervals until max level 
STIMULI 
TONEPIPS 
Linear ramp (Trapezoidal envelope), 2-1-2 cycle rise/plateau/fall times. 
Alternating polarity. Repetition rate 37.7/s. 
CLICKS 
100 µs drive voltage pulse duration 
Alternating, condensation, rarefaction polarity as specified. 
Repetition rate 21.5/s 
MASKING 
Ipsilateral: None.  
Contralateral: discretional 60 dB broad-band noise. 
STIMULUS TRANSDUCER 
CALIBRATION OFFSETS  
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APPENDIX D: IHP VIVOSONIC INTEGRITY STIMULUS TRANSDUCER CALIBRATION 
 
All IHP Vivosonic Integrity’s must be set up identically, as specified in this protocol. The application software version in current use in 
the IHP is the Integrity 8.7 with calibration files of Version 8.3.3 (see table below). 
 
Whichever software is installed on any given Integrity, correct stimulus calibration settings are essential in order to use that Integrity 
for IHP ABRA. The stored values are not dB SPL values but are internal ‘offset’ values in dB peSPL that produce the desired SPLs for 0 
dB ‘dial’ to equal 0 dB nHL for the specific stimuli to be used in ABRA. See the table below. 
 
On the Integrity, to access the transducer calibration version, click on the System screen. In the middle of this screen, you should see 
the version number under RETSPL Conversion File. The current RETSPL Conversion File is 8.3.3. 
 
ABR Integrity V500 G2 RETSPL adjustment for 0 dB nHL 
These values are numbers specified by the IHP that are intended to produce appropriate stimulus levels, such that dial values 
approximate dB nHL values.  
 
 Frequency (Hz)  
Transducer 500 1000 2000 4000 Click 
ER-3A 25 23 28 30 38 
B-71W 62 49 47 39 47 
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APPENDIX E: IHP VIVOSONIC INTEGRITY PROTOCOLS 
The DTCs will help IHP Audiologists to set up their own protocols. If there are changes to the parameter below, the changes will be 
uploaded via TeamViewer or emailed through the DTCs. Below are the protocol parameters for reference. There is also a quick guide 
to protocol setup for general information. 
 
IHP ABR PROTOCOLS 
 
Air Conduction 500 Hz, 1000 Hz, 2000 Hz, 4000 Hz 
 
Stimulus type:  500 Hz, 1 kHz, 2 kHz or 4 kHz High Pass Filter Cutoff Frequency: 30                
Transducer Type: Insert Earphone Low Pass Filter Cutoff Frequency: 1500 
Stimulus Rate: 37.7   High Pass Filter Rolloff: 12 dB/Octave 
Maximum Number of Stimuli: Unlimited (33930) Low Pass Filter Rolloff: 24 dB/Octave 
Windowing: Linear                    Artifact Rejection: Checked off 
Ramp Number of Cycles: 2-1-2 Display Zoom: 25 ms 
Polarity: Alternating   Default Masking Level: None 
Level: Checked from 0 to max DB in 5 dB step size  
 
 
Bone Conduction 500 Hz, 2000 Hz, 4000 Hz 
 
Stimulus type:  500 Hz, 2 kHz or 4 kHz High Pass Filter Cutoff Frequency: 30                
Transducer Type: B-71 Low Pass Filter Cutoff Frequency: 1500 
Stimulus Rate: 37.7   High Pass Filter Rolloff: 12 dB/Octave 
Maximum Number of Stimuli: Unlimited (33930) Low Pass Filter Rolloff: 24 dB/Octave 
Windowing: Linear                    Artifact Rejection: Checked off 
Ramp Number of Cycles: 2-1-2 Display Zoom: 25 ms 
Polarity: Alternating   Default Masking Level: None 
Level: Checked from 0 to max DB in 5 dB step size  
  
 
Air Conduction Click 
 
Stimulus type:  Click High Pass Filter Cutoff Frequency: 150  
Transducer Type: Insert Earphone Low Pass Filter Cutoff Frequency: 2000 
Stimulus Rate: 21.5   High Pass Filter Rolloff: 12 dB/Octave 
Maximum Number of Stimuli: Unlimited (18990) Low Pass Filter Rolloff: 24 dB/Octave 
Windowing: Linear                    Artifact Rejection: Checked off 
Ramp Number of Cycles: 2-0-2 Display Zoom: 25 ms 
Polarity: Rarefaction   Default Masking Level: None 
Level: Checked from 0 to max DB in 5 dB step size  
 
  
For Reference:  AEP SETUP 
 
Double click the Integrity icon to open the program. A system menu with appear, click on Diagnostics.  
 
SETUP DISPLAY PARAMETERS 
In the Main Menu shown at the top of the screen on startup: 
 
1) Choose any existing protocol in the list found on the left 
2) Change the parameters according to new IHP protocol 
3) Click on Save Protocol located in the top right corner 
 
 
Page | 70  
 
4) Name the new protocol according to the parameters used (e.g. IHP Insert 2 kHz) 
5) Click OK 
6) Note: You cannot make additional changes to the protocol once it is saved. If changes are made, you will be required 
to create a new protocol.  
7) If you would like to remove protocols from the drop down list in the Test Screen, uncheck the box corresponding to the 
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APPENDIX F: CLINICAL TIPS FOR A HAND-HELD OR TENSOR BANDAGE BONE OSCILLATOR 
When hand-holding or using a tensor bandage for BC ABR, proper placement and consistent pressure of the bone oscillator are 
important. The following tips are recommended: 
 
 Ensure the oscillator is flat against the baby’s temporal bone. 
 
 Place the oscillator high on the temporal bone rather than low, as in the image below. 
 
 Ensure even pressure is applied. If the baby is being held during the test, instruct the caregiver to keep the baby still (i.e., no 
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THRESHOLD CORRECTIONS AND IHP MINIMUM TEST LEVELS  
 
The correction factors for 500 Hz AC and BC have been adjusted to reflect recent data and to approximate more closely the BC Early 
Hearing Program values.  
The IHP minimum levels are now set at dial values that correspond to 25 dB eHL after correction, for all stimulus conditions. These 
levels are consistent with a target impairment equivalent to 30 dB HL or greater at any frequency in the set [0.5, 1, 2, 4 kHz].  
* For AC ABR threshold estimates greater than 70 dB dial, if 5 dB final step size is used for the threshold bracket then the absolute 
value of the Adjustment should be reduced by 5 dB at any frequencies. The rationale is that with a 10 dB step size, the possibility of 
response presence at a level 5 dB lower (untested) is included in the statistical adjustment for bias, whereas with a 5 dB step there is 
no such possibility, because the 5 dB lower level was now demonstrated to be No Response.  
Examples: 2k 80 dB nHL (RP), 70 (NR): EHL = 80-5 = 75 dB eHL 
2k 80 dB nHL (RP), 75 (NR): EHL = 80-(5-5) = 80 dB eHL    
*where (RP) and (NR) represent definite response detection outcomes (see Protocol text). 
 
 
For any AC ABR threshold, it is discretional to reduce the absolute value of the Adjustment by 5 dB, if the response at the lowest 
level considered Response Positive is minimal AND the EEG noise level is very low (such as a Residual Noise Level below 20 nV). The 
rationale is that with exceptionally quiet EEG, the ability to identify small, near-threshold responses is increased, and if such a 
response is seen, the negative offsets normally used are likely to be on average excessive. 
Examples: AC 500 Hz 60 dB nHL (RP), 50 (NR): EHL = 60 -15 = 45 dB eHL 
AC 500 Hz 60 dB nHL (RP, small, very low noise, e.g., 18 nV), 55 (NR): 
EHL = 60 – (15-5) = 50 dB eHL 
 
 
Because current correction factors typically reflect only the mean or median values of the normative difference between ABR 
thresholds and measured behavioural thresholds in the same subjects, and both measures are subject to random error, it is 
statistically possible that valid RP outcomes might occur at dB eHL levels that are judged NR by BC, implying negative air-bone gaps. 














             AIR CONDUCTION BONE CONDUCTION 
Frequency (Hz) 0.5k 1k 2k 4k 0.5k 2k 4k 
Minimum Level (dB Dial) 40 35 30 25 25 <1 yr 






-15 -10 -5   0 0 -5 0 
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 APPENDIX H: DPOAE PARAMETERS 
 
Use of specific makes and models of DPOAE measurement equipment is now at the discretion of the IHP test facility. Clinics should 
use settings that are matched closely to those shown below. For the Vivosonic Integrity system, the “Fast” protocol is recommended 
and may be used with the S/N Ratio of 8 dB. Use of “Accurate” or “Medium” will provide higher DPOAE levels with longer test times 
and their use is therefore discretional. Infant normative data for the “Accurate” protocol are available (Hunter et al., 2018). 
 
Spectrum Ranges 
Upper Frequency Limit (kHz): 10  Decibel Range (dB): 100 
Autoscale Frequency: check  Bar Plot Spectral Data: blank 
 
DP-Gram Analysis Range 
Maximum Level (dB): 70   Minimum Level (dB): -30 
Maximum Frequency (Hz): 16000  Minimum Frequency (Hz): 250 
Reference Data: do not use. 
 
Setup/Collection Parameters  Protocol Name: 1-4 kHz Diagnostic Test 
Frequencies and Levels   Frequency Begin: 4000  Frequency End: 1000 
F2/F1 Ratio: 1.22    Points per Octave: 2 
L1 Level dB: 65    L2 Level dB: 55 
 
Stopping Criteria 
Min DP amplitude (dB): -5  Noise Floor (dB): -17 
S/N Ratio: 8    Point Time Limit (sec): 20 
Sample Size: 1024   Number of Tests: 1 
Minimum # Samples 50  
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APPENDIX I: MIDDLE-EAR ANALYSIS TECHNICAL SUMMARY 
TYMPANOMETRY 
 
Middle ear analysis may be completed using any make or model of equipment, provided that it meets calibration requirements, and 
offers a 1 kHz probe tone for use with infants younger than 6 months corrected age. As per CASLPO (2008) requirements, middle ear 
analysis must be performed using a type 1 tympanometer. A pressure sweep range that includes -200 daPa is required to facilitate 
measurement of negative middle ear pressures.  
 
For tympanometry, the following normative ranges are recommended, and intended for use with a 226 Hz probe tone unless 
otherwise specified. Visual examples of plat and normal tympanograms are available in Rosenfeld et al., (2016) Clinical Practice 
Guideline: Otitis Media with Effusion (Update) 
 
 If the tympanic membrane is intact:1 
Age group 








<6 months (1000 
Hz probe) 
0.2 – 0.8 cc 
> 0.6 mmho 
(negative tail 
compensation) 
<150 daPa N/a 
6 – 18 months 0.5 – <1.0 cc >0.2 mmho <250 daPa -75 to + 25 daPa are 
typical, but peak 
pressure as low as -
199 may be consistent 
with transient middle 
ear issues and may 
resolve. Consider 
results together with 
other findings. 
>18 months – 10 
years 
0.6 – 1.2 cc >0.3 mmho <200 daPa 
 If otoscopy reveals a patent tube or perforation 
1 to 7 years3 1.0 – 5.5 cc    
  
MIDDLE-EAR MUSCLE REFLEXES (ACOUSTIC REFLEXES, ARS) 
 
ARs are always discretional but their measurement is recommended as a limited crosscheck in situations of suspected ANSD. If a 
significant ANSD component is present, ARs are usually absent, but the quantitative evidence for such a finding is limited. ARs may 
be elicited by a 1 kHz tone or a broad-band noise (BBN) stimulus; the latter is preferable because BBN stimuli are more effective 
than tones for reflex elicitation, thereby reducing false-negative reflex absence. The AR is measured ipsilaterally using a 1 kHz probe 
frequency. Stimulus level should start at 85 dB and increase in 5 dB steps up to no greater than 100 dB. Note that for a given 
nominal level, real-ear SPLs in young infants may be up to 20 dB greater than in adults. Reflex presence is usually defined by a 
repeatable, clear, negative deflection, though biphasic and even positive deflections sometimes occur. Printout is discretional but is 





                                                                
1 Hunter, 2013, BSA 2013, Rosenfeld et al., 2016 
2 For information purposes only 
3 ASHA, 2004 
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End of ABRA protocol Version 2018.02, October 6, 2020 
END OF PROTOCOL  
